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Proteins are attractive bioavailability enhancers for poorly absorbed 
nutraceuticals or drugs, owing to their natural abundance, amphiphilic nature, 
and desirable biocompatibility. This study systematically investigated the 
preparation, characterization, and application of protein-based nanoparticles as 
effective nutraceutical/drug carriers. Soy protein, one of the most widely 
utilized proteins, was firstly employed for preparing nanoparticles. The 
particle formation involved partial unfolding of protein molecules, limited 
aggregation in the presence of the antisolvent, crosslinking via chemical bonds, 
and refolding of the constituent monomers. Satisfactory encapsulation 
efficiency (EE) and time-dependent release of curcumin, a chemopreventive 
compound, were observed. The nanoparticles were further subjected to 
conjugation with folic acid, a cancer cell-targeting ligand. A pronounced 
increase in the accumulation in tumor cells such as Caco-2 was achieved upon 
folic acid conjugation, which demonstrated the potential of this technique for 
  
the targeted delivery of anti-cancer drugs. To overcome the rapid digestion of 
soy protein nanoparticles in the gastrointestinal tract, carboxymethyl chitosan 
was employed as a second coating layer by a simple ionic gelation method. 
The formed particles exhibited satisfactory EE for vitamin D3 and controlled 
releasing profile in vitro.  
Beta lactoglobulin (BLG) as another protein of interest is a major component 
of whey protein, serving as a natural carrier for lipophilic nutrients. Our study 
suggested that the interaction between BLG and curcumin could be promoted 
by tuning the antisolvent content. A loading capacity (LC) and EE of up to 11% 
and 98% respectively could be achieved under the optimal conditions. 
Moreover, nanoparticles prepared with cationic beta lactoglobulin (CBLG) 
were able to transport most of the encapsulated drug intact through the 
gastrointestinal (GI) tract owing to its desirable particle integrity. Other 
advantages of CBLG-based systems included superior mucoadhesion, 
permeation across the small intestine epithelia, and cellular uptake. Finally, as 
CBLG molecules/nanoparticles absorbed the negatively charged serum 
proteins in the cell culturing medium, their surface properties, cytotoxicity, 
and cellular uptake were significantly altered. This series of studies not only 
demonstrated the efficiency and versatility of protein-based nanoparticles as 
bioavailability enhancers but also shed some light on the mechanisms for the 
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Chapter 1 Introduction 
1.1 Background of nano-encapsulation 
Nano-encapsulation has been extensively studied as an effective approach for 
enhancing the bioavailability of poorly absorbed nutraceuticals or drugs [1, 2]. 
This technique takes advantage of the ability of a polymer or multiple layers of 
polymers that assemble spontaneously into nano-scale matrices in the presence of 
certain stimuli (e.g., pH, organic solvent, temperature, electrolytes). The target 
compounds being encapsulated are either insoluble or unstable in the freestanding 
from. They associate with the polymeric matrix through various interactions, such 
as electrostatic attraction, hydrophobic interaction, hydrogen bonding, and van der 
Waals force. A broad range of food and pharmaceutical compounds, from natural 
colorant to anti-cancer drugs, from vitamins to antimicrobial agents, have been 
encapsulated into polymeric nanoparticles. By carefully selecting the matrix 
composition and fine-tuning the environmental parameters, one could prepare 
bioactive compound-loaded particles with an average size of 50-500 nm, together 
with narrow size distribution and desirable dispersion stability. These nano-scaled 
systems provided the compounds with numerous benefits, such as improved water 
solubility, increased resistance against chemical degradation, better absorption in 
human body, prolonged circulation, controlled release, elevated cellular uptake 
and target-specific delivery.  
1 
 
1.2 Key factors for successful encapsulation and delivery 
1.2.1 Loading capacity (LC) 
LC is the mass ratio between the encapsulated compound and the polymeric 
matrix, and it indicates the efficiency of the delivery system. LC is dependent on 
the type and strength of association between the compound and the matrix [3]. In 
general, charged compounds interact strongly with oppositely charged polymers 
via electrostatic attraction [1], and hydrophobic chemicals tend to associate with 
the core region of the encapsulant through hydrophobic interaction [2]. It is also 
important to note that these interactions are significantly influenced by 
environmental factors, such as pH, ionic strength, and temperature [4]. Therefore, 
for each compound of interest, it is essential to choose an (or a combination of) 
appropriate encapsulant(s) and suitable particle forming conditions that provide 
sufficient core-shell association. These considerations are crucial for achieving 
desirable loading capacity for a specific compound in a physiologically relevant 
environment. 
1.2.2 Dispersion stability 
The stability of a colloidal system (e.g., an aqueous dispersion of nanoparticles) is 
governed by the attraction and repulsion between colloidal particles, and it is vital 
for the bioabsorption of the target compounds. Attractive forces include hydrogen 
bonding, van der Waals interaction, hydrophobic association, and electrostatic 
attraction, while the repulsive interaction arises from the electrostatic repulsion 
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and steric hindrance between particles. Zeta potential gauges the electric charge at 
the boundary of a colloidal particle, and it is an important index for its surface 
charge. Zeta potential determines the electrostatic repulsion among them and is 
accountable for their stability against precipitation, and it is usually obtained by 
measuring and converting from the electrophoretic mobility of the particles. As 
recommended by American Society for Testing and Materials (ASTM), zeta 
potentials with an absolute value of higher than 30 mV are indicative for 
“moderate to good” stability of colloidal systems [5].The higher the zeta potential, 
the better the stability of a dispersion. A desirable zeta potential could be obtained 
by choosing highly charged polymers (e.g., soy protein or chitosan) as an 
encapsulant. On the other hand, when poorly charged materials (e.g., zein) are 
employed for encapsulation, a second layer of highly charged polymers may be 
introduced to improve the dispersion stability [6-8]. 
1.2.3 Controlled release 
When the encapsulated compound is consumed via the oral route, it enters the 
digestive system and needs to be delivered in a controllable manner. The term 
“controlled release” indicates (1) timed release of entrapped compounds or (2) 
delivery of the compound at designated regions in the gastrointestinal (GI) tract. 
The former goal could be achieved in virtually all encapsulation systems because 
the core-shell association could delay the release of entrapped compounds. The 
latter feature is vital for elevating the bioavailability of orally administrated 
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compounds while lowering their side effects. For common nutraceuticals such as 
vitamins and polyphenols, they should be well protected against acidic 
degradation in the stomach and completely released in small intestine where 
absorption takes place [6]. This could be realized by choosing proper polymers 
that is indigestible by strong acids and pepsin in the stomach while being 
degradable in the intestinal environment. In some other applications, the 
encapsulated compounds should arrive intact at the wanted regions (such as colon) 
without significant loss in other tissues. This requires an encapsulant that resists 
both gastric and intestinal digestion and degrades only upon the exposure to a 
specific stimulus, such as pH and enzyme, at the target site. 
1.2.4 Mucoadhesion 
Upon arrival to the small intestine, the bioactive compounds traverse the intestinal 
lining before entering the systemic circulation. Mucin is a negatively charged 
glycoprotein secreted by the small intestine epithelia. It covers the intestinal wall 
densely as a gel-like layer and serves as the first barrier for incoming molecules or 
microorganisms [9]. Adhesion to mucin, known as mucoadhesion, is therefore 
essential for the bioavailability of nutraceuticals or drugs [10]. Mucoadhesion 
improvement could be achieved by encapsulating bioactive molecules in cationic 
polymer matrices, among which chitosan is the most popular choice [11, 12]. 
Anionic or neutral polymers such as sodium alginate and dextran derivatives, 
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respectively, also exhibit remarkable mucoadhesive properties, probably due to the 
extensive hydrogen bonding with the mucin layer [13].  
1.2.5 Circulation 
After entering the circulative system, it becomes important for the delivering 
vehicle to reside for sufficient time before the bioactive compounds are released 
and absorbed. However, as many types of vehicles are recognized by the immune 
system as invading substances, they are rapidly opsonized and cleared by the 
macrophages [14]. One of the common approaches to prolonged circulation is the 
surface modification by PEG, whose long polymeric chain prevents the binding of 
serum components by steric hindrance. Several other strategies have been 
developed, including modification with CD47 (a protein recruited by the human 
body to identify cells as “self”), modulation of mechanical properties, engineering 
particle morphology and hitchhiking on red blood cells [15].  
1.2.6 Cellular uptake 
The last step for the delivery is the uptake by target cells. For bioactives that do 
not require site-specific delivery, their cellular uptake could be improved by 
carefully tuning the surface properties of the delivery vehicles. For example, 
cationic vehicles exhibit higher affinity to most types of cells because of the 
abundance of negatively charged glycoprotein on cell membrane [16]. Delivery 
vehicles with higher surface hydrophobicity have also been revealed to permeate 
the cell membrane better, thus promoting cellular uptake [17, 18]. For compounds 
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that have effect on specific sites (e.g., tumors), they could be incorporated to a 
polymeric vehicle that is conjugated with target-specific ligands such as folic acid 
[19]. 
1.3 Protein-based nanoparticles as a delivery system 
Nanoparticles are nano-scale assemblies of inorganic or organic molecules. Their 
sub-micron size provides several advantages such as prolonged gastrointestinal 
residence, better tissue penetration and superior cellular uptake [20]. Proteins are 
amphiphilic polymers that possess well defined charged, hydrophilic (polar but 
non-charged) and hydrophobic domains [20, 21]. This character allows 
protein-based nanoparticles to associate strongly with various types of bioactive 
compounds, providing satisfactory encapsulating capacity. In addition, since 
proteins are natural biopolymers, protein nanoparticles exhibit satisfactory 
biodegradability and biocompatibility [22]. Depending on the nature of different 
proteins, various strategies have been developed to synthesize nanoparticles, 
including organic solvent desolvation, liquid-liquid dispersion, and ionic gelation. 
1.3.1 Protein nanoparticles prepared by organic solvent desolvation 
This method is applicable to proteins that are highly soluble in water whereas 
virtually insoluble in certain water-miscible organic solvents [23]. A wide variety 
of albumins (including bovine and human serum albumins) [3, 23] and globulins 
(such as soy proteins and BLG) [24, 25] have been employed to encapsulate 
hydrophobic compounds using this method. A typical protocol using this method 
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includes the following procedures. Protein is firstly dispersed in an aqueous buffer 
at a relatively high concentration (e.g., 50 mg/mL), while the compound of interest 
is dissolved in an organic solvent (e.g., ethanol or acetone). Then, the organic 
phase is introduced dropwise into the aqueous phase under vigorous stirring. This 
initiates the aggregation of protein molecules and allows the interaction between 
the protein and the target compound. When a desirable concentration of organic 
solvent (usually higher than 80%) is achieved, the mixture turns from a clear 
solution into an opaque colloidal dispersion, indicating the extensive formation of 
nanoparticles. Trace amount of crosslinker (e.g., glutaraldehyde or genipin) is 
introduced at this point to harden the structure of particles via chemical bonds. 
After several hours of reaction, the dispersion is subjected to evaporation under 
reduced pressure to remove the organic solvents. During this process, the 
nanoparticles are able to maintain their structure owing to the crosslinking 
procedure. In the meantime, the interaction between the hydrophobic compound 
and the hydrophobic sites on protein molecules is enhanced because of the 
increase in both solvent polarity and protein (and bioactive compound) 
concentration. Lastly, water is supplemented to the mixture to replace the 
evaporated solvents (optional). Further purification steps including gel filtration, 
dialysis, and ultracentrifugation could be taken, but they are not necessary. 
Optimal particle size (100-200 nm) and LC (5-10%, weight ratio) could be 
obtained by tuning the concentrations of protein, compound of interest, organic 
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solvent, and crosslinkers [23]. Other parameters such as pH and ionic strength also 
play an important role in the encapsulation process [26]. Nanoparticles prepared 
through this approach exhibit desirable dispersion stability due to the high 
solubility of the protein chosen, and they are also stable against dissociation upon 
dilution or in the presence of salts. The major challenge for this method lies in the 
relatively low loading capacity, because the content of hydrophobic sites of 
globulins and albumins are significantly lower than that of more hydrophobic 
proteins, such as prolamines [27, 28]. In addition, the application of toxic 
crosslinker (glutaraldehyde) leads to the concern on the safety of these 
nanoparticles. 
1.3.2 Protein nanoparticles prepared by liquid-liquid dispersion 
Liquid-liquid dispersion is a simple yet effective way to synthesize nanoparticles 
with water insoluble prolamines [29, 30], such as zein (the major protein from 
maize). These proteins show unique solubility that they could only dissolve in a 
water-alcohol system with a limited range of mixing ratio. Due to the hydrophobic 
nature of these proteins, this approach is suitable for encapsulating hydrophobic 
compounds. In a typical liquid-liquid dispersion process, the protein and target 
compound are co-suspended in a binary system containing more than 70% alcohol 
(e.g., ethanol). After a short period (about 30 min) of equilibrium, the organic 
phase is poured into a large amount of aqueous buffer under vigorous stirring to 
achieve an alcohol: water ratio of approximately 15:85. The burst in solvent 
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polarity drives extensive protein-protein and protein-compound association 
through hydrophobic interaction, in order to compensate the sudden decrease in 
systemic entropy. Such interaction results in the entrapment of bioactive 
compounds into of a considerable number of nanoparticles. Satisfactory particle 
size of 100-200 nm and loading capacity of typically 10-20% could be achieved 
by adjusting the composition of the organic phase, i.e., alcohol content, protein 
concentration, protein/compound ratio, etc. An additional evaporation step can be 
taken to remove residual alcohol. The greatest advantages of this method are the 
simplicity of operation and the absence of toxic crosslinking reagents. The formed 
particles maintain the original morphology upon dilution, but they are susceptible 
to precipitation in the presence of salt. In addition, the dispersion stability of these 
nanoparticles is not as ideal as that of albumin or globulin nanoparticles because 
of the lack of hydrophilic and charged amino acid residues [31]. To overcome this 
weakness, a bilayer nanoparticle system containing a protein emulsifier (e.g., 
sodium caseinate) and a water-insoluble protein (e.g., zein) has been developed 
[32, 33]. The idea was to disperse the organic phase in an aqueous solution of the 
emulsifier. The mixing of the two dispersions induces the encapsulation of zein, 
together with the hydrophobic compound, in a more hydrophilic layer comprising 
mainly sodium caseinate. The resultant nanoparticle suspension exhibits desirable 
dispersion stability owing to the high zeta potential, and it is resistant against 
precipitation at a salt concentration of 1.5M [34]. The introduction of a second 
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layer, however, has a negative effect on the LC, considering that the total weight 
of encapsulant is significantly increased [32, 33]. 
1.3.3 Protein nanoparticles prepared by ionic gelation 
Ionic gelation, also known as cold gelation, is especially effective in incorporating 
charged nutraceuticals or drugs into a polymeric matrix. It is applicable to not only 
charged proteins (albumins or globulins) [25] but also polysaccharides such as 
chitosan and its derivatives [35, 36]. In this procedure, the protein is firstly 
solubilized in an aqueous buffer at pre-determined pH to ensure sufficient surface 
charge on the protein molecules. Another aqueous solution of a similarly (or 
oppositely) charged target compound is then introduced into the protein dispersion 
under mild stirring. After a brief period of equilibrium (around 30 min), a 
chemical reagent bearing multiple opposite electric charges is dripped slowly into 
the abovementioned dispersion. The added chemicals contain multivalent ions 
such as calcium (Ca2+) and tripolyphosphate (TPP, P3O105-), which could act as an 
ionic bridge between the proteins through strong electrostatic attraction. An 
opaque aqueous dispersion of nanoparticles is formed in less than 30 min, which 
could be then separated from excessive salts and non-incorporated compound via 
centrifugation, dialysis or gel filtration. Particles with satisfactory size (around 
200 nm) and LC (typically 20-50%) could be formed by carefully tuning the pH 
and salt concentration, both of which have a significant impact on the surface 
charge of the polymer [37]. This method is highlighted for its simplicity and the 
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exemption from chemical crosslinking procedure. While it is more suitable for 
encapsulating charged molecules (e.g., water-soluble vitamins and peptides), it has 
also been widely applied to incorporate hydrophobic compounds The major 
shortcoming of this method is the dissociation of nanoparticles upon pH 
fluctuation, dilution or high salt concentrations, since all of these factors could 
disrupt the electrostatic interaction. In addition, since two oppositely charged 
molecules are mixed in this method, the prepared nanoparticles usually exhibit 
relatively low surface charge, which is unfavorable for their dispersion stability in 
the long term [38]. This problem could be overcome by adding stabilizers (such as 
Tween 20 or Pluronic® F-68) or using diluted product [39-41]. Lastly, in spite of 
the claimed high loading capacity, it was found that a considerable part of the 
“encapsulated” compound might be loosely bound at the perimeter of the 
polymeric matrix, rather than being embedded inside the nanoparticles. This 
hypothesis has been supported by FT-IR and X-ray diffraction study in many 
articles [35, 37, 40, 41]. Therefore, the protection to the incorporated compound 
by the nanoparticles may be limited. 
1.3.4 Advantages and disadvantages of protein-based nanoparticles 
As is discussed above, protein-based nanoparticles exhibit several significant 
advantages over polysaccharide- or synthetic polymer-based systems. Protein 
nanoparticles are capable to encapsulate different types of compounds-charged, 
polar or hydrophobic, owing to the variety of amino acid residues in the protein 
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molecules. Compared to polysaccharide nanoparticles that are mostly formed via 
ionic gelation, protein nanoparticles can be formed via several types of techniques, 
each of which endows them with desirable stability under different conditions. In 
comparison with nanoparticles formed with synthetic polymers (such as 
poly-lactic-co-glycolic-acid), protein-based systems exhibit superior 
biodegradability and lower toxicity. Lastly, the abundance of function groups on 
proteins (amino group, thiol group, etc.) allows further surface modification [42, 
43], which could confer protein nanoparticles with more attractive attributes, such 
as target-specific delivery, prolonged circulation, and enhanced mucoadhesive 
properties.  
Despite the abovementioned merits, several drawbacks limit the application of 
protein-based nanoparticles in food and pharmaceutical industry. One of the major 
problems is the susceptibility to degradation by the digestive system [44, 45]. Like 
the constituent molecules, most protein-based nanoparticles are digested rapidly in 
the stomach by pepsin [46]. As a result, the embedded compounds are left 
unprotected before they reach small intestine, where the majority of absorption 
process takes place. Therefore, most protein-based nanoparticle formulas are only 
suitable for injection and cannot work for oral administration. Another 
shortcoming lies in the complexity of protein molecules [47]. Synthetic polymers 
consist of only one or two repeating units, and they can aggregate into 
nanoparticles with preset diameters and narrow size distribution in a quite 
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controllable manner [14, 41, 48]. In contrast, proteins are rather delicate 
macromolecules comprising well-defined secondary structures that are assembled 
with twenty different amino acids. Therefore, protein-based nanoparticle systems 
tend to exhibit a relatively wide size distribution, and the sizes are more easily 
changed upon environmental fluctuation. The subtle structure of protein also 
indicates the potential instability of protein nanoparticles against heat or other 
harsh treatments [49]. To avoid protein denaturation during food processing, 
non-thermal treatment may be required to replace traditional sterilization methods, 
which may add to the cost of industrial production. Finally, a number of proteins 
(e.g., soy protein and whey protein) exhibit significant allergenicity, which should 
also be taken into account when preparing protein-based delivery systems. 
1.4 Protein-polysaccharide complex nanoparticles for controlled release 
To take advantage of the merits of protein-based nanoparticles while overcoming 
their drawbacks, a series of complex nanoparticles containing both proteins and 
polysaccharides have been developed in the past decades [6, 34, 46, 50, 51]. Two 
methods, liquid-liquid dispersion and ionic gelation, are employed to prepare these 
nanoparticles. The first method [32, 51] starts with the dissolvation of protein 
(usually zein) and the target compound in aqueous alcohol, which is similar to the 
procedure introduced in Section 1.4.2. Thereafter, the organic phase is poured into 
an aqueous solution of a charged polysaccharide (e.g., chitosan) instead of pure 
water. In order to obtain stable complex nanoparticles, an ionic crosslinker (TPP 
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and CaCl2 for cationic and anionic polymers, respectively) is added dropwise to 
the mixture. After a brief equilibrium phase, nanoparticles consisting presumably 
of a polysaccharide shell and a hydrophobic protein core are formed spontaneously. 
Nanoparticles prepared through this approach are highlighted for the following 
merits: (1) desirable dispersion stability due to high surface charge; (2) increased 
loading capacity because of the involvement of both polysaccharides and proteins 
in the encapsulation; and (3) protection against peptic digestion in the stomach, 
leading to satisfactory controlled release properties. The chief shortcoming of this 
method may be the poor solubility in salt solutions, probably due to the 
deprivation of surface charge together with the salting-out effect on zein. 
The second method utilizes a protein and a polysaccharide that are oppositely 
charged at a certain pH and ionic strength [46, 52]. Since most water-soluble 
proteins are negatively charged at neutral pH, cationic polysaccharides such as 
chitosan are frequently selected to provide desirable electrostatic attraction. In a 
procedure for preparing chitosan-β-lactoglobulin (CS-BLG) complex 
nanoparticles, CS was firstly solubilized in acetic acid and added dropwise to an 
aqueous solution of BLG. Nanoparticles with an average size of 100-200 nm were 
formed spontaneous under mild stirring. Ionic crosslinkers such as TPP was then 
added to harden the particulate structure. The sign and magnitude of the surface 
charge on the formed nanoparticles could be engineered by varying the mixing 
ratio of CS and BLG, as well as the pH of the solution. The formed nanoparticles 
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might possess significant resistance to peptic digestion and achieve controlled 
release due to the low digestibility of both ingredients, although this was not tested 
by the authors. The major downside of this formula may be the poor solubility of 
CS at neutral or basic pH [39]. This causes the low dispersion stability of CS-BLG 
nanoparticles in physiologically relevant systems and limits their application 
severely. 
1.5 Protein modification for enhanced encapsulation capacity 
As stated before, protein molecules possess ample functional groups such as 
hydroxyl groups (-OH), amino groups (-NH2) and thiol groups (-SH). These 
groups are frequently exploited for chemical modification that provides the protein 
with desirable properties, such as site-specific delivery, enhanced mucoadhesion, 
and prolonged clearance time, all of which contribute to increased bioavailability. 
When it comes to nano-encapsulation, the merits of the modified proteins can be 
conveyed to the nanoparticles. In this section, two protein modification methods, 
folic acid conjugation and cationization, are discussed in context with their 
potential in bioavailability enhancement. 
1.5.1 Folic acid conjugation 
Folic acid (FA, structure shown in Figure 1.1) is an essential micronutrient 
that plays a key role in DNA synthesis and cell differentiation [53]. The cell 
accumulation of FA is achieved mainly through two types or proteins, namely, 
15 
 
reduced folate carrier (RFC) and folic acid receptor proteins (FRps). RFC 
mediates the transmembrane transport of FA. It exhibits an FA dissociation 
constant (Kd) in the range of μM, and it is expressed ubiquitously in human body 
[54]. FRps, on the other hand, bind to FA with much higher affinity (Kd in the 
range of 0.1-1 nM), but their expression is highly restricted in normal cells [19]. 
At least four forms of FRps, namely, FR-α (FOLR1) and FR-β (FOLR2), FR-γ 
(FOLR3) and FR-δ (FOLR4), have been identified by now [55]. FR-α and FR-β 
are glycosyl-phosphatidylinositol anchored glycoproteins, and they are the most 
abundant forms of FRps in human body. Elevated expression of FR-α was 
reported in a variety of carcinomas, including ovarian, prostate, breast, colon and 
lung cancer cells, resulting in a significantly increased affinity to FA in 
comparison with normal cells. For example, the FA binding capacity of fibroblast 
and CHO (human ovary) cells were less than 0.1 pmol per 106 cells, while it was 
found to be 20 and 50-200 pmol/106 cells in Caco-2 and KB cells, respectively 
[39]. Likewise, FR-β is amplified in 70% of acute myelogenous leukemias (AML) 
as well as activated macrophages associated with rheumatoid arthritis and other 
chronic inflammatory diseases [56]. The overexpression of FRps by cancer cells, 
together with the fact that FRps exhibit >103 fold higher affinity to FA than RFC, 
enables cancer cells or macrophages to accumulate FA at a remarkably higher rate 




Figure 1.1 Chemical structure of folic acid (FA) 
To take advantage of specificity toward FA, various polymers including 
chitosan [57], human serum albumin [58], bovine serum albumin [56] and 
polylysine [59] have been conjugated with FA and used as carriers for anti-cancer 
drugs. The conjugation utilizes the primary amino group present in these 
molecules, which act as a nucleophile and attack the carbon atom on the 
α-carboxyl group of FA. To aid the coupling reaction, a co-reactant such as EDC 
(1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide) is premixed with FA to 
activate its carboxyl group. The reaction is typically finished within 2 hours at 
room temperature for proteins and peptides. Excessive reactants can be easily 
removed by dialysis or gel filtration. It has been shown that conjugation of one FA 
molecule to a protein molecule is sufficient to yield a considerable enhancement in 
protein uptake by Caco-2 and KB cells. Owing to the simplicity and efficacy of FA 
conjugation, it has found application in areas such as immunotherapy, 
chemotherapeutics and therapeutic imaging [19, 53]. 











As mentioned in Sections 1.3.4 and 1.3.6, cationic polymers show high 
affinity to two important anionic molecules, the mucin on the small intestine wall 
and the glycoprotein on the cell membrane. Such affinity enhancement leads to 
significantly improved in bioavailability. However, most natural proteins possess 
negative net charges at neutral or basic pH due to their amino acid composition. 
Cationic polysaccharides such as chitosan and its several derivatives are employed 
to develop mucoadhesive materials [60]. However, chitosan loses its positive 
charges and becomes insoluble in water at pH higher than 6.2, the pKa of its 
amino groups [21]. This character makes its claimed mucoadhesive capability 
questionable at neutral pH. Cationized proteins, on the other hand, retain their 
positive charge (pKa ~ 12.5 and 10.5 for arginine and lysine side chains, 
respectively) and thus exhibit desirable water solubility at a wide range of pH [16]. 
This feature makes them attractive candidates for the encapsulation of 
nutraceuticals or drugs. 
The cationization process of protein is illustrated in Figure 1.2. Common 
cationizing reagents include diamines such as ethylenediamine (EDA) and 
polyamines such as polyethyleneimine (PEI). They usually possess two or more 
amine groups. One of the amine groups reacts with the carboxylic groups on the 
aspartic acid or glutamic acid residues, neutralizing their negative charge and 
forming an amide bond. The other amine groups remain intact and exhibit 
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different amount of positive charges depending on the type of cationizer. Ionic 
crosslinking is observed when more than one amine group of a same cationizer 
molecule react with one protein molecule, but such reaction can be prevented by 
providing a large excess of cationizing reagent [61]. The product can be further 
purified with dialysis, gel filtration or ion exchange chromatography. Several 
proteins, including bovine serum albumin and BLG, have been studied for 
cationization. These cationic proteins exhibited a prominent shift in their 
isoelectric points from pH~5 to pH~9.0, together with a reversal in the sign of 
their surface charges at neutral pH. Significant changes in the physicochemical 
and functional properties as well as transmembrane delivery were observed on 





Figure 1.2 Illustration for protein cationization process.  
The upper panel shows a simplified chemical reaction for cationization with EDA. 
Both aspartic acid and glutamic acid residues were appropriate substrates. The net charge 
of each residue was altered by +2 (from -1 to +1) upon cationization. R or R’ was adjacent 
peptide chains. The lower part displays the different molecules that could be employed for 
protein cationization. 
1.6 Protein of choice as nanoparticle formers 
1.6.1 Soy proteins 
Soybean (Glycine max L.) is currently one of the most abundant sources of 
plant proteins [49]. The enriched form of soy protein, known as soy protein isolate 
(SPI), has been reported to exhibit high nutritional values and desirable 
functionalities, and its wide application as a food ingredient has been well 
documented [24, 25, 49, 64, 65]. The major components of SPI (shown in Figure 
1.3) are glycinin (MW=360,000, approximately 60%) and β-conglycinin 
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(MW=180,000, approximately 40%) [66]. SPI is unique in its high content (>60%, 
molar ratio) of hydrophobic amino acids, together with a considerable percentage 
of charged residues [27]. The first property enables a strong hydrophobic 
interaction with encapsulated compounds. The latter feature does not only lead to 
desirable water solubility but also facilitates the protein-drug interaction through 
electrostatic attraction or hydrogen bonding. In aqueous environment, SPI exist 
majorly as globular molecules consisting of a hydrophilic shell and a hydrophobic 
kernel, together with a certain amount of small water-soluble aggregates. Upon the 
addition of anti-solvent or crosslinking agents, SPI molecules aggregate into 
various structures, such as microspheres, hydrogels and polymer blends [64, 67, 
68].  
 




1.6.2 β-lactoglobulin (BLG) 
 
Figure 1.4 Structure of BLG 
Figures 4a and 4b depict the abundance of rigid β-sheet structures. Figures 4c and 4d 
illustrate the ligand-binding sites existing in a native BLG molecule. 
BLG (Figure 1.4), a 162-residue globular protein, makes up approximately 
60% of bovine whey protein (72, 73). Commercially available BLG products 
contain two variants, namely, BLG variant A and B, which differ in only two 
amino acid residues (74). BLG possesses high water solubility even near its 
isoelectric point, and it contains well-defined patches for binding lipophilic 
compounds. These unique properties make BLG a natural carrier for various 
nutrients, such as vitamins and fatty acids (50). Furthermore, BLG demonstrated a 
significant resistance to peptic digestion due to its compactly folded conformation 
originated from the abundance of rigid β-sheet structures. On the other hand, it is 
much more readily degraded by trypsin in small intestine (75). These characters 
provide BLG-based delivery systems with desirable controlled release property. 
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By far, various encapsulating systems have been developed with BLG, including 
microemulsions (76), nanoparticles (74) and nanocomplexes (77). These 
techniques demonstrated satisfactory protection to the entrapped compounds. 
1.7 Compounds to be encapsulated 
1.7.1 Curcumin 
Curcumin or diferuloylmethane (Figure 1.5) is a yellow polyphenolic dye 
that is enriched in the extract from turmeric (Curcuma longa), a plant grown in 
tropical Southeast Asia [69]. It was firstly employed as a natural colorant in food 
and beverages [70]. Recently, curcumin has been reported to induce cell cycle 
arrest and/or apoptosis in a number of human cancer cell lines, including 
colorectal, lung, breast, pancreatic and prostate carcinoma, etc. [71]. These 
findings suggested the potential of curcumin in cancer therapy. In addition, several 
studies on experimental (chemical) carcinogenesis models have revealed that 
curcumin can also ameliorate the progression to cancer in a variety of organ sites, 
indicating the potential of this compound as a chemopreventive agent [72]. 
Furthermore, curcumin has been found to possess a wide range of other beneficial 
properties, including anti-inflammatory, antioxidant, and antimicrobial effects [70]. 
Despite these merits, the stability and solubility of curcumin remains a hurdle of 
its application. Curcumin has very low solubility (several micrograms per liter) in 
water, resulting in agglomeration and therefore a significant decrease in its 
bioavailability [35]. More importantly, it becomes less chemically stable as the 
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systematic pH increases to neutral or basic values. Study showed that more than 
90% of curcumin degraded into ferulic acid, feruloylmethane and vanillin at 37 oC 
in PBS (phosphate buffered saline, 0.1 M, pH 7.2) within 30 min [73]. Besides, 
light irradiation also causes the generation of curcumin-derived radicals, which 
leads to the condensation of curcumin [74].  
 
Figure 1.5 Chemical structure of curcumin 
To address these issues of curcumin, a broad variety of encapsulation 
methods have been developed, employing proteins, synthetic polymers or 
surfactants as a protectant [32, 35, 72, 75]. While these methods promoted the 
solubility of curcumin and prevented its degradation, they suffered from several 
drawbacks such as unsatisfactory LC and the utilization of non-biodegradable 
materials. These shortcomings necessitate the development of innovative 
encapsulating systems for curcumin. Another reason for choosing curcumin as a 
target compound is the abundance of data on its encapsulation, together with the 
convenience of its quantification. Based on these considerations, curcumin was 
chosen as a model drug in our study that may provide reliable result for evaluating 
the encapsulating performance of newly developed nanoparticle systems.  
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1.7.2 Vitamin D 
Vitamin D (VD, Figure 1.6) is a fat soluble vitamin consisting of two 
major physiologically active forms, namely, vitamin D2 (ergocalciferol) (VD2) 
and vitamin D3 (cholecalciferol) (VD3). The latter one has been reported as a more 
effective form of VD [76]. The functions of VD include not only calcium 
absorption and homeostasis regulation, but also the prevention of a range of 
chronic diseases, such as type 2 diabetes, hypertension, cardiovascular disease, etc. 
[77]. Despite its importance, insufficient serum level of VD has been reported 
frequently in the US and Europe, where 30-60% populations have been diagnosed 
recently with VD deficiency [78]. As a result, the Food and Drug Administration 
has taken measures to encourage the fortification of VD to milk and cereals. In 
addition, the recommended daily allowance of VD in Dietary Guideline for 
Americans released by United States Department of Agriculture in 2010 has been 
raised to 600 IU per day for children and 800 IU per day for adults [79].  
In addition to the amount of VD present in foods, the bioavailability of VD 
has also attracted extensive attention. VD as a hydrophobic vitamin exhibits very 
low solubility in water and is susceptible to degradation upon light or heat 
exposure [80]. These properties have a significantly negative effect on the 
absorption and utilization of fortified VD. As a result, various micro- and 
nano-encapsulation systems have been developed to protect and deliver VD. 
Several examples include β-cyclodextrin micelles [81], ethylcellulose/chitosan 
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microspheres [82], casein microparticles [83], and zein/carboxymethyl chitosan 
nanoparticles [51]. However, the application of these methods in food industry is 
impeded by several drawbacks, such as the involvement of harsh thermal 
treatment, existence of toxic organic solvent, low loading capacity, and 
precipitation in the presence of salts. A novel, industrially facile method of 
encapsulation is hence needed to solve these problems and boost the VD level 
among world population. 
 
Figure 1.6 Chemical structure of VD2 (left) and VD3 (right) 
1.8 Research goals 
This dissertation is focused on the fabrication, characterization, and application of 
food protein-based nanoparticles as effective encapsulants. Two food-based 
proteins, SPI and BLG, will be studied systematically for the first time for the 
particle formation and surface modification process. The physicochemical 
structure, encapsulating capacity, and release/delivery performance will be 
investigated. The ultimate goal of this work is to prepare protein nanoparticles that 
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inherit the merits introduced in Section 1.3.4, while overcoming those 
disadvantages. Several objectives are proposed below. 
Preparation and characterization of protein-based nanoparticles. SPI and 
BLG will be investigated for their particle forming behaviors by two methods, 
namely, ionic gelation and organic solvent desolvation. Particles with desirable 
sizes, stabilities, and encapsulation capacities were obtained by adjusting 
parameters such as pH, organic solvent content, protein concentration, and 
crosslinking time. The possible mechanism involved at each stage of nanoparticle 
formation was systematically investigated by a series of techniques including 
dynamic light scattering (DLS), ζ-potential measurement, Fourier-transform 
infrared spectroscopy (FT-IR), X-ray diffraction (XRD), and scanning electron 
microscopy (SEM). Curcumin as a model compound was encapsulated into the 
as-prepared nanoparticles. The encapsulation efficiency and releasing profile of 
the nutraceutical-incorporated nanoparticles were systematically evaluated.  
Surface modified nanoparticles as advanced delivery vehicles. Based on the 
synthesized nanoparticle platforms, different surface modification methods were 
employed to confer the nanoparticles with new properties. Folic acid was 
conjugated to soy protein nanoparticles to provide target-specific delivery in 
tumor cells. Cationization (the process of rendering a molecule positively charged) 
was performed to promote the bioavailability of encapsulated compounds by 
enhancing mucoadhesion and cellular uptake. The effect of chemical modification 
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on the structural properties, digestibility, dispersion stability, particle forming 
behaviors, mucoadhesive properties, and encapsulating efficiency was assessed 
using different techniques. Besides, the cytotoxicity and cellular uptake of the 
target compounds encapsulated in modified protein nanoparticles were assessed 
using cell culture assays.  
Protein-polysaccharide complex nanoparticles as nutraceutical/drug carriers 
with controlled release properties. To overcome the rapid digestion of proteins 
in the stomach, polysaccharides such as carboxymethyl chitosan were utilized as a 
second coating layer via ionic gelation. The polysaccharide was expected to 
protect protein nanoparticles from peptic digestion, thus maximizing the 




Chapter 2 Preparation, Characterization, and Application of 
Nanoparticles Synthesized from Soy Protein 
2.1 Abstract 
Nanoparticles were synthesized from soy protein, one of the most abundant and 
widely utilized plant proteins, for the encapsulation of nutraceuticals and drugs. 
The preparation process consisted of dispersion, desolvation, drug incorporation, 
crosslinking and evaporation. The role of each procedure in the formation of 
nanoparticles was systematically investigated by means of particle size, size 
distribution, zeta potential, and as morphology observation. Curcumin as a model 
compound was encapsulated successfully into the nanoparticles, evidenced by 
Fourier transform infrared spectroscopy and X-ray diffraction. The average size of 
the curcumin-loaded nanoparticles was 220.1 to 286.7 nm, and their zeta potential 
was around -36 mV. The highest encapsulation efficiency and loading capacity 
achieved were 97.2% and 2.7%, respectively. The release of curcumin in 
phosphate buffer saline followed a biphasic pattern. Possible mechanisms of the 
formation of soy protein nanoparticles as well as the incorporation of curcumin 
were discussed based on the data obtained from this study. 
2.2 Introduction 
Biopolymer-based nanoparticles have gained increasing interest as delivering 
systems for drug and nutraceuticals in the past few decades [1, 22, 84]. Their 
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sub-cellular size provides several advantages such as prolonged gastrointestinal 
residence [2], better tissue penetration and superior cellular uptake [85]. Besides, 
they exhibit low toxicity owing to their biodegradability and non-antigenic 
property [23]. Proteins as amphiphilic biopolymers are deemed as ideal materials 
for preparing nanoparticles because they interact well with both the drug and 
solvent [84]. By far, drug-loaded nanoparticles have been synthesized successfully 
from various proteins [23, 30, 84, 86], including both water-soluble (bovine or 
human serum albumin) and insoluble proteins (zein, gliadin, etc.). These 
nano-scaled systems exhibited various advantages, such as improved solubility, 
controlled release property and enhanced bioavailability of encapsulated 
nutraceuticals. However, several limitations hindered their applications in 
pharmaceutical and food industry. For instance, albumins contain a relatively low 
content of hydrophobic amino acids, and they incorporate drugs majorly via 
electrostatic attraction or hydrogen bonds [58, 87]. Therefore, they are less 
capable in encapsulating highly hydrophobic drugs which are minimally charged 
and form few hydrogen bonds. On the other hand, nanoparticles prepared with 
zein or gliadin performed satisfyingly in incorporating hydrophobic chemicals [86, 
88], but their low content in hydrophilic and charged amino acids resulted in a 
limited solubility in aqueous environment, unless a considerable amount of 
polysaccharides or surfactants was added [32, 88].  
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Soybean (Glycine max L.) is currently one of the most abundant sources of plant 
proteins. The enriched form of soy protein, known as soy protein isolate (SPI), has 
been reported to exhibit high nutritional values and desirable functionalities, and 
its wide application as a food ingredient has been well documented [27, 67, 89]. 
Besides, SPI possesses a balanced composition of non-polar, polar and charged 
amino acids [27], thus being able to incorporate drugs with its various functional 
groups. The major components of SPI were glycinin (MW=360,000, approximate 
60%) and β-conglycinin (MW=180,000, approximate 40%) [66]. In aqueous 
environment, these components exist majorly as globular molecules consisting of 
a hydrophilic shell and a hydrophobic kernel, together with a certain amount of 
small water-soluble aggregates [26, 90]. Upon the addition of antisolvent or 
crosslinking agents, SPI molecules continue to aggregate and form various 
structures, such as microspheres [24], hydrogels [89] and polymer blends [64, 67]. 
However, to the best of our knowledge, there has been no systematic report by 
now on the fabrication of nanoparticles with SPI.  
In this study, nanoparticles were synthesized with SPI using a desolvation 
technique followed by glutaraldehyde crosslinking [23]. The nanoparticles were 
characterized by the particle size, size distribution, count rate, zeta potential, and 
morphology. The effects of each step of preparation (i.e., desolvation, crosslinking 
and evaporation) on the abovementioned parameters were investigated 
systematically. Curcumin (diferuloylmethane) was selected as a model drug for 
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evaluating the encapsulating property of SPI nanoparticles. The Fourier transform 
infrared (FT-IR) spectrum, X-ray diffraction (XRD) pattern, encapsulation 
efficiency, and releasing profile of the curcumin-loaded particles were measured. 
Finally, a possible mechanism of the formation of blank and curcumin-loaded SPI 
nanoparticles was proposed based on the data obtained in this study. 
2.3 Materials and Methods 
2.3.1 Materials 
ProliaTM 200/70 Defatted Soy Flour was a sample donated by Cargill Inc., Cedar 
Rapids, IA. The soy flour contained 54% protein (dry basis) and less than 1% oil. 
Curcumin (95% pure) was purchased from Sigma-Aldrich (St. Louis, MO, USA). 
All other chemicals (glutaraldehyde, Tween 20, phosphate buffer saline, etc.) were 
of analytical grade. 
2.3.2 Preparation of SPI 
SPI was prepared following an isoelectric precipitation method [91]. The defatted 
soy flour was suspended in 15-fold of deionized water with mild stirring, and the 
pH of the suspension was adjusted to 8.0 with 1 mol/L NaOH. After 1 h of 
extraction, the dispersion was centrifuged at 10,000 g for 15 min. The supernatant 
was acidified with 1 mol/L HCl to pH 4.5 and centrifuged under the same 
condition. The precipitate was re-dispersed in water, adjusted to pH 7.5 with 1 
mol/L NaOH, dialyzed against deionized water for 24 h and then lyophilized. The 
32 
 
moisture content of the final product was less than 5%, while the protein content 
was 90% as determined by Bradford assay using bovine serum albumin as the 
standard protein. 
2.3.3 Preparation of blank nanoparticles with SPI 
Nanoparticles were prepared with freshly prepared SPI following a desolvation 
method [23] with modifications. SPI was dissolved in deionized water at 
concentrations of 4 to 60 mg/mL and equilibrated for 1 h at room temperature. 
Desolvating agent (ethanol) was added dropwise into the dispersion. The 
concentrations of SPI and ethanol after mixing ranged from 4~12 mg/mL and 
0~80%, respectively. After 15 min of equilibration, glutaraldehyde (25 mg/mL 
aqueous solution) was added as a crosslinker. The amount of glutaraldehyde was 
calculated as below. The average molecular weight of SPI (288,000) was 
estimated based on its composition which was described in the introduction, while 
the lysine content of SPI was obtained from previous literature [27]. These values, 
together with the fact that one glutaraldehyde molecule reacted with two lysine 
residuals, gave the amount of glutaraldehyde required for stoichiometric 
crosslinking, which was 28 μg/mg SPI or 77 mol/mol SPI. This ratio was defined 
as 100% glutaraldehyde equivalent, and the amount of added glutaraldehyde 
ranged from 0% to 150% calculated based on this value in our study. The purpose 
of adding more than 100% equivalent of glutaraldehyde was to achieve a higher 
reaction rate [3, 23]. After 16 h of crosslinking reaction at room temperature, 
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threefold of aqueous ethanol was added to dilute the dispersion without changing 
its ethanol/water ratio. Thereafter, rotary evaporation was applied using a Buchi 
Rotavapor RII at 30℃ (BUCHI Labortechnik AG, Flawil, Switzerland) to remove 
ethanol, which was then replaced with same volume of deionized water. The 
resultant dispersion, containing less than 10% ethanol, was centrifuged at 10,000 g 
for 15 min to remove large aggregates. The percentage of protein in the 
supernatant was higher than 95%. The supernatant was either lyophilized or stored 
at 4 oC for subsequent assays. 
2.3.4 Preparation of curcumin-loaded SPI nanoparticles 
The encapsulation of curcumin into SPI nanoparticles was achieved as described 
below. Typically, SPI (60 mg/mL) was suspended in deionized water, while 
curcumin (3 mg/mL) was dissolved in ethanol as stock solution. After 1 h of 
equilibration, pure ethanol was added dropwise to the SPI dispersion to the 
concentration of approximately 60%. Curcumin stock solution was then added 
dropwise to attain a curcumin/SPI ratio of 1:20, 1:50 or 1:100 (w/w). Additional 
ethanol was introduced finally to achieve an ethanol/water ratio of 80:20 (v/v). 
The dispersion was then crosslinked, diluted, evaporated, re-diluted and 
centrifuged as described in the above section. The supernatant obtained after 
centrifugation was stored at 4 oC for subsequent analyses. 
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2.3.5 Determination of particle sizes and count rates 
The dispersions of both empty and curcumin-loaded SPI nanoparticles were 
analyzed at different preparation stages. The particle size as well as the count rate 
was determined by dynamic laser scattering (DLS) using a BI-200 SM 
Goniometer Version 2 (Brookhaven Instrument Corp., Holtsville, New York, USA) 
equipped with a 35 mW He-Ne laser beam at a wavelength of 637 nm and a 
scattering angle of 90° [23]. The z-average size and size distribution were 
calculated by using the BIC Dynamic Scattering Software (Brookhaven 
Instrument Corp., Holtsville, New York, USA) based on the intensity of the 
scattered light. The refractive index and viscosity of water/ethanol mixtures with 
different volume ratios were applied for obtaining accurate results. In order to 
obtain comparable count rates, the samples were not diluted, and the power of 
laser was fixed at 10 mW. All of the analyses were conducted at 25ºC for 1 min.  
2.3.6 Determination of zeta-potential of the nanoparticles 
During the preparation process, the nanoparticle dispersions were measured for 
their electrophoretic mobility by laser Doppler velocimetry using a Nano ZS90 
Zetasizer and compatible fold capillary cuvettes provided by Malvern Inc. 
(Malvern, UK). The electrophoretic mobility of each sample was measured three 
times, and at least twelve runs were performed in each measurement. The data 
were then converted to zeta potentials using the Smoluchowski model.  
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2.3.7 FT-IR study of the nanoparticles 
The blank and curcumin-loaded nanoparticles were lyophilized before FT-IR 
analysis. Each sample (3 mg) was loaded on a Jasco FT/IR 4100 spectrometer 
(Jasco inc., Easton, MD, USA). The infrared spectra were collected from the 
wavenumber of 700 to 4000 cm-1 at a resolution of 4 cm-1. Each sample was 
subjected to at least 60 repeated scans. The spectra were averaged and smoothed, 
and their baselines were calibrated with the Spectra Manager software (Jasco inc., 
Easton, MD, USA).  
2.3.8 X-ray diffraction (XRD) analysis 
The X-Ray diffraction (XRD) patterns of SPI, curcumin, their physical mixture 
(curcumin: SPI=1:40, w/w) and SPI-encapsulated curcumin were recorded on a 
Bruker D8-Advance Diffractometer (Bruker AXS Inc., Madison, WI) with 
backgroundless sample holders. The working parameters were: voltage of 40 kV, 
current 40 of mA, and scanning rate of 3 min-1. 
2.3.9 Scanning electronic microscopy (SEM) analysis 
SEM was performed to examine the morphological structure of empty and 
curcumin-loaded nanoparticles. Dispersions of particles were diluted with aqueous 
ethanol, so that the ethanol concentration was unchanged, while the protein 
concentration was approximately 0.5 mg/mL. Fifty microliters of the dispersion 
was cast-dried on an aluminum pan, which was cut into an appropriate size. The 
pan was adhered to a 1-inch specimen stub with conductive carbon tapes (Electron 
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Microscopy Sciences, Ft. Washington, PA). The stub was then coated with a thin 
layer (<20 nm) of conductive gold and platinum using a sputter coater (Hummer 
XP, Anatech, CA) before observation under SEM (Hitachi SU-70 Pleasanton, CA). 
Representative images were reported. 
2.3.10 Determination of encapsulation efficiency and loadingcapacity  
The encapsulation efficiency (EE), defined as the percentage of curcumin 
encapsulated in the suspended protein nanoparticles, was estimated as below. 
After the centrifugation mentioned in the nanoparticle preparation sections, both 
the precipitate and supernatant (defined as the ‘primary’ supernatant) were 
collected. The precipitate was extracted in 5 mL of ethanol with mild stirring for 5 
min, after which the suspension was centrifuged at 9,000 g and 20 oC for 5 min to 
remove protein aggregates. The resultant supernatant (defined as the ‘secondary’ 
supernatant’) was subjected to spectrophotometric analysis at 426 nm with a 
DU-730 UV/VIS spectrophotometer (Beckman Coulter Inc., Fullerton, CA). The 
absorbance was converted to curcumin concentration based on the established 
standard curve (R2=0.9991). Meanwhile, the primary supernatant was decanted 
into a Macrosep® centrifuge tube (Pall Corp., Ann Harbor, MI) with a built-in 
filtering membrane (MW cutoff = 10,000) with appropriate dilution [37]. After 
centrifugation at 5,000 g and 20 oC for 30 min, the free (non-encapsulated) 
curcumin permeated the membrane and was quantified spectrophotometrically. 
The EE of the samples were calculated with the equation:  
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EE (%) = 100 −   
Precipitated curcumin + Free curcumin
Total curcumin
 × 100 
On the other hand, the non-permeable part of the dispersion was collected and 
lyophilized. The mass of dry nanoparticles was measured, and the loading capacity 
(LC) was calculated as the mass ratio of entrapped curcumin to the nanoparticles.  
2.3.11 Release of curcumin in phosphate buffer saline (PBS) 
Five milligrams of lyophilized nanoparticles was weighed and dispersed in 10 mL 
of the release medium (PBS, pH 7.5 with 0.5% Tween 20). The dispersion was 
incubated at 37 oC with mild shaking on a Multi-Purpose Rotator/Rocker 
(Scientific Industries Inc., NY, USA) for 0.5 to 8 h. The mixture was centrifuged 
at 51,500 g and 20 oC for 15 min, after which over 90% of the nanoparticles were 
precipitated (preliminary data not shown). The supernatant containing released 
curcumin was analyzed spectrophotometrically as mentioned before, using a 
calibration curve established in curcumin/Tween 20/PBS system (R2=0.9993). The 
precipitate was disposed, and a fresh dispersion was then made for another 
measurement. The kinetic release profile of curcumin was plotted versus time. 
2.3.12 Statistics 
All measurements were performed in triplicates. The experimental results obtained 
were expressed as means ± standard error. Data were analyzed by analysis of 
variance (p < 0.05) using the Origin 7.5 software (OriginLab Corp., MA, USA). 
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2.4 Results and Discussion 
2.4.1 Effect of the desolvation process 
Figures 2.1 showed the particle size and zeta potential of SPI dispersions, 
respectively, as influenced by ethanol and protein concentrations. Neither 
glutaraldehyde addition nor centrifugation was undertaken at this stage. The 
z-average size of SPI dispersion in pure water was around 320 nm, which was in 
accordance with previous literatures [68, 92]. As the concentration of ethanol 
increased to 30-40% (depending on the final protein concentration), the particle 
sizes increased gradually before reaching a peak. This was probably because that 
high ethanol content favored the exposure and interaction of the hydrophobic 
chains in protein molecules, which led to the formation of aggregates [26, 93]. 
Similar behavior was reported in the study on human serum albumin (HSA) 
nanoparticles [23]. Besides, the peak particle size averaged at 606 nm and 862 nm 
at SPI concentrations of 4 mg/mL and 12 mg/mL, respectively. This difference 
might be attributed to the fact that higher protein concentration favored the 
collision and aggregation of protein molecules [94]. As the percentage of ethanol 
increased to 80%, the particle sizes decreased significantly, and smaller average 
particle sizes were observed at higher protein concentrations (Figure 2.1A). The 
decrease in average size at high ethanol concentrations was unexpected and has 
not been reported in previous literatures. It could be attributed to either breakdown 
of larger aggregates or the extensive formation of smaller ones. To elucidate the 
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behavior of soy protein at high ethanol levels, the size distribution and count rate 
of the dispersion were analyzed and presented as below. 
 
 
Figure 2.1 Effect of ethanol and protein concentrations on the size (A) and zeta potential 
(B) of SPI nanoparticles 
Data were presented as mean ± standard error (n=3) in this and following figures. 
Figures 2.2 showed the size distributions of two SPI dispersions at the same 
protein concentration (i.e., 8 mg/mL) but different ethanol percentages (i.e., 0% 
for Figure 2.2A and 80% for Figure 2.2B). Two groups, one corresponding to 
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small particles (50-200 nm, similarly hereinafter) and the other representing for 
large aggregates (500-1000 nm, similarly hereinafter), were observed in both 
diagrams. Compared with the SPI dispersed in pure water, the one in 80% aqueous 
ethanol exhibited a significantly higher percentage of small particles, as suggested 
by the peak areas. Further study revealed that this percentage increased gradually 
from 20% in pure water to 60% in 80% ethanol (Figure 2.2C), and the trend was 
the same at all protein concentrations investigated. Besides, the total number of 
particles could be estimated indirectly from the count rate, the cumulative light 
pulses of the sample over the duration of the DLS experiment [23]. The count rate 
is proportional to the concentration of particles, but it also varies as the sixth 
power of their size, according to the Rayleigh scattering theory. Assuming the 
particle numbers were equal, because the particle size of the SPI dispersion in 80% 
ethanol was approximately 33% of that with 40% ethanol (Figure 2.1A), the count 
rate of the former one should have been less than 0.15% (0.336) of that with the 
latter one. However, the count rate actually increased nearly threefold as the 
ethanol concentration increased from 40% to 80% (Table 1), which implied an 
extensive increase in the number of particles. Moreover, the turbidity of the 
dispersion increased significantly as the ethanol concentration increased from 40% 
to 80% (data not shown), which also suggested the existence of aggregates in large 
quantity [95, 96]. These results, combined with the size distribution, indicated a 
rapid increase in both the number and the percentage of small particles. In addition, 
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because of the overwhelming increase in the total number, the count of the large 
aggregates might also have increased, although not as rapidly as the small ones. 
As inferred from the above discussion, the apparently smaller particle sizes 
observed in 80% ethanol was probably due to the extensive formation of new 
particles, especially the small ones, rather than the breakdown of large aggregates. 
Table 2.1 Effect of ethanol on the count rate of SPI nanoparticle dispersion* 
EtOH% Count (kcps)** EtOH% Count (kcps) 
0 110±15e  50  200±13 cd 
10 120±10de 60  250±19 c 
20 140±20d 70  320±18 b 
30 165±13d 80  550±17 a 
40 140±16d   
* Data with different letters showed significant difference (n=3, P<0.05). 
** Kilo counts per second, a unit describing the total number of scattered photons. 
The zeta potential of SPI/ water dispersion ranged from -43.2 mV to -34.7 mV, 
depending on the protein concentrations (Figure 2.1B). The zeta potential 
decreased (in terms of magnitude, similarly hereinafter) with increasing ethanol 
concentration and reached a minimum value of -8.3 mV at 80% ethanol. This 
phenomenon was possibly due to the deprivation of water by ethanol that impaired 
the ionization of the charged groups in soy protein molecules [68]. It was 
noteworthy that the zeta potential continued decreasing as ethanol concentration 
increased from 40% to 80%. As a result, the electrostatic repulsion among protein 
molecules was weakened, thus promoting the formation of protein aggregates and 
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preventing their dissociation [26]. This was supportive for the above discussion on 




































































Figure 2.2 Size distributions of SPI nanoparticles. 
The protein concentration was 8 mg/mL. Particles were formed in (A) pure water or (B) 
80% ethanol. Figure 2.2C showed the effect of ethanol concentration on the percentage of 
the small particles 
2.4.2 Effect of crosslinking and evaporation procedures 
Glutaraldehyde is used widely to harden protein nanoparticles or hydrogels as it 
crosslinks the ε-amino groups of lysine residues [1, 22]. One treatment (8 mg/mL 
SPI desolvated by 80% ethanol) was chosen to be further crosslinked by 
glutaraldehyde, and the effect of crosslinking and evaporation step on the particle 
size, count rate, and zeta potential was summarized in Figures 2.3A, 2.3B, and 
2.3C, respectively. Similar results were observed at different protein and ethanol 
concentrations (data not shown). The sizes were measured after 16 h of 
crosslinking and were around 200-500 nm, generally higher than those observed 
immediately after the desolvation without crosslinking (Figure 2.1A). Before 
ethanol was evaporated, the particle size appeared independent on the 
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concentration of glutaraldehyde. Similar results were reported on HSA and 
legumin nanoparticles [23, 97]. Besides, the count rates did not change 
significantly at glutaraldehyde levels lower than 100% equivalent, but it increased 
by 50% at glutaraldehyde concentrations of 125% and 150% equivalent (Figure 
2.3B). Since the particles sizes exhibited no statistical difference, the increase in 
count rate indicated that more particles with the same size were formed [23].  
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Figure 2.3 Effect of glutaraldehyde on the size (A), count rate (B) and zeta potential (C) 
of soy protein nanoparticles after and before evaporation 
After the removal of ethanol via rotary evaporation, the particle size and count rate 
increased and decreased respectively at the glutaraldehyde concentrations ranging 
from 0% to 50% equivalent (Figures 2.3A and 2.3B). These values, as well as the 
size distribution (data not shown), were similar with those of the particles formed 
initially without ethanol. In Section 2.4.1, increased count rate and decreased 
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average size indicated the extensive formation of small nanoparticles upon the 
addition of ethanol. Similarly, the reversed change of these values after the 
removal of ethanol suggested that part of the particles might have dissociated. This 
might be related to the hydrophilic nature of soy proteins as explained in the 
introduction part. At glutaraldehyde levels higher than 75% equivalent, however, 
the particle sizes and count rates did not change significantly after evaporation. 
This indicated adequate hardening of the soy protein nanoparticles, which is vital 
for their stability and application in physiological systems [1]. When more than 
100% equivalent of glutaraldehyde was added, both the size and count rate 
increased significantly (P<0.05). Based on the result above, it could be inferred 
that at low concentration glutaraldehyde played a role in maintaining the size and 
count of existing particles, while at high concentrations glutaraldehyde contributed 
to the formation of new particles. 
Figure 2.3C displayed the effect of glutaraldehyde on the zeta potential of 
nanoparticles formed with 8 mg/mL SPI desolvated with 80% ethanol. Before 
evaporation, the zeta potentials ranged from -7.6 mV to -10.7 mV. According to 
the American Society for Testing and Materials, these values indicated “incipient 
instability” of the nanoparticle dispersions [5], which was in consistence with the 
emergence of minor flocculates. After ethanol was evaporated, the zeta potential 
increased to -28.3 mV or -44.2 mV in the presence of 0% or 150% equivalent of 
glutaraldehyde, respectively. These data were indicative for “moderate to good” 
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stability [5]. The removal of organic solvent increased the polarity of the 
dispersion, which might have facilitated the electrolysis of protein molecules and 
increased the zeta potential consequently. In addition, higher glutaraldehyde 
concentrations resulted in more negative zeta potentials, probably because of the 
consumption of positively charged ε-amino groups by glutaraldehyde [23]. 
2.4.3 Encapsulation of curcumin into SPI nanoparticles 
Table 2.2 presented the EE, LC, particle size and zeta potential of blank and 
curcumin-loaded SPI nanoparticles. The EE increased with decreasing 
curcumin/protein (C/P) mass ratios and reached 97.2% at the C/P ratio of 1/100. 
The maximum LC achieved in this study was 2.7%, which was approximately 40% 
lower than the one attained with zein nanoparticles [32]. In comparison with soy 
protein, zein exhibited a higher hydrophobicity, which might have contributed to 
the protein-curcumin interaction and yielded a higher LC [27, 28]. Furthermore, 
considerable amount of sodium caseinate was added with the zein nanoparticles 
(zein: caseinate= 1.25: 1, w/w) as a stabilizer [32], which might further facilitate 
the encapsulation of curcumin in zein nanoparticles. 









Zeta potential  
(mV) 
0 (pure SPI) - - 201.5±9.2c -36.8±1.0a 
1.00% 97.2±2.0a 1.1±0.1c 220.1±17.8b -36.0±2.1a 
2.00% 81.2±1.2a 1.7±0.1b 252.6±13.4ab -35.2±0.8a 
5.00% 52.8±3.0b 2.7±0.2a 286.7±10.1a -34.5±1.4a 
* Data with different letters showed significant difference (n=3, P<0.05). 
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The sizes and zeta-potentials of empty and curcumin-loaded SPI nanoparticles 
were measured after the encapsulation procedures. As shown in Table 2.2, the size 
of empty nanoparticles averaged at 201.5 nm, and it increased with the C/P ratio to 
a maximum of 286.7 nm. The zeta potentials of blank and curcumin-loaded 
nanoparticles were around -35 mV with no significant difference. Similar results 
were reported by Ashok et al. on curcumin-loaded zein nanoparticles [32]. 
Curcumin possesses four ionizable protons and exhibited a zeta potential of 
around -6 mV in ethanol or Tween 20/water as measured in our study (data not 
shown). Therefore, curcumin was unlikely to interact electrostatically with the 
negatively charged soy proteins, and the zeta potential of the nanoparticle 
dispersion was thus not influenced by the presence of curcumin. 
2.4.4 FT-IR study 
The FT-IR spectra of SPI, curcumin, their physical mixture (S/C Mix, SPI: 
curcumin=40:1) and curcumin-loaded SPI nanoparticles (S/C Encap, SPI: 
encapsulated curcumin=39:1) were presented in Figure 2.4A. The characteristic 
peaks of SPI [98] were amide I (band a, C=O stretching, 1637 cm-1), amide II 
(band b, N-H bending, 1536 cm-1), C-N stretching (band c, 1450 cm-1) and amide 
III (band d, C-O and C-O-C vibration, 1238 cm-1). On the other hand, CUR 
exhibited several absorbance peaks [99], of which three were also observed in the 
S/C mixture: band e, C-O stretching, 1206 cm-1, band f, trans CH=CH stretching, 
1026 cm-1, and band g, C-O-C asymmetric stretching, 856 cm-1. The spectrum of 
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S/C Encap, however, nearly overlapped with that of SPI, and none of these three 
peaks was detected. This phenomenon indicated that no or little amount of 
curcumin existed in S/C Encap as free molecules [75, 100]. 
     
Figure 2.4 FT-IR spectra (A) and XRD patterns (B) of soy protein isolate (SPI), curcumin 
(CUR), their physical mixture (S/C Mix) and curcumin-loaded SPI nanoparticles (S/C 
Encap.) 
Figure 2.4B showed the XRD patterns of SPI, curcumin, their physical mixture 
(S/C Mix, SPI: curcumin=40:1) and curcumin-loaded SPI nanoparticles (S/C 
Encap, SPI: curcumin=39:1). The characteristic peaks of curcumin at 8.84, 12.10, 
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14.39, 17.20, 23.33, 24.50, 25.52 and 28.87 degree suggested its highly crystalline 
nature, which was in consistence with previous literatures [32]. These peaks were 
also observed in the S/C Mix, but with significantly lower intensities. On the 
contrary, these peaks disappeared in the XRD pattern of S/C Encap, which 
consisted mostly of amorphous humps. These results indicated the successful 
incorporation of curcumin in the nanoscale SPI matrix, which facilitated the 
conversion of crystalline curcumin into the amorphous state [32, 101].  
2.4.5 SEM analysis of the blank and curcumin-loaded nanoparticles 
The morphology of blank and curcumin-loaded SPI nanoparticles was investigated 
under SEM (Figure 2.5). When 12 mg/mL of SPI was dispersed in pure water), a 
film-like structure was observed under SEM. Similar images were obtained when 
the same concentration of SPI was desolvated with 80% ethanol without 
crosslinking (not shown). This structure was possibly formed by non-particulate 
soy proteins that attached each other during the drying process [30]. 
Intermolecular attraction and hydrophobic interaction might have played a role in 
the formation of the network structure [49]. After crosslinking was performed with 
75% equivalent of glutaraldehyde, the proportion of particulate soy protein 
appeared to increase significantly. The particles exhibited an approximately 
spherical shape with a smooth surface. The particle size under SEM ranged from 
50 to 200 nm, which was about 30% lower than the values obtained by DLS. This 
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difference was probably due to the shrinkage caused by the cast-drying process as 
well as the vacuum environment in SEM imaging [97].  
 
Figure 2.5 SEM images of soy protein nanoparticle dispersions at different stages of 
synthesis 
After the removal of ethanol by rotary evaporation, the particles tended to separate 
from each other. This result could be attributed to the increased polarity of the 
solvent, which induced the burial of hydrophobic chains of protein molecules [94]. 
In addition, the nanoparticles carried more negative charges on the surface after 
the evaporation as discussed before. These factors led to strengthened electrostatic 
repulsion and weakened hydrophobic interaction among protein nanoparticles, 
both of which inhibited the association of particles upon drying. After the 
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incorporation of curcumin, clusters of individual particle units were formed with 
particles, which was responsible for the aforementioned increase in particle sizes.  
2.4.6 Release of curcumin from SPI nanoparticles 
Figure 2.6 showed the kinetic release profiles of curcumin from SPI nanoparticles 
in the PBS/Tween 20 system. A biphasic trend was observed for the samples with 
different C/P ratios, namely, 1/100, 2/100, and 5/100. In the first 1.5 h, over 50% 
of the encapsulated curcumin was released for all formulations. This phenomenon 
known as the burst effect was due to the swelling and breakage of the protein 
matrix [37]. In addition, the majority of curcumin that was initially bound to the 
peripheral domain of the protein matrix might have migrated to the releasing 
medium during the first 1.5 h [86]. Similar results have been reported on the 
nanoparticles prepared with different proteins, such as albumin [87] and zein [32]. 
Possible strategies for reducing the burst effect include chemical modification of 
proteins, optimization of encapsulation procedure as well as preparation of 
multilayer encapsulation systems with protein and polysaccharides, such as 
chitosan derivatives [51, 102]. Between hours 2 and 8, a sustained release phase 
was observed, in which the concentration of released curcumin increased slowly 
with time. At the end of 8 h, the total percentage of curcumin released ranged from 
58% to 78%, and it continued to increase in the following 24 hours (data not 
shown). These results correspond to the migration of curcumin encapsulated 
within the hydrophobic core of protein molecules. In addition, nanoparticles with 
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lower C/P ratio exhibited higher releasing rates in the PBS/Tween 20 system. This 
was probably due to their smaller sizes and greater area-to-volume ratios, which 
facilitated the contact with the releasing medium [103].  
Time (h)


























Figure 2.6 Release of curcumin from the soy protein nanoparticles in phosphate buffer 
saline with Tween 20 
2.4.7 Proposed mechanism of nanoparticle preparation and encapsulation 
Based on the results obtained in previous sections, an illumination for the 
formation of blank and curcumin-loaded SPI nanoparticles was proposed in 
Figure 2.7. When dispersed in pure water (phase 1), soy protein existed mostly in 
its native state, i.e., globular molecules consisting of a shell of charged or polar 
groups together with a kernel formed by hydrophobic chains [26, 49]. There 
existed a small amount of aggregates, especially the large ones with diameters of 
500-1000 nm. When ethanol was added to the concentration of 40%, the hydration 
54 
 
and ionization of protein were disrupted, leading to a decrease in the zeta potential 
(phase 2). Meanwhile, part of the hydrophobic chains were exposed to the surface 
of the molecule [26]. As a consequence, the attraction among protein molecules 
was enhanced, and a relatively small amount of protein aggregate began to form, 
resulting in an increase in the average particle size. As shown in our study, the 
desolvation process could be partly reversed if ethanol was evaporated at this 
point. Then, curcumin-ethanol solution was added to achieve an ethanol content of 
50-60%, so that (a) curcumin could disperse well without agglomeration, (b) the 
hydrophobic chain of protein was further exposed, and (c) extensive aggregation 
of protein did not occur and the hydrophobic sites in soy protein molecules was 
not consumed completely for protein-protein interaction (phase 3). Thereafter, the 
concentration of ethanol was increased to 80% (with 8-12 mg/mL SPI), which led 
to extensive formation of nanoparticles, especially those with smaller sizes 
(50-200 nm). At this stage, part of curcumin was entrapped inside the protein 
particles, while some curcumin molecules were bound to their peripheral domains. 
A certain amount of the curcumin also existed as freely dissolved molecules.  
After adequate hardening by glutaraldehyde, sufficient amide bond were formed to 
prevent the deformation of the particles (phase 4). Therefore, the size and number 
of the particles was not changeable upon the removal of ethanol. However, the 
constituent part of the nanoparticles, either protein monomers or oligomers, was 
prone to adopting their native core-shell conformation (phase 5). This was 
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speculated from the fact that the zeta potential of the nanoparticles after ethanol 
removal was close to that of the SPI dispersion before desolvation took place. In 
addition, as was discussed before, the SEM images of samples before and after 
evaporation also suggested the burial of hydrophobic chains and the exposure of 
polar and charged sites. In addition, the removal of ethanol resulted in an 
increased polarity of the dispersion, which favored thermodynamically the 
hydrophobic interaction (a) among curcumin molecules and (b) between curcumin 
and the non-polar groups of the protein. The former interaction might have caused 
the precipitation of the unbound curcumin [30], while the latter one facilitated the 
entrapment of curcumin into the protein matrix [86, 88]. As a result, little or no 
curcumin existed in the final product as freestanding molecules. 
 




Nanoparticles were successfully synthesized with SPI using the desolvation 
method. An ethanol concentration greater than 80% was required for extensive 
formation of particles, while more than 75% equivalent of glutaraldehyde was 
necessary for adequate hardening. The zeta potential of the nanoparticle dispersion 
was around -36 mV, which indicated moderate to good stability. The synthesized 
nanoparticles exhibited an approximate spherical structure with a smooth surface. 
These particles were then evaluated for their encapsulating capability, and a 
highest encapsulation efficiency of 97.2% was achieved. No or little curcumin 
existed as unbound molecules in the yielded particles, as was supported by FT-IR 
and XRD results. The release of curcumin in PBS/Tween 20 system followed a 
biphasic trend, and the releasing rate varied with the C/P ratio. Nanoparticles 
prepared from SPI exhibited satisfactory encapsulating properties and a desirable 
stability at high concentrations. These properties made SPI nanoparticles a 
promising delivery system for drugs or nutraceuticals.  
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Chapter 3 Development and Application of Nanoparticles 
Synthesized with Folic Acid-Conjugated Soy Protein 
3.1 Abstract 
In this chapter, soy protein isolate (SPI) was conjugated with folic acid (FA) to 
prepare nanoparticles for target-specific drug delivery. Successful conjugation was 
evidenced by UV spectrophotometry and primary amino group analysis. An 
increase in count rate by at least 142% was observed in FA-SPI nanoparticles 
compared to the non-conjugated ones, whereas the particle size was decreased 
upon FA conjugation. This was probably attributed to the substitution of positively 
charged lysine residues by the FA backbone. The zeta potential ranged from -36 to 
-42 mV depending on the conjugation degree, indicating desirable dispersion 
stability. Curcumin as a model drug was encapsulated successfully into FA-SPI 
nanoparticles, evidenced by X-ray diffraction study. The highest encapsulation 
efficiency and loading capacity were around 92.7% and 5.4%, respectively, which 
were significantly higher (P<0.05) than those with non-conjugated SPI 
nanoparticles. In addition, a faster and more complete release of curcumin was 
observed for FA-SPI nanoparticles in PBS/Tween 20 buffer. Cell culture study 
showed that conjugation of FA resulted in an increase in cellular uptake by at most 
93% in Caco-2 cells. These results suggested that FA-SPI is a potential wall 




Targeted delivery of nano-encapsulated drugs has attracted increasing interest in 
the past decades. By improving the cellular uptake at specific sites, this method 
could significantly increase the efficacy of bioactive compounds while minimizing 
the toxicity to healthy tissues [43]. Targeted delivery can be achieved in two 
approaches, namely, enhanced permeability and retention (EPR) and specific 
binding [54]. The first approach involves decreased systemic drug elimination 
through renal excretion, prolonged circulation, and low tumor lymphatic drainage 
when the drug forms a complex with a polymeric matrix, such as a protein 
nanoparticle [20]. The second approach requires the attachment of target-specific 
ligands to the drug carrier, which facilitates the acquisition and internalization of 
the encapsulated drugs or nutraceuticals into the target cells or tissues [53]. 
Protein-based nanoparticles have been studied extensively as a vehicle for 
delivering nutraceuticals and drugs [25, 30, 48, 51, 86]. The amphiphilic nature of 
protein molecules facilitates the interaction with both the solvent and the packaged 
drugs or nutraceuticals leading to improved solubility, better tissue penetration and 
enhanced cellular uptake of compounds [1, 2]. Compared with synthetic polymers, 
proteins exhibited lower toxicity and better degradability, which made them an 
attractive candidate in the food and pharmaceutical industry [1]. Soy protein 
isolate (SPI) is the most widely produced and utilized plant protein in the world. It 
is unique in its high content (over 60%, molar ratio) of hydrophobic amino acids 
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[104], together with a considerable percentage of polar and charged residues [27]. 
The first property enables a strong hydrophobic interaction with encapsulated 
compounds. The latter feature not only leads to desirable water solubility, but also 
facilitates the protein-drug interaction through electrostatic attraction and 
hydrogen bonding. In our previous study [105], nanoparticles were successfully 
prepared with SPI using an ethanol desolvation method. These nanoparticles 
exhibited desirable average size (150 nm), zeta potential (-36 mV), and 
encapsulation and releasing properties. In addition, the chemical crosslinking 
reaction during the preparation process helped preventing the nanoparticles from 
dissociation, thus providing additional protection to the embedded drugs. 
Furthermore, the abundance of functional groups, such as primary amino groups 
on the lysine residues, enables the conjugation of site-specific ligands to soy 
protein molecules, making it a potential candidate for drug delivery vehicles.  
Folic acid (FA, structure shown in Figure 1.1), a diet-derived micronutrient, has 
been found to be an effective target-specific ligand for tumor cells [19]. The cell 
accumulation of FA is achieved mainly through a folic acid receptor protein (FRp) 
identified as GP38, which is an overexpressed, glycosyl-phosphatidylinositol 
anchored glycoprotein. Elevated expression of GP38 was reported in a variety of 
carcinomas, including ovarian, prostate, breast, colon and lung cancer cells [20], 
resulting in a significantly increased affinity of FA in comparison with normal 
cells. For example, the FA binding capacity of fibroblast and CHO (human ovary) 
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cells were less than 0.1 pmol per 106 cells, while it was found to be 20 and 50-200 
pmol/106 cells in Caco-2 and KB cells, respectively [106]. To take advantage of 
specificity toward FA, various polymers including chitosan [55], human serum 
albumin [107], bovine serum albumin [108] and polylysine [59] have been 
conjugated with FA and used as carriers for anti-cancer drugs. These conjugates 
formed nanoparticles with satisfactory encapsulation capabilities and enhanced 
target delivery properties. However, the major drug-matrix interaction involved in 
these systems was electrostatic attraction and hydrogen bonding, which could be 
significantly weakened changing temperature, pH and ionic strength [1]. Soy 
proteins, on the other hand, may provide a stronger interaction with the bioactive 
compound as described above. However, to our best knowledge, the synthesis and 
evaluation of FA-conjugated SPI nanoparticles (FA-SPI) have not been reported. 
In this study, FA-SPI conjugates were synthesized by a carbodiimide aided 
method and then employed to prepare nanoparticles via ethanol desolvation. The 
sizes, zeta potentials, and morphologies of the FA-SPI particles were compared 
with the ones prepared with non-conjugated SPI. Curcumin (structure shown in 
Figure 1.5) was chosen as a model drug to be incorporated into SPI and FA-SPI 
nanoparticles, due to its known chemopreventive activity [109], need for improved 
solubility and stability [101], and ease of quantification [32]. The encapsulation 
and releasing profiles of curcumin-loaded SPI and FA-SPI nanoparticles were 
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compared. Finally, the nanoparticles were subjected to cell culture studies to 
verify the enhanced uptake of FA-SPI nanoparticles in cancer cells.  
3.3 Materials and Methods 
3.3.1 Materials 
ProliaTM 200/70 Defatted Soy Flour was a sample donated by Cargill Inc., Cedar 
Rapids, IA. The soy flour contained 54% protein and less than 1% oil (dry basis). 
Folic acid (98% purity), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC, 
97% purity), curcumin (98% purity), and 2, 4, 6-trinitrobenzenesulfonic acid 
solution (TNBS, 5%, w/v in H2O) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Cell culture-related reagents were purchased from Invitrogen Inc. 
(Carlsbad, CA, USA). All other chemicals (dimethyl sulfoxide, valine, 
trichloroacetic acid, etc.) were of analytical grade. 
3.3.2 Preparation of SPI 
SPI was prepared following an isoelectric precipitation method [105]. In brief, 
defatted soy flour was firstly extracted with water at pH 8.0 and centrifuged to 
precipitate insoluble fibers. The supernatant was then acidified to pH 4.5 and 
centrifuged again, and the protein-rich curd was recovered, neutralized, dialyzed 
against deionized water and lyophilized. The moisture content of the final product 
was less than 5%, while the protein content was 90% as determined by Bradford 
assay with bovine serum albumin as the standard protein. 
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3.3.3 Preparation of FA-conjugated SPI (FA-SPI) 
FA molecules were conjugated with SPI using a previously reported 
carbodiimide-catalyzed method [43], with several modifications. To avoid the 
degradation of FA, all of the following procedures were carried out in darkness. 
SPI powder was dissolved in deionized water at a concentration of 5 mg/mL, and 
the pH of the dispersion was adjusted to 8.5 using 1 mol/L NaOH. FA was 
dissolved in dimethyl sulfoxide (DMSO) at a concentration of 2.5 mg/mL, to 
which EDC was added as a coupling reagent at a molar ratio of FA: EDC=1:5. 
The resulting solution was stirred at room temperature for 1 h to allow the 
activation of the carboxylic group on FA molecules. Then, the activated FA 
solution was added to the SPI dispersion at an SPI: FA molar ratio from 1:5 to 
1:75. Upon the addition of FA, the pH of the SPI solution was kept at 8.5 
manually using 1 mol/L NaOH. This step was taken instead of using sodium 
bicarbonate as a buffering solvent, because precipitates of both FA and SPI were 
observed in this buffer. The conjugation was finished in 30 min, after which the 
mixture was dialyzed thoroughly against deionized water (adjusted to pH 8.0 
using 1 mol/L NaOH) for 48 h. The retentate exhibiting a pH of 7.0-7.5 was then 
lyophilized. A control sample was prepared similarly with the abovementioned 
procedures, except that the FA solution was not activated by EDC. 
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3.3.4 Determination of conjugation degrees and primary amino group 
contents 
FA-conjugated or control SPI was dissolved in phosphate buffered saline (PBS) at 
a concentration of 10 mg/mL and equilibrated for 15 min. The protein content was 
determined by Bradford Assay after appropriate dilution, while FA was quantified 
by measuring the optical density at 345 nm using a DU-730 UV/VIS 
spectrophotometer (Beckman Coulter Inc., Fullerton, CA). This wavelength was 
chosen based on the data from a preliminary wavelength scanning analysis. The 
conjugation degree was calculated as the molarity of FA divided by that of SPI.  
The contents of primary amino groups in SPI and FA-SPI were determined using a 
TNBS assay that was reported previously [56]. In brief, SPI and FA-SPI powders 
were dissolved in water and reacted with TNBS in a NaHCO3 buffer. Dialysis 
centrifugation (5,000 g, 1 h) was then performed using a Macrosep® centrifuge 
tube (Pall Corp., Ann Harbor, MI) with a built-in filtering membrane (MW cutoff 
= 10,000). The filtrate containing non-reacted TNBS was reacted with a water of 
valine for 1 h and subjected to spectrophotometric measurement at 410 nm. A 
blank solution was prepared following the same procedure, except that 
trichloroacetic acid solution was used instead of valine. The content of 
non-conjugated TNBS was calculated by a linear regression equation (R2=0.9996). 
The number of primary amino groups that was theoretically equal to the content of 
reacted TNBS was reported. 
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3.3.5 Preparation of nanoparticles with SPI and FA-SPI conjugates 
Nanoparticles were formed with freshly prepared SPI or FA-SPI conjugate using 
an ethanol desolvation method [105] with modifications. SPI or FA-SPI was 
dissolved in deionized water at a concentration of 15-30 mg/mL (pH 7.5-8.0), and 
the dispersion was equilibrated for 1 h at room temperature. For the preparation of 
empty nanoparticles, ethanol was added dropwise into the dispersion to achieve an 
ethanol/water ratio of 80/20 (v/v). To prepare curcumin-loaded nanoparticles, the 
ethanol/water ratio was firstly adjusted to 60/40 (v/v) using pure ethanol, and 
curcumin/ethanol solution (3 mg/mL) was added dropwise to a curcumin: protein 
mass ratio of 1:10 or 1:20. Additional ethanol was then added to achieve a final 
ethanol/water ratio of 80/20 (v/v). In both blank and curcumin-loaded nanoparticle 
dispersions, the concentration of FA-SPI or SPI in the binary solvent was 3-6 
mg/mL. After 15 min of equilibration, glutaraldehyde (25 mg/mL aqueous 
solution) was added as a crosslinker. The requirement of glutaraldehyde was 
estimated as 28 μg/mg SPI or 77 mol/mol SPI (or FA-SPI), according to our 
previous study [105], and the crosslinking reaction was finished in 16 h. The 
ethanol was then removed using a Buchi Rotavapor RII at 30oC (BUCHI 
Labortechnik AG, Flawil, Switzerland) and replaced with same volume of 
deionized water. For some of the samples, it was necessary to remove the large 
aggregates in the dispersion by centrifugation at 10,000 g for 15 min. The 
percentage of protein remaining in the supernatant was higher than 95%, as 
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determined by Bradford Assay. The supernatant was lyophilized or stored at 4oC 
for subsequent assays. 
3.3.6 Characterization of SPI and FA-SPI nanoparticles 
Both SPI and FA-SPI nanoparticle dispersions were subjected to the following 
measurements. The particle size and count rate were determined separately by 
dynamic laser scattering [105] using a BI-200 SM Goniometer Version 2 
(Brookhaven Instrument Corp., Holtsville, New York, USA). Particle dispersions 
in both 80% ethanol (before evaporation) and deionized water (after evaporation) 
were measured without dilution. The refractive index of soy protein solution (1.43) 
and the viscosity of different ethanol/water mixtures were applied to obtain 
accurate results. The laser power and aperture pinhole size were set consistently at 
10 mW and 400 μm, respectively. All analyses were conducted at 25ºC for 1 min.  
The electrophoretic mobility of nanoparticle dispersions in deionized water was 
determined by laser Doppler velocimetry using a Nano ZS90 Zetasizer. (Malvern, 
UK). Each sample was measured three times, and at least twelve runs were 
performed per measurement. The data were then converted to zeta potentials using 
the Smoluchowski model.  
Morphology was observed under scanning electron microscopy (SEM). Fifty 
microliters of nanoparticle dispersion (4 mg/mL, in 80% ethanol or deionized 
water) was drawn, cast dried on an aluminum pan, mounted on a conductive 
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carbon tape, coated with gold/platinum and observed under SEM (Hitachi SU-70 
Pleasanton, CA). Representative images were reported. 
The X-ray diffraction (XRD) patterns of dry nanoparticles were recorded on a 
Bruker D8-Advance Diffractometer (Bruker AXS Inc., Madison, WI) with 
backgroundless sample holders. The working parameters were as follows: voltage 
40 kV, current 40 mA, and a scanning rate of 3 min-1. 
3.3.7 Determination of EE and LC 
The EE of curcumin-loaded nanoparticles was determined as previously reported 
[105]. The insoluble (suspending) curcumin was precipitated by centrifugation 
(9,000 g, 10 min). The resultant supernatant was subjected to dialysis 
centrifugation as was described for the TNBS assay, and free (non-encapsulated 
but soluble) curcumin was recovered in the filtrate. The two parts of curcumin 
were combined, diluted with ethanol and subjected to spectrophotometric analysis 
at 426 nm, using an established standard curve (R2=0.9991). The EE of the 
samples were calculated with the equation:  
 
In addition, after the dialysis centrifugation mentioned above, the retentate 
consisting mainly of curcumin-encapsulated nanoparticles was collected and 
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lyophilized. The dry nanoparticles were weighed, and the LC was calculated as the 
mass ratio of encapsulated curcumin to the obtained nanoparticles.  
3.3.8 Release of curcumin in phosphate buffer saline (PBS) 
After lyophilization, five milligrams of the curcumin-loaded nanoparticles was 
dispersed in 10 mL of the release medium (PBS, pH 7.4, containing 0.5% Tween 
20). The dispersion was incubated at 37oC with mild shaking on a Multi-Purpose 
Rotator/Rocker (Scientific Industries Inc., NY, USA). At designated intervals, the 
suspension was centrifuged at 51,500 g and 20oC for 15 min. The supernatant was 
then subjected to dialysis centrifugation as mentioned above. The released 
curcumin recovered in the filtrate was quantified spectrophotometrically at 426 
nm, using a calibration curve established in the curcumin/Tween 20/PBS system 
(R2=0.9993). The precipitate was disposed, and a fresh dispersion was then 
prepared for another measurement. The kinetic release profile of curcumin was 
plotted as a function of time. 
3.3.9 Cell culture 
Human colon adenocarcinoma cell line (Caco-2) was purchased from the 
American Type Culture Collection (Manassas, VA, USA) and cultured in folic 
acid-free RPMI 1640 medium, which was supplemented with 10% (v/v, same in 
this section) fetal bovine serum, 1% nonessential amino acids and 1% 
penicillin-streptomycin. The cells were cultured in a humidified environment with 
5% CO2 at 37 °C. The medium was changed every other day, and the cells were 
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subcultured after reaching 80-90% confluence. Caco-2 cells between 10-15 
passages were used in this study. 
3.3.10 Cell uptake study 
Both SPI and FA-SPI nanoparticle dispersions were labeled with an FITC 
Labeling Kit (Thermo Fisher Scientific Inc., Rockford, IL, USA). The cells were 
seeded in a black 96-well plate at 3×104 cells/well and incubated to achieve 80% 
confluence. The growth medium was then replaced with a transport buffer (HBSS, 
pH 7.4, containing 50 mmol/L HEPES) and incubated at 37oC for 30 min. After 
the removal of transport buffer, two hundred microliters of the labeled 
nanoparticle dispersion was added and incubated with the cells for 2 to 24 h. At 
designated time intervals, the cell monolayer was washed with PBS for three times 
to remove unabsorbed nanoparticles. The cells were then treated with lyse buffer 
containing 0.5% Triton X-100 and 0.2 mol/L NaOH to expose the internalized 
nanoparticles. The fluorescent intensity was measured using a PerkinElmer Victor 
X3 multilabel plate reader (PerkinElmer Inc., Waltham, MA, USA) with an 
excitation and emission wavelength at 485 nm and 535 nm, respectively. 
3.3.11 Statistics 
The cellular uptake study was conducted in at least six replicates. All other 
measurements were performed in triplicates. The results were expressed as means 
± standard error. T test was performed for the in vitro release and cellular uptake 
studies. All other data were subjected to analysis of variance (P < 0.05) followed 
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by Tukey’s test with an experimentwise confidence level of α=0.10 using SAS 9 
software (SAS Institute Inc, Cary, NC). 
3.4 Results and Discussion 
3.4.1 Conjugation of FA on SPI  
 
Figure 3.1 UV spectra of FA (dotted line), SPI (dash line) and FA-SPI conjugates (solid 
line) in PBS. 
FA has been reported to conjugate to different polymers via an amide linkage 
through the γ-carboxylic group of FA [19]. In this study, the γ-carboxylic group of 
FA was firstly activated by EDC and then reacted mainly with the primary (ε-) 
amino group on the lysine residue of SPI [43]. Figure 3.1 showed the UV spectra 
of FA, SPI and FA-SPI conjugate. Within the range of wavelength tested, SPI 
showed a single absorption peak at 280 nm (peak B). A control sample was 
prepared through a similar process as for the FA-SPI conjugate, except that FA 
was physically mixed with SPI without the activation by EDC. The spectrum of 
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the control sample was observed to overlap with that of SPI, suggesting that the 
majority of free (non-conjugated) FA molecules have been removed by dialysis 
during the preparation process.  
On the other hand, FA exhibited two absorption peaks at 278 nm (peak A) and 345 
nm (peak C) respectively. Unlike the overlapping peaks A and B, peak C was not 
found in that of the control sample but was observed in the spectrum of FA-SPI, in 
spite of its low intensity. This result confirmed successful conjugation of FA to 
soy protein molecules. Therefore, peak C was chosen for the determination of 
conjugation degree in this study.  





Conjugation degree  
mol FA/mol SPI 
Primary amino groups  
mol/mol SPI 
Control 0 0 69.82±0.25a 
F5 5 1.28±0.20e 69.09±0.35a 
F10 10 4.54±0.35d 68.15±0.43b 
F20 20 9.21±0.17c 65.11±0.60c 
F50 50 16.97±0.18b 55.11±0.98d 
F75 75 32.48±1.25a 48.17±1.17e 
* Data with different letters showed significant difference (n=3, P<0.05). 
Table 3.1 showed the conjugation degree and the content of primary amino groups 
of FA-SPI as a function of mixing ratio. As the FA: SPI ratio increased from 0 to 
75, the conjugation degree increased gradually and reached a maximum value of 
32.48 (mol/mol) at a mixing ratio of FA: SPI = 75:1. Concomitantly, the content 
of primary group decreased from 69.82 to 48.17 mol/mol protein. The data from 
these two different assays matched approximately, which further indicated that FA 
71 
 
was conjugated to SPI via a chemical linkage to the primary amino groups. The 
minor discrepancy between these data could be explained by the following reasons. 
Firstly, a small amount of free FA molecules might have not been completely 
removed by dialysis and were counted as conjugated FA. Secondly, part of FA 
might have been conjugated with the secondary amino group on the arginine 
residues [108]. 
3.4.2 Particle sizes and count rates of FA-SPI nanoparticles 
In this study, nanoparticles were prepared with FA-SPI by a desolvation method 
[110], and its physicochemical properties were compared with the counterparts 
prepared with control SPI. The polydispersity indices for all samples were 
between 0.100 and 0.180 without significant difference (P<0.05, same hereinafter; 
data not shown). As can be seen in Table 3.2, FA-SPI formed nanoparticles at a 
concentration between 3 and 6 mg/mL, and the maximum protein concentration 
for particle formation decreased as the conjugation degree increased. In addition, 
at a same protein concentration (4 mg/mL), FA-SPI nanoparticles exhibited a 
significantly lower size (up to 15% less) and higher count rate (up to eight-fold) 
than the ones formed with control SPI. Besides, in order to achieve a comparable 
particle count rate, the required concentration of control SPI was three to four 
times that of FA-conjugated SPI. It was also noteworthy that the particle size and 
count rate tended to decrease and increase respectively with increasing 
conjugation degree. Similar results have been reported on FA-conjugated human 
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serum albumin (HSA) and bovine serum albumin (BSA) nanoparticles [58, 107]. 
The count rate of a colloidal system indicates the intensity of the scattered laser, 
which is proportional to the number of the particles as well as the sixth power of 
their size [23]. As discussed in the last chapter [105], an increase in count rate and 
a simultaneous decrease in average particle size suggested that a greater number of 
smaller nanoparticles were formed by FA-SPI as compared to control SPI.  
Table 3.2 Characteristics of FA-SPI nanoparticles * 











Control  12** 162.5±3.5b 98.0±7.5d 171.2±8.5ab 100.2±2.5c 
F10  6** 111.8±9.5d  99.3±8.2d  122.6±4.2c  82.8±3.2d  
F10  5  170.2±5.3a  75.7±5.7e  190.1±7.3a  67.9±1.2f  
F20 5** 113.7±7.2d  137.5±8.3b  123.4±4.7c  123.8±7.5b  
Control 4 150.3±2.7bc 27.6±4.5f 155.4±8.1b 28.4±2.8g 
F10 4 168.7±2.6a 69.8±5.0e 181.4±4.3a 62.3±2.4f 
F20  4 109.7±5.6d  80.8±6.3e  132.2±8.5c  77.7±3.7e  
F50 4** 137.6±5.3c  210.1±10.7a  124.6±9.5c  153.5±10.2a  
F50 3 124.0±6.2cd  114.4±5.3c 156.5±5.6b  98.5±3.4c  
* Data with different letters showed significant difference (n=3, P<0.05). 
** Maximum protein concentration for nanoparticle formation in 80% ethanol. 
Precipitation was observed at protein concentrations higher than these values. 
The formation of protein nanoparticles were considered as driven by attractive 
forces between protein molecules, such as hydrogen bonding, van der Waals 
interaction and hydrophobic interaction [2]. When SPI was grafted with FA 
molecules, part of its primary amino groups lost their positive charges after they 
formed covalent bonds with FA backbone, which consists of a relatively long 
non-polar chain and an alpha carboxylic group. The latter group exhibited a 
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negligible ionization at neutral pHs (pKa=6.8) and contributed little to the polarity 
of SPI [111]. Therefore, conjugation with FA might have resulted in a higher 
hydrophobicity of the soy protein molecules. In addition, the amino and hydroxyl 
groups on the pteridine ring could provide additional hydrogen-bonding, if 
appropriate orientation was allowed. Both of these changes facilitated the 
aggregation of SPI into nanoparticles.  
In our previous study [105], a crosslinking agent (glutaraldehyde) was employed 
to harden the structure of SPI nanoparticles via amide bonds between the primary 
amino residues of soy protein. Insufficient crosslinking would result in the 
dissociation of nanoparticles into free polymers upon the removal antisolvent, 
which could be characterized by a significant change in either size or count rate 
[23, 105]. After conjugation with FA, the number of these amino groups was 
reduced as shown in Table 3.1. Therefore, it was important to determine whether 
the amount of glutaraldehyde applied on non-conjugated SPI (28 μg/mg or 77 
mol/mol) was sufficient to fix the structure of FA-SPI nanoparticles. As presented 
in Table 3.2, the particle sizes and count rates of nanoparticles formed by FA-SPI 
were not significantly decreased after the removal of ethanol by rotary evaporation. 
These indicated sufficient crosslinking between the formed protein nanoparticles. 
Addition of excessive glutaraldehyde should be avoided, because it led to partial 
precipitation of the nanoparticles as we have observed and might increase the 
toxicity of the product [112]. 
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Figure 3.2 Effect of FA conjugation on the zeta-potential of SPI nanoparticles 
The effect of FA conjugation on the zeta potential of SPI nanoparticle dispersions 
was displayed in Figure 3.2. The dispersions were evaporated to remove ethanol 
prior to the measurements. The nanoparticles formed with control SPI showed a 
zeta potential of -35.3 mV. The value became more negative as the conjugation 
degree increased and achieved a minimum of -43.2 mV when the initial FA: SPI 
molar ratio was 75:1. The decrease in zeta potential was attributed to the 
substitution of the positively charged primary amino group by the non-charged (or 
partly negatively charged) residue of FA. According to the American Society for 
Testing and Materials [5], zeta potentials with an absolute value of higher than 30 
mV were indicative for “moderate to good” stability of colloidal systems, owing to 
the strong electrostatic repulsion between the charged particles. 
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3.4.4 Encapsulation of curcumin into FA-SPI nanoparticles 
The particle size, zeta potential, EE and LC of curcumin-loaded SPI or FA-SPI 
nanoparticles were summarized in Table 3.3. For comparison purpose, the control 
SPI was used to form curcumin-loaded particles at a same concentration (4 
mg/mL). The sizes of FA conjugated SPI nanoparticles were significantly greater 
than that of non-conjugated ones, and they increased from 170.3 nm to 338.8 nm 
with increasing conjugation degree. This was possibly because the samples with 
higher conjugation degree possessed a larger amount of the hydrophobic FA 
backbone as discussed before, which promoted the hydrophobic interaction and 
allowed more protein molecules to aggregate into nanoparticles. In addition, the 
particle size increased expectedly when a higher curcumin: protein ratio was 
adopted. The zeta potential, on the other hand, was not significantly changed when 
curcumin was incorporated.. 
The LC and EE of the FA-SPI nanoparticles were observed to increase and 
decrease respectively with increasing curcumin: protein ratio, regardless of the 
conjugation degree (Table 3.3). The highest EE of approximately 90% was 
observed when the curcumin/protein mass ratio was 1:50 (w/w), which was 
comparable with other polymeric delivery systems [32, 99, 113]. In addition, there 
was a significant difference in the LC between the nanoparticles formed with 
control and FA-conjugated SPI. The maximal LC achieved with FA-SPI were 
within the range of 4.4-5.4%, which was approximately 57% higher than that for 
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control SPI nanoparticles. Compared to other curcumin-loaded delivery systems 
such as FA-PLGA particles [114], FA-SPI nanoparticles showed a lower LC (5.4% 
vs. 6.2%) but higher EE (89% vs. 62%). In addition, both LE and EE were higher 
than those for nanoparticles prepared with some non-conjugated polymers 
including zein-caseinate [32] and fibrinogen [115]. An important contributor to the 
improved LC by FA conjugation might have been the enhanced hydrophobic 
interaction and hydrogen bonding that was discussed above. Besides, similar to the 
case for empty nanoparticles, the count rate of curcumin-loaded FA-SPI 
nanoparticles was significantly higher than that for non-conjugated ones at 4 
mg/mL (data not shown). This difference indicated that a larger number of FA-SPI 
molecules were involved in particle formation and curcumin encapsulation than 
non-conjugated SPI, which allowed a stronger protein-curcumin interaction and 
thus resulted in higher EE and LC.  











F10 4 mg/mL 1:10 198.3±9.2d  53.7±2.5b  5.37±0.25a -35.6±0.78c  
F10 4mg/mL 1:20 173.4±1.5e  89.0±1.2a  4.45±0.34b -35.7±0.98c  
F20 4mg/mL 1:10 276.1±7.3b  32.5±3.5c  3.25±0.27d -37.4±0.63b  
F20 4mg/mL 1:20 251.9±2.1c 88.4±4.2a  4.42±0.15b -38.2±0.74ab  
F50 3mg/mL** 1:10 338.8±7.5a  40.6±3.5c  4.06±0.08c -39.0±0.92a  
F50 3mg/mL** 1:20 313.0±10.2ab 87.9±5.0a  4.39±0.30b -39.1±0.58a  
Control 4mg/mL 1:20 160.7±7.3e  57.8±3.4b  2.89±0.17e -35.7±0.88c  
* Data with different letters showed significant difference (n=3, P<0.05). 




It was suggested from the results above that hydrophobic interaction played an 
important role in the formation and drug incorporation of FA-SPI nanoparticles. 
However, there has been no standard method to quantify hydrophobic interaction 
directly to our knowledge. Instead, several methods are proposed for further 
studies to measure this interaction in an indirect way. Tryptophan fluorescence 
could be altered when the hydrophobicity of its micro-environment changed, thus 
reflecting the conformational change of FA-SPI upon curcumin loading. Titration 
calorimetry could be used to gauge the gross energy change when the 
protein-curcumin association takes place, giving data on the protein-curcumin 
affinity. Furthermore, if the hydrophobic interaction involves the burial of surface 
groups of the protein, its intensity could be estimated by surface properties such as 
surface charge and hydrophobicity.  
3.4.5 SEM analysis of blank and curcumin-loaded FA-SPI nanoparticles 
Figure 3.3 showed the morphology of curcumin-loaded FA-SPI nanoparticles at 
different stages of preparation. When FA-SPI molecules were desolvated by 
ethanol, they aggregated into spherical particles with smooth surfaces (Figure 
3.3A). The size varied from 150 to 250 nm, which was consistent with the data 
from DLS study. The conjugation degree did not show any significant influence 
on the size and shape of the particles under SEM; therefore, only one 
representative image for F20 (Figure 3.3A) and one for control SPI (Figure 3.3D) 





Figure 3.3 SEM images of FA-SPI nanoparticles. 
(A) FA-SPI (F20) nanoparticles desolvated by 80% (V/V) ethanol, (B) curcumin-loaded 
FA-SPI (F20) nanoparticles, (C) same as B, with ethanol evaporated, and (D) 
nanoparticles formed with control SPI. The white bars indicated 100 nm. 
When curcumin was incorporated, the particles maintained their spherical 
structure, although some of them were observed to approach each other and form 
denser clusters (Figure 3.3B). Similar results were reported in our study on 
non-conjugated SPI nanoparticles as well as some other research articles [62, 108]. 
After the evaporation of ethanol, part of the particles tended to separate from each 
other (Figure 3.3C). Such separation behavior was also reported in our previous 
study [105], and it was considered as driven by the folding of hydrophobic sites 
that caused a decreased hydrophobic attractive interaction, together with an 
increase in electrostatic repulsion upon the removal of desolvating reagents. On 
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the other hand, the size and shape of the particles were maintained, indicating 
successful crosslinking within these particles by glutaraldehyde. 
3.4.6 XRD analysis of blank and curcumin-loaded FA-SPI nanoparticles 






















Figure 3.4 XRD patterns of FA-SPI, curcumin (CUR), their physical mixture (F/C Mix, 
Curcumin: protein=1:20) and FA-SPI encapsulated curcumin (F/C Encap, Curcumin: 
protein= 1:20) 
The encapsulation of curcumin in FA-SPI nanoparticles was further evidenced by 
XRD analysis. As shown in Figure 3.4, curcumin exhibited several peaks at 8.84, 
12.10, 14.39, 17.20, 23.33, 24.50, 25.52 and 28.87 degrees. These peaks suggested 
the highly crystalline nature of curcumin, which was in consistence with previous 
literatures [32]. On the contrary, FA-SPI nanoparticles showed only two humps 
that suggested its amorphous structure. The characteristic peaks for curcumin was 
also found on the XRD pattern of the physical mixture (F/C Mix) of curcumin and 
FA-SPI (curcumin: protein = 1: 20, w/w), but they were not observed on the 
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diagram for the curcumin-loaded FA-SPI nanoparticles (F/C Encap). These results 
were indicative for the dispersion of curcumin in the polymeric matrix, which 
facilitated the conversion of curcumin to amorphous state. 
3.4.7 Release profile of curcumin in PBS-Tween 20 buffer 
Figure 3.5 depicted the release of curcumin from control SPI and FA-SPI 
nanoparticles in PBS-Tween 20 buffer. For both samples, a burst effect was 
observed in the first 1 h, in which 24% (SPI) and 29% (FA-SPI) of the 
encapsulated curcumin was detected in the releasing medium. This phenomenon 
has been reported in a previous literature [37], and it was attributed to the swelling 
and decomposition of the protein matrix, as well as the migration of curcumin 
bound to the peripheral domains of the nanoparticles. In the following 7 h, a 
sustained release profile was observed, in which the curcumin content in the 
releasing medium increased at a lower rate as compared to the first hour. This 
phenomenon was possibly related to the release of curcumin entrapped inside the 
polymeric matrix. At the end of the eighth hour, 39% and 58% of the encapsulated 
curcumin was released from SPI and FA-SPI nanoparticles, respectively. The fact 
that less curcumin was released from SPI than the one reported in our previous 
study [105] was probably the application of dialysis centrifugation, which gave a 
higher efficiency of separating released (free) curcumin molecules from the bound 
ones. Compared with SPI, FA-SPI nanoparticles exhibited a faster and more 
complete releasing profile. This might be explained by the higher EE and LE of 
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FA-SPI nanoparticles, i.e., more curcumin molecules were encapsulated in the 
nanoparticle, resulting in a higher local concentration of curcumin. Therefore, the 
migration of curcumin molecules into the releasing buffer was facilitated.  
In comparison with other FA-conjugated nanoparticles [53, 58, 108], the releasing 
rate observed for FA-SPI particles was significantly higher. This difference could 
be partly ascribed to the difference in methodology. In the literatures mentioned 
above, membrane dialysis was used to measure the releasing kinetics. In our 
preliminary study, however, it was found that the free drug permeated through the 
membrane at a relatively low rate (only 20% accumulative release after 4 h). 
Therefore, not all of the released drug can be collected timely in the filtrate, 
resulting in a lower releasing rate than observed in our study. 
 
Figure 3.5 Release of curcumin from SPI and FA-SPI nanoparticles in Tween 20/PBS  
3.4.8 Cellular uptake of SPI and FA-SPI nanoparticles 
Figure 3.6 presented the time-dependent cellular uptake of FITC-labeled SPI and 



























weaker but detectable fluorescence. In addition, non-encapsulated curcumin could 
pass across the cell membrane in a certain amount, which complicates the 
interpretation of the results. To examine the ‘pure’ effect of FA on the uptake of 
SPI nanoparticles, empty particles were used instead of those loaded with 
curcumin. At all investigated concentrations, no significant cytotoxicity was 
detected by MTT assay (data not shown). At 200 μg/mL, the initial fluorescence 
intensities of the two nanoparticle dispersions were approximately 110,000 
without significant difference. Compared with the control, FA-SPI nanoparticles 
exhibited consistently higher cellular uptake, and the advantage became more 
significant as the time or protein concentration increased. After 24 h, the uptake of 
FA-SPI nanoparticles was at most 93% higher than that for control SPI.  
 
Figure 3.6 Uptake of SPI and FA-SPI nanoparticles in Caco-2 cells. 
The concentrations of protein nanoparticles were 200 (A), 100 (B) and 50 (C) μg/mL. 
Bars with different letters (a and b) indicate significant (P<0.05) difference. 
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Enhanced cellular uptake by FA conjugation was also evidenced by the 
fluorescence micrographs of FITC-labeled nanoparticle loaded Caco-2 cells 
(Figure 3.7). Yang et al [55] reported the abundance of folate receptor protein in 
colorectal cancer cell lines such as HT29 and Caco-2. In their study, an improved 
uptake (50-75%) of positively charged chitosan nanoparticles by these two cell 
lines was achieved by FA conjugation, which was attributed to the 
receptor-mediated endocytosis. Our results were consistent with the 
aforementioned study, indicating that FA conjugation also improved the uptake of 
negatively charged SPI nanoparticles by Caco-2 cells. In addition, more 
significant improvement in the uptake of FA-conjugated nanoparticles has been 
reported on other cell lines [58, 108, 116], including prostate cancer (FA-HSA, 
accurate values not given), Y79 (FA-PLGA, 3-fold increase) and HeLa cells 
(FA-PEG-L-tyrosine polyphosphate, 5-fold increase). Therefore, we speculated 
that the improvement in uptake of FA-SPI nanoparticles by these cells would be 
more significant in those cells compared to Caco-2 cells.  
 
Figure 3.7 Uptake of FITC-labeled SPI (A) and FA-SPI (B) nanoparticles by Caco-2 cells 




FA-SPI conjugate was synthesized successfully by a carbodiimide aided method 
and employed as a nano-encapsulant. Particles with an average size of 150-170 nm 
and zeta potential of -35 to -42 mV were prepared. Compared with control SPI, 
FA-SPI conjugates formed a greater number of nanoparticles with a lower average 
size in 80% aqueous ethanol. In addition, they exhibited an LC that was 57% 
higher than SPI nanoparticles, and they demonstrated a faster and more complete 
release of curcumin in Tween 20-PBS buffer. These differences could be probably 
attributed to the introduction of folic acid backbone, which might have provided 
SPI with additional hydrophobicity and hydrogen bonding capacity. Cellular 
uptake of the SPI nanoparticles was improved by at most 93% upon the 
conjugation with folic acid, and no significant cytotoxicity was detected to Caco-2 
cells. These merits made FA-SPI nanoparticles an attractive candidate for the 




Chapter 4 Carboxymethyl Chitosan-Soy Protein Complex 
Nanoparticles for the Encapsulation and Controlled Release of 
Vitamin D3 
4.1 Abstract 
In this chapter, complex nanoparticles were developed from carboxymethyl 
chitosan (CMCS) and soy protein isolate (SPI) via a simple ionic gelation 
approach. The effect of Ca2+ concentration, pH, and mass ratio on the formation of 
nanoparticles was systematically investigated. Vitamin D3 (VD), a hydrophobic 
micronutrient, was successfully incorporated into the polymeric complex, forming 
particles with sizes between 162 and 243 nm and zeta potentials ranging from -10 
to -20 mV. In comparison with CMCS, the CMCS/SPI complex formed a larger 
quantity of smaller nanoparticles at lower CaCl2 concentrations, resulting in an 
increased loading capacity to 6.06%. Furthermore, the complex nanoparticles 
achieved significantly higher encapsulation efficiency (up to 96.8%), possibly due 
to their compact structure and high capability of hydrogen bonding as evidenced 
by Fourier transform infrared spectroscopy (FTIR). In contrast to the ones 
prepared with SPI, the complex nanoparticles exhibited a reduced (42.3% 
compared to 86.1%) release of VD in simulated gastric fluid and an increased 
(36.0% compared to 8.2%) release under simulated intestinal condition. These 
characteristics made CMCS/SPI complex nanoparticles an attractive candidate for 




Nutraceuticals and bioactives are frequently fortified in functional foods to 
provide desirable health benefits. However, the efficacy of these compounds is 
often compromised by their poor water solubility, rapid degradation and low 
absorption [117-119]. In the past decades, biopolymer-based nanoparticles have 
drawn increasing interest as a vehicle for the protection and delivery of bioactive 
compounds [1]. The nano-scaled size contributes to higher solubility, better tissue 
permeability, prolonged clearance time, and improved cellular uptake of the 
entrapped compounds [22]. In addition, the polymeric matrix provides remarkable 
protection to the incorporated compounds against thermo- or photo-degradation 
[32]. Compared with the synthetic polymer-based systems, these nanoparticles 
exhibit lower cytotoxicity and higher degradability [23]. All of these features 
make them an attractive candidate as an efficacy enhancer for the functional foods. 
Proteins are amphiphilic biomacromolecules that can interact effectively with both 
the solvent and the encapsulated compounds. Among the proteins that have been 
utilized to develop nano-scaled delivery systems [23, 30, 86], soy protein has been 
highlighted for its natural abundance, desirable water solubility, and balanced 
amino acid profile that facilitates the protein-nutraceutical interaction [27]. 
Various soy protein-based delivery systems have been developed by far, including 
hydrogels, microspheres and microemulsions [24, 67, 89]. Recently, nanoparticles 
have been successfully prepared with soy protein isolate (SPI) by two methods, 
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ethanol desolvation from our lab [105] and Ca2+-induced cold gelation from other 
labs [25], both of which resulted in a particles size of 150 to 200 nm with desirable 
stability. Our previous study showed that SPI nanoparticles exhibited satisfying 
encapsulation efficiency for hydrophobic compounds such as curcumin [105]. 
However, SPI exhibited a high digestibility under gastric conditions [120]. This 
makes SPI nanoparticles only capable for delivering bioactive compounds through 
injection, while their application in oral administration is limited. 
Polysaccharides as another major category of biopolymers have found numerous 
applications in the food and pharmaceutical industry [121, 122]. Chitosan, the 
deacetylated form of chitin, has been reported extensively as an encapsulant for 
bioactive compounds, such as vitamins and minerals [39, 123], catechins [110] 
and proteins [41]. One of its derivatives, carboxymethyl chitosan (CMCS), 
exhibited desirable solubility at neutral pH because of its charged –COO- group 
[51]. Similar to SPI, CMCS was able to form nanoparticles through a simple ionic 
gelation process with Ca2+. These nanoparticles were applied in the encapsulation 
of a number of therapeutic drugs [38, 124]. In addition, CMCS has been employed 
in complexation with proteins such as zein to prepare hybrid nanoparticles [51]. 
Probably due to a more compact structure, the complex nanoparticles were found 
to provide additional protection to the embedded compounds against heat or 
light-induced degradation. More importantly, CMCS becomes insoluble and forms 
a gel-like barrier in the polymeric matrix at gastric pH (1.4~2.0) due to the 
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protonation of the carboxylic group. Such feature allows CMCS to detain 
significantly the decomposition of the protein matrix, thus minimizing the release 
of the embedded compounds in the stomach and maximizing their availability for 
intestinal absorption.   
In the present study, complex nanoparticles were prepared from CMCS and SPI by 
ionic co-gelation with Ca2+. The particles were analyzed for their average size, 
count rate, and morphology, in comparison with those formed by single 
encapsulants (i.e., CMCS or SPI). The effects of CaCl2 concentration, CMCS/SPI 
mass ratio and pH were systematically investigated. A typical micronutrient, 
vitamin D3 (VD), was incorporated in the nanoparticles as a model compound. 
The encapsulation capability and releasing profile in simulated gastrointestinal 
tract were evaluated. Finally, Fourier transform infrared (FT-IR) spectrometry and 
zeta potential analysis were carried out to probe into the possible interactions 
involved in the encapsulation process. 
4.3  Materials and methods 
4.3.1 Materials 
ProliaTM 200/70 Defatted Soy Flour was a sample generously provided by Cargill 
Inc., Cedar Rapids, IA. The soy flour contained 54% protein and less than 1% oil 
(dry basis). Chitosan with deacetylation degree of 77% and medium molecular 
weight was purchased from Sigma-Aldrich (St. Louis, MO, USA). Calcium 
chloride, vitamin D3 (VD) and all other reagents were of analytical grade. 
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4.3.2 Preparation of SPI 
SPI was prepared by an isoelectric precipitation approach. Defatted soy flour was 
extracted for 1 h with 15-fold (w/w) of deionized water, which was adjusted to pH 
8.0 using 1 mol/L NaOH. The dispersion was centrifuged at 10,000 g for 15 min, 
after which the precipitation was discarded, and the supernatant was then acidified 
to pH 4.5 with 1 mol/L HCl. A second centrifugation was undertaken, after which 
the protein-rich precipitate was re-suspended in water and adjusted to pH 7.5 with 
1 mol/L NaOH. The suspension was dialyzed against deionized water for 24 h and 
lyophilized for 48 h. The moisture content of the final product was less than 5%, 
and the protein content was 90% as determined by Bradford assay with bovine 
serum albumin as a standard protein. The following composition of the product 
was estimated by SDS-PAGE densitometry [66]: 56% glycinin, 37% 
β-conglycinin, and 7% others (aggregates, α-conglycinin, lipoprotein, etc.). 
4.3.3 Preparation of CMCS 
CMCS was prepared using a previously reported method [125]. Sodium hydroxide 
(27.2 g) was dissolved in an isopropanol-water mixture (160: 40, v/v), in which 20 
g chitosan was added and stirred gently at 50 oC for 1 h. Thereafter, 30 g of 
monochloroacetic acid dissolved in 40 mL isopropanol was added dropwise to the 
dispersion and incubated at 50 oC for 4 h. The resultant suspension was then 
filtered with a Whatman No. 1 filter paper and washed with 80% aqueous alcohol 
(v/v) until the filtrate was neutral. The remaining solid was oven dried at 60°C to 
obtain the CMCS powder. The degree of carboxymethylation of the product was 
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0.67 as was determined by a previously reported conductimetric titration method 
[126]. The average molecular weight of CMCS was 139 kDa estimated by 
viscosity measurement together with classic Mark–Houwink equation [η] = 
7.92×10–5 M [127]. 
4.3.4 Preparation of empty and VD-loaded SPI/CMCS nanoparticles 
Nanoparticles were synthesized with SPI, CMCS, and their mixtures, using an 
ionic gelation method [25]. To avoid the degradation of VD, all of the treatments 
and assays in the following paragraphs were conducted in darkness. The stock 
solutions of SPI and CMCS were prepared by dissolving them in deionized water 
at a concentration of 10 mg/mL, followed by the removal of large aggregates via 
centrifugation at 10,000 g for 15 min. In order to prepare nanoparticles with single 
ingredient, appropriate dilution was carried out so that a concentration of SPI or 
CMCS of 0.9 mg/mL was achieved. For the preparation of CMCS/SPI complex 
nanoparticles, the stock solution of CMCS was added to that of SPI dropwise, 
after which proper dilution was performed. The mass ratio of CMCS and SPI in 
the mixed dispersion was set at 2:1, 1:1 and 1:2, while the total polymer 
concentration was fixed at 0.9 mg/mL. Mild stirring was applied throughout the 
mixing process to avoid precipitation. The pH of the aforementioned suspension 
varied from 7.5-9.8, and it was adjusted to 6.5, 7.5, 8.5 and 9.5 ,using 1 M HCl or 
NaOH. To prepare VD-encapsulated nanoparticles, VD solution (10 mg/mL in 
pure ethanol) was added dropwise to the resulting solution to achieve a polymer: 
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VD mass ratio of 10:1. For the preparation of empty nanoparticles, a same amount 
of pure ethanol without VD was mixed with the dispersion. To 2.5 mL of the 
mixture, 4 mL of CaCl2 solution was added dropwise under vigorous stirring. The 
final concentration of SPI, CMCS, or their mixture in the resulting suspension was 
0.36 mg/mL, while the content of CaCl2 ranged from 0.1 to 1.8 mg/mL. The 
formed nanoparticles were purified by centrifugation at 30,000 g for 15 min, 
re-dispersed in deionized water at the same concentration and freeze dried. 
4.3.5 Determination of particle sizes and count rates 
At different stages of preparation, both empty and VD-loaded nanoparticles were 
measured for their particle sizes and count rates by dynamic laser scattering (DLS). 
A BI-200 SM Goniometer Version 2 (Brookhaven Instrument Corp., Holtsville, 
NY, USA) with a 35 mW He-Ne laser beam at a wavelength of 637 nm and a 
scattering angle of 90° was used. The obtained data were analyzed using cumulant 
algorithm, and the z-average size was reported. All samples were measured in two 
separate assays, and no dilution was performed before each measurement. To 
obtain an accurate particle size, appropriate apertures were selected so that the 
count rates were within the range of 100 to 300 kcps, and the refractive indices for 
CMCS (1.55) and SPI (1.43) were applied. The influence of CMCS, SPI and Ca2+ 
on the viscosity of solvent was not detected at all investigated concentrations (data 
not shown). Therefore, the viscosity of solvent (water) at 25 °C was used 
throughout the study. In order to obtain comparable count rates, the power of laser 
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was fixed at 10 mW (except for the dispersions containing only CMCS and less 
than 0.2 mg/mL CaCl2, for which 20 mW was used), and an aperture pinhole size 
of 400 μm was adopted consistently. All assays were conducted at 25ºC for 1 min, 
and the data were analyzed by the BIC Dynamic Scattering Software (Brookhaven 
Instrument Corp., Holtsville, NY, USA). 
Based on the results obtained from this section, the range of Ca2+ concentrations 
for nanoparticles formation and precipitation were determined as a function of pH 
[38]. Nanoparticles were deemed ‘formed’ in a solution when the following two 
criteria were met: (1) the average particle size exceeded 50 nm, and (2) the 
turbidity was at least than twice that of the polymer solution without Ca2+.  
4.3.6 Determination of the zeta potential 
Both empty and VD-loaded nanoparticle dispersions were measured for their 
electrophoretic mobility by laser Doppler velocimetry, using a Nano ZS90 
Zetasizer (Malvern Inc., Malvern, UK) with compatible fold capillary cuvettes. 
The samples were prepared and measured in triplicates, and at least twelve runs 
were carried out for each measurement. The data were then converted to zeta 
potentials using the Smoluchowski model.  
4.3.7 Morphological and compositional analysis 
The morphology of empty and VD-loaded nanoparticles was observed by 
scanning electron microscopy (SEM). Forty microliters of the nanoparticle 
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dispersions was dripped and cast-dried on an aluminum pan, which was cut into 
appropriate sizes and then adhered to a 1-inch specimen stub with conductive 
carbon tapes (Electron Microscopy Sciences, Ft. Washington, PA, USA). The 
samples were then coated with a thin layer (<20 nm) of gold and platinum using a 
sputter coater (Hummer XP, Anatech, CA, USA) and observed under SEM 
(Hitachi SU-70 Pleasanton, CA, USA). Representative images were reported. 
Meanwhile, the dispersions of the empty nanoparticles were cast dried, coated and 
analyzed for their composition under SEM with an energy dispersive X-ray (EDX) 
detector [128]. In the SEM-EDX analysis, the elements in the nanoparticles were 
excited by the electron beam from the SEM anode and produced characteristic 
X-ray peaks, which were acquired by the a Bruker SOL-XE detector and analyzed 
by the integrated software (Bruker AXS Inc., Madison, WI). In this study, the 
contents of different elements (C, O, N, Ca and Cl) were estimated as the 
percentage of their corresponding peaks by normalized area in the EDX spectrum. 
4.3.8 Determination of EE and LC 
The EE of VD-loaded nanoparticles was calculated by a previously reported 
method [51]. Ten milligrams of the freeze-dried nanoparticles was washed with 
approximately 5 mL hexane, and the suspension was filtrated through a Whatman 
No. 1 filter paper. The filtrate was subjected to spectrophotometric measurement 
at 264 nm with a DU-730 UV/VIS spectrophotometer (Beckman Coulter Inc., 
Fullerton, CA, USA). This procedure was repeated for two to four times until the 
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last filtrate did not exhibit any absorbance. Then all the filtrates were combined 
and measured again for its absorbance at 264 nm, which was converted to the 
content of free (non-encapsulated) VD using an established calibration curve 
(R2=0.9997). The powder (nanoparticles) remaining after the filtration was dried 
under reduced pressure and weighed. The EE and LC of the samples were 
calculated with the equations:  
EE (%) = 100 −  
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑜𝑜𝑜𝑜 𝑜𝑜𝑓𝑓𝑊𝑊𝑊𝑊 𝑉𝑉𝑉𝑉
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑜𝑜𝑜𝑜 𝑜𝑜𝑜𝑜𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑡𝑡𝑊𝑊𝑓𝑓 𝑉𝑉𝑉𝑉
 × 100 
LC (%) =
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑜𝑜𝑜𝑜 𝑜𝑜𝑜𝑜𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑡𝑡𝑊𝑊𝑓𝑓 𝑉𝑉𝑉𝑉 −𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑜𝑜𝑜𝑜 𝑜𝑜𝑓𝑓𝑊𝑊𝑊𝑊 𝑉𝑉𝑉𝑉
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑜𝑜𝑜𝑜 𝑛𝑛𝑓𝑓𝑛𝑛𝑜𝑜𝑛𝑛𝑓𝑓𝑓𝑓𝑡𝑡𝑊𝑊𝑛𝑛𝑓𝑓𝑊𝑊𝑛𝑛
 × 100 
4.3.9 Release of VD in simulated gastrointestinal tract 
After lyophilization, the VD-loaded nanoparticles were washed with hexane as 
discussed above. Eight milligrams of the resulting powder was dispersed in 15 mL 
of simulated gastric fluid containing 1 mg/mL pepsin and 5 mg/mL Tween 20. 
The suspension was incubated at 37 oC with gently shaking on a Multi-Purpose 
Rotator/Rocker (Scientific Industries Inc., NY, USA) for 0.5 h, after which the 
mixture was adjusted to pH 7.5 to deactivate pepsin. After a centrifugation at 
20,000 g and 4 oC for 15 min, the supernatant containing the released VD was 
collected and freeze-dried, while the precipitate was re-dispersed in simulated 
intestinal fluid containing 10 mg/mL pancreatin and 5 mg/mL Tween 20. The 
dispersion was incubated and shaken as abovementioned for 4 h, and a second 
centrifugation under the same condition was carried out. The supernatant was 
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freeze-dried, while the precipitate was discarded. The powder yielded after 
lyophilization was suspended in cold hexane and extracted under vigorous stirring 
for 10 min. The suspension was then filtered again and measured for its 
absorbance at 264 nm, which was converted to the content of released VD.  
4.3.10 FT-IR study of the nanoparticles 
Both the empty and VD-incorporated nanoparticles were analyzed for their 
infrared spectra. After being freeze-dried and washed with hexane, approximately 
three milligrams of each sample was mounted onto a Jasco FT/IR 4100 
spectrometer (Jasco Inc., Easton, MD, USA). The infrared transmittance was 
acquired from the wavenumber of 1000 to 4000 cm-1 at a resolution of 4 cm-1. At 
least 90 scans were performed for each sample. The spectra were averaged and 
smoothed, and their baselines were calibrated with the Spectra Manager software 
(Jasco Inc., Easton, MD, USA). Quantitative studies were performed using the 
OMNIC software (Thermo Scientific, West Palm Beach, FL, USA). 
4.3.11 Statistics 
All measurements were performed in triplicates. The results obtained were 
presented as means ± standard error. Data were analyzed by analysis of variance 
(p < 0.05) using the Origin 7.5 software (OriginLab Corp., MA, USA). 
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4.4 Results and Discussion 
4.4.1 Effect of Ca2+ on the formation of CMCS/SPI nanoparticles 
The sizes and count rates of the nanoparticles formed with CMCS, SPI and their 
complexes in the presence of different concentrations of CaCl2 at pH 7.5 were 
compared in Figure 4.1. At CaCl2 concentrations of 0 and 0.2 mg/mL, the average 
sizes of CMCS were 7.4 and 20.5 nm, respectively (Figure 4.1A). The majority of 
CMCS molecules might have existed as free polymers or oligomers as indicated 
by low count rate (Figure 4.1B) and turbidity (not shown). As the concentration of 
CaCl2 increased to 1.2 mg/mL, the particle size increased gradually to 206.7 nm, 
together with a continuous increase in the count rate. The count rate of a colloidal 
system was derived from the intensity of the scattered laser, which is proportional 
to the number of the particles as well as the sixth power of their sizes [23]. When 
the sizes are comparable, increasing count rates was indicative for an increase in 
the number of nanoparticles [105]. When more than 1.6 mg/mL of CaCl2 was 
present in the dispersion, particles with sizes of greater than 1000 nm were formed, 
and they precipitated within 30 minutes after the formation.  
The dispersion of SPI, on the contrary, exhibited an average particle size of 94.8 
nm and a count rate of 15.4 kcps in the absence of CaCl2, and these numbers 
increased rapidly to 427.7 nm and 490 kcps as the concentration of CaCl2 
increased to 0.2 mg/mL. Further addition of CaCl2 induced the precipitation of the 
particles. These results implied that SPI tended to aggregate into nanoparticles at 
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relatively low CaCl2 concentrations. In addition, a comparison was made between 
the nanoparticle dispersions formed with 0.35 mg/mL SPI, 0.1 mg/mL CaCl2, and 
those with 0.35 mg/mL CMCS, 1.2 mg/mL CaCl2. The former dispersion 
exhibited a lower particle size, but its count rate was 107% higher than that of the 
latter one. According to our previous study [105], such results suggested that 























































Figure 4.1 Effect of CaCl2 concentrations on the size (A), count rate (B) and zeta 
potential (C) of CMCS/SPI nanoparticles at pH 7.5 and a total polymer concentration of 
0.35 mg/mL. 
Electrostatic interaction between oppositely charged molecules is the chief driving 
force of nanoparticles formation through cold gelation [2]. To elucidate whether 
the surface charge was the major reason for the different particle forming 
behaviors between CMCS and SPI, we measured the zeta potentials of the 
prepared nanoparticle dispersions. As can be seen in Figure 4.1C, at pH 7.5, 
CMCS and SPI exhibited a zeta potential of -19.4 and -23.2 mV, respectively, and 
all of the mixtures were negatively charged. When CaCl2 was introduced into the 
dispersion, the zeta potential decreased gradually (in terms of its absolute value, 
same hereinafter), indicating the adsorption of Ca2+ to the surface of CMCS or SPI 
molecules, which helped crosslinking these molecules into nanoparticles. 
However, the minor difference in zeta potentials between CMCS and SPI was 




























phenomena of these two molecules. Instead, two other factors, surface 
hydrophobicity and chain rigidity, might have played a major role. Compared with 
polysaccharides, protein molecules are known to possess a greater amount of 
hydrophobic side chain on their surfaces [52, 129]. In addition, polysaccharides 
such as CMCS tend to adapt an extended linear conformation because of the 
existence of its bulky sugar ring [130], whereas globulins such as SPI generally 
exhibited a convoluted structure with higher chain flexibility [65]. Therefore, it 
could be speculated that CMCS molecules exhibited weaker hydrophobic 
associative interactions together with stronger steric repulsions in comparison with 
SPI. Therefore, more Ca2+ was required to adsorb to CMCS in order to provide 
stronger electrostatic attraction, which brought the CMCS molecules into 
proximity and then cross-linked them to form spherical nanoparticles. This 
inference was supported by the fact that the Ca2+-crosslinked CMCS nanoparticles 
exhibited a less negative zeta potential than the SPI counterparts.  
For the CMCS/SPI complexes, they formed nanoparticles with similar sizes and 
count rates as SPI in the presence of 0 to 0.2 mg/mL CaCl2 (Figure 4.1A, 4.1B). 
These values continued to increase until precipitation occurred at a threshold 
CaCl2 concentration, depending on the mixing ratio. Besides, the complex 
dispersion exhibited significantly (P<0.05, same hereinafter) higher count rates 
than the single ones. A maximal count rate of 626.8 kcps was achieved in the 
presence of 0.12 mg/mL CMCS, 0.23 mg/mL SPI and 0.8 mg/mL CaCl2. This 
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value was 46% and 190% higher than the highest ones obtained with SPI and 
CMCS, respectively. Meanwhile, the average size of CMCS/SPI particles pairing 
with the greatest count rate was 265.6 nm, which was lower than the 
corresponding values for SPI (267.4 nm) and CMCS (417.6 nm). These results 
indicated that a larger quantity of nanoparticles with smaller size could be formed 
by the complexation of CMCS and SPI. At the CaCl2 concentration of 0.2 to 1.6 
mg/mL, the particles formed with a CMCS/SPI ratio of 1:1 exhibited a highest 
zeta potential (Figure 4.1C). This result suggested that a maximum number of 
charged groups were exposed to the surface of the particles at this mass ratio. 
4.4.2 Effect of pH on the formation of CMCS/SPI nanoparticles 
The boundary CaCl2 concentrations for nanoparticle formation and precipitation 
were depicted in Figure 4.2. The natural pH of water solutions were 9.5 and 7.5 
for CMCS and SPI, respectively. The minimal concentration required for CMCS 
nanoparticle formation was highly dependent on pH, increasing from 0.2 mg/mL 
at pH 6.5 to 3.0 mg/mL at pH 9.5. In contrast, the critical concentration for SPI 
nanoparticle formation only increased from 0.02 to 0.04 mg/mL as pH increased. 
At CaCl2 concentrations higher than 0.225 mg/mL, rapid precipitation was 
observed in the SPI dispersion at all the pH studied. CMCS, however, did not 
precipitate until a CaCl2 concentration varying from 0.8 mg/mL (pH 6.5) to 4.0 
mg/mL (pH 9.5) was achieved. These results revealed the difference between 






Figure 4.2 Critical concentrations of CaCl2 for the formation of SPI, CMCS and 
CMCS/SPI mixture (1:1, w/w) as a function of pH. White open bars – clear solution, gray 
shaded – nanoparticles, gray solid – precipitate. 
In addition to the critical concentrations, the optimal CaCl2 concentrations for the 
formation of CMCS/SPI nanoparticles at different pH were determined and 
summarized in Table 4.1. At each pH, an optimized CaCl2 concentration was 


























































particle formation listed in Section 4.2.5 were met. When the first requirement 
was satisfied, a minimal particle size should be achieved at this pH. Lastly, when 
the size difference between two formulas was less than 20 nm, the CaCl2 
concentration that resulted in a maximal count rate was chosen. As the pH was 
decreased from 9.5 to 6.5, there was a significant decrease (from 6.0 to 0.4 mg/mL) 
in the optimal concentration of CaCl2 for CMCS to form nanoparticles. In the 
meantime, the sizes of the formed particles decreased greatly from 1068 nm at pH 
9.5 to 162.7 nm at pH 6.5, while the count rates increased from 7.5 to 190.0 kcps 
concomitantly. On the contrary, the mean size and count rate of SPI nanoparticles 
kept stable at around 150 nm and 190 kcps, respectively, at pH 6.5-9.5. In addition, 
the optimal Ca2+ concentration was only one fourth (pH 6.5) to one thirtieth (pH 
9.5) of that for CMCS nanoparticles. 
From the results discussed above, it is clear that the particle forming behaviors of 
CMCS and SPI were significantly different, especially at neutral to basic pH. 
Theoretically, this difference could be attributed to two factors, i.e., surface charge 
and polymeric chain rigidity. The zeta potential of CMCS dispersion at pH 9.5 
(-58.7 mV) was significantly higher than that at pH 6.5 (-16.3 mV), suggesting 
that more Ca2+ was required to overcome the stronger electrostatic repulsion 
among CMCS molecules and crosslink them into nanoparticles at pH 9.5. In 
addition, the potent repulsion between the –COO- groups on a single CMCS 
molecule might have further increased the chain rigidity, especially at higher pHs 
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[12]. This added to the difficulty for CMCS to fold, rotate, or approach each other, 
which might explain for the large particle size and low count rate at relatively high 
pH. On the other hand, SPI dispersion exhibited more similar zeta potentials (-36.8 
and -24.2 mV, respectively) at pH 9.5 and 6.5. Besides, the globular conformation 
of SPI might have facilitated the formation of nanoparticles as discussed in the 
previous section. Therefore, there was no need for additional Ca2+ to overcome the 
electrostatic or steric repulsion at pH 9.5 compared to pH 6.5. 
From the perspective of application, the above results suggested that SPI was a 
more suitable particle former than CMCS in the presence of Ca2+. Firstly, a larger 
quantity of nanoparticles (indicated by higher count rate) with smaller average size 
could be formed by SPI, giving a higher yield of particles. Secondly, the CaCl2 
content in SPI nanoparticles was less than one tenth that for CMCS, which helps 
lowering the risk of calcium overdose after oral administration. Lastly, since the 
particle formation of SPI was virtually not influenced by pH, it could be utilized 
over a broader range of pH or in the environment with fluctuating pH. 
Table 4.1 Effect of pH on the CaCl2 dose, size and count rate of CMCS/SPI nanoparticles 
pH CaCl2 
(mg/mL) 




CMCS    
9.5 6.0 1068.0±25.4a 12.5±0.8i 
8.0 3.6 637.5±10.5b 25.8±2.5h 
7.5 1.2 417.6±7.8c 87.9±4.5g 
7.0 1.0 255.1±6.5d 181.1±12.7e 
6.5 0.6 162.7±10.2f 190.0±10.6e 
    
SPI    
104 
 
9.5 0.20 157.4±5.3f 180.4±10.2e 
8.0 0.14 143.6±2.4g 190.7±9.5e 
7.5 0.12 137.1±1.7g 186.1±10.0e 
7.0 0.12 141.7±4.2g 200.5±7.7e 
6.5 0.10 152.6±7.6f 201.7±2.5e 
    
C:S=1:1    
9.5 0.40 238.8±9.5d 96.5±4.6g 
8.0 0.30 243.2±6.7d 125.3±10.5f 
7.5 0.20 267.4±3.5d 314.3±23.5d 
7.0 0.20 265.1±7.4d 360.9±13.2c 
6.5 0.15 162.7±5.2f 425.7±15.7b 
* Data with different letters showed significant difference (n=3, P<0.05). 
When CMCS and SPI were co-dispersed in water, the abovementioned advantages 
of SPI were inherited. At pH 6.5-8.0, the CMCS/SPI complex formed 
nanoparticles at CaCl2 concentrations lower than 0.1 mg/mL. The average size 
was 163 nm at pH 6.5 and kept stable at 240-260 nm as pH was increased from 
7.0-9.5, and the count rate was more than two times that achieved by CMCS at 
any given pH. Similar to the case of SPI, these results indicated that CMCS/SPI 
complex could form a larger quantity of smaller particles than CMCS alone over a 
wide range of pH. Therefore, it could be postulated that stronger protection might 
be provided by CMCS/SPI complex than CMCS alone to the encapsulated 
compounds. In addition, this similarity suggested that SPI might have played a 
major role in the extensive formation nanoparticles.  
4.4.3 Effect of centrifugation and lyophilization on the nanoparticles 
Two preparation procedures, centrifugation and lyophilization, were investigated 
for their influence on the size and count rate of the nanoparticles. Results were 
presented in Figure 4.3. Centrifugation is frequently used for separating the 
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nanoparticles from non-encapsulated drugs/nutraceuticals. In our study, all of the 
samples tested could be reconstituted after centrifugation at 30,000 g for 15 min. 
Increasing the centrifugal force or time, however, led to the inability of 
reconstitution. The particle size and count rate after reconstitution were decreased 
approximately by 10% and 40%, respectively. This was probably due to the partial 
separation of the nanoparticles as well as Ca2+ into the supernatant. In addition, the 
zeta potential of the nanoparticles was virtually unchanged upon centrifugation. 
After lyophilization, the samples could be re-dispersed in water at a concentration 
of 5 mg/mL, and they were stable for at least 1 week. However, the particle size 
increased by approximately 80%. The removal of solvent might have allowed the 
nanoparticles to approach each other and then aggregate via hydrophobic and van 


























Figure 4.3 Effect of centrifugation and lyophilization on the size (A) and count rate (B) of 
CMCS/SPI nanoparticles 
4.4.4  Characteristics of VD-loaded nanoparticles 
Table 4.2 summarized the particle sizes, zeta potentials, EE, and LC of the 
VD-loaded nanoparticles. Compared with the SPI, the CMCS nanoparticles 
yielded a higher EE (80.5%). A possible explanation for this difference was that 
CMCS nanoparticles possessed a greater particle size, which allowed for a higher 
capacity of VD incorporation [105]. As for the CMCS/SPI complex nanoparticles, 
they exhibited higher EE than the ones prepared with a single ingredient. In 
addition, increased ratio of CMCS in the complex resulted in increased EE and LC. 
This result suggested that the complex nanoparticles possessed a more compact 
structure, with more functional groups involved in the polymer-vitamin interaction. 
A highest EE of 96.8% was achieved with the nanoparticles formed with a 
CMCS/SPI mass ratio of 2:1, a VD/polymer mass ratio of 1:10 and a CaCl2 
concentration of 0.8 mg/mL CaCl2. However, the overall LC of the CMCS or 



























probably because of the higher CaCl2 concentration applied in these formulas, 
which added to the total weight of the nanoparticles. Our follow-up study showed 
that a higher LC could be achieved by increasing the polymer concentration while 
reducing the CaCl2: polymer mass ratio (data not shown).  
Table 4.2 Characteristics of VD-loaded nanoparticles 










CMCS 213.7±10.5b -10.35±0.25a 80.52±2.54b 2.99±0.16c 10.76±0.52c 
SPI 162.4±6.7c -18.36±0.37c 50.19±1.97c 5.88±0.26a 21.16±0.77a 
C:S=2:1 225.2±10.3ab -9.97±0.09a 94.83±2.54a 4.64±0.37b 16.71±1.01b 
C:S=1:2 178.4±9.6c -13.97±0.19b 84.46±1.67b 6.06±0.15a 21.83±0.47a 
C:S=1:1 243.1±12.4a -16.25±0.86bc 96.75±1.99a 5.48±0.25ab 19.74±0.74ab 
* Data with different letters showed significant difference (n=3, P<0.05). 
The final concentration of loaded VD in the nanoparticle dispersion ranged from 
10.8 to 21.8 μg/mL as indicated in Table 4.2. It is worth mentioning that these 
values were measured before centrifugation and lyophilization; therefore, they 
corresponded to a total polymer concentration of 0.36 mg/mL. After lyophilization, 
the particles could be reconstituted at 5 mg/mL, and the concentration of VD in 
the dispersion was increased accordingly to at most 303 μg/mL.  
Regardless of the formula, there was no significant difference in the zeta potentials 
of the empty and VD-loaded nanoparticles. This could be attributed to the fact that 
VD was slightly negatively charged in water, with a zeta potential of -6 mV. 
Therefore, there was little likelihood that VD was encapsulated by the negatively 
charged SPI or CMCS via electrostatic interaction. Other factors including 
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hydrogen bonding, hydrophobic and van der Waals interaction might have played 
a significant role in the incorporation process. 
4.4.5 FT-IR study on the nanoparticles 
The FT-IR spectra of blank and VD-loaded nanoparticles formed with CMCS, SPI 
and their complex were presented in parallel with that of free VD, as shown in 
Figure 4.4. A major band at 3366 and 3280 cm-1 was observed in the spectra of 
CMCS and SPI nanoparticles respectively. These peaks were denoted to the 
stretching of hydrogen-bonded O-H groups [131]. The sharp peak at 1589 cm-1 in 
the spectrum of CMCS nanoparticles was assigned to the stretching of ionized 
carboxylic group (-COO-), which indicated successful carboxymethylation of the 
chitosan molecules [125]. On the other hand, SPI nanoparticles exhibited two 
characteristic bands [105] at 1635 (amide I, C=O stretching) and 1526 cm-1 (amide 
II, N-H bending).  
 
Figure 4.4 FT-IR spectra for empty CMCS, SPI, VD-loaded CMCS (C-V), SPI (C-V) and 
CMCS/SPI complex (C-S-V) nanoparticles (CMCS: SPI=1: 1, w:w),. and VD. 
A series of bands were observed on the spectrogram of VD, one for hydrogen 
bonded O-H stretch (3292 cm-1), two for alkyl C-H stretch (2935 and 2874 cm-1) 
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and several others in the wavenumber range of 1000-800 cm-1 indicating C-H 
bend. These peaks, however, were not detected in the spectra of VD-loaded 
nanoparticles (the minor band at 2949 in the spectrum SPI-VD was derived from 
that of SPI instead of VD). The disappearance of these characteristic peaks 
indicated successful encapsulation of VD in the polymeric matrix [105]. On the 
other hand, as shown in Table 4.3, there was an increase by up to 246% in the 
intensity of the peaks corresponding to O-H stretch in the spectra of VD-loaded 
nanoparticles, compared to those for the empty nanoparticles. In the meantime, the 
position of these peaks shifted to higher wavenumbers (Table 4.3). These 
differences suggested increased involvement of hydrogen bonding, especially in 
the hydroxyl groups [8], probably with the incorporated VD. In addition, the area 
percentage of this peak was the highest in the spectrum of CMCS-SPI complex, 
followed by that of CMCS and SPI. This sequence was consistent with that of the 
EE as discussed above, which indicated that hydrogen bonding might have played 
a major role in the incorporation of VD into the polymeric matrix. Similar results 
have been reported in previous studies on protein-vitamin complexation [8, 51]. 
From these results, it is speculated that a maximal hydrogen bonding was achieved 
through the complexation between CMCS and SPI, which was favorable for the 
encapsulation of VD. 
Table 4.3 Peak assignment for the spectra of empty and VD-loaded nanoparticles* 





3366 3384 3280 3302 3363 3292 
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 Normalized  
Area% 
18.08% 59.75% 21.02% 44.59% 62.67% 17.03% 
Amide I Position 
(cm-1) 










ND ND ND ND ND 
2935 
2874  
* Refer to Figure 4.4 for original spectra and denotation for samples. CMCS and SPI: empty 
nanoparticles formed with individual ingredients. CMCS-VD and SPI-VD: vitamin D3-loaded 
nanoparticles formed with individual ingredients. CMCS-SPI-VD: vitamin D3-loaded CMCS/SPI 
complex nanoparticles. VD free: non-encapsulated vitamin D3 crystal. 
** Mixed components of amide I and COO-- stretching. 
4.4.6 SEM-EDX study on the nanoparticles 
The morphology of nanoparticles formed with different formulas was compared in 
Figure 4.5. All of the prepared nanoparticles exhibited an approximate spherical 
shape and a smooth surface (Figures 4.5A, B and C). The particle size varied 
from 150 to 250 nm, which was consistent with the data from DLS study. Figure 
4.5D showed the structure of VD-loaded CMCS/SPI complex nanoparticles (VD: 
polymer= 1:10, w/w) after centrifugation, lyophilization and reconstitution. The 
nanoparticles maintained their structure, but they varied in sizes more significantly 
than the freshly prepared samples. At lower magnifications, aggregates having 
size bigger than 1000 nm were observed in the micrograph of the freeze dried 
nanoparticles (data not shown), which could explain for the increased average 





Figure 4.5 SEM-analysis of CMCS (A), SPI (B) and CMCS/SPI (C) nanoparticles, and 
VD-loaded CMCS/SPI nanoparticles after lyophilization (D), as well as the elemental 
analysis of the abovementioned samples (E). 
 
The elemental compositions of the prepared nanoparticles were presented in 
Figure 4.5E. The spectra were acquired at chosen locations on the SEM images 




































CMCS, SPI exhibited a higher content of nitrogen and lower content of oxygen. 
This was consistent with their chemical composition. In the spectra of the complex 
nanoparticles, the contents of oxygen and nitrogen were between those of the 
single ingredients, and they varied according to the mixing ratio. These results 
suggested that both CMCS and SPI participated in the formation of the complex 
nanoparticles.  
4.4.7 Release of VD in simulated digestive fluids 
 
Figure 4.6 Release of VD in simulated gastric and intestinal fluid from CMCS, SPI and 
CMCS/SPI nanoparticles 
The releasing profiles of VD-loaded nanoparticles were depicted in Figure 4.6. 
After incubation at 37 oC in simulated gastric fluid for 30 minutes, over 80% of 
the VD was released from the SPI nanoparticles. In contrast, less than 35% of the 
VD was detected in the releasing medium containing CMCS nanoparticles. Such 
significant difference might be attributed to the following two factors. Firstly, 

























positively charged and soluble [132], whereas CMCS carried none electric charge 
and agglomerated into a gel layer [51]. Besides, the polymeric matrix formed with 
SPI was highly digestible by pepsin [27], while that consisting of CMCS was 
resistant to pepsin digestion and acted as a barrier for the diffusion of vitamins 
[51]. For the CMCS/SPI complex nanoparticles, the releasing rates were at most 
56% lower than that for SPI, suggesting the protection effect provided by CMCS. 
When transferred to the simulated intestinal fluid (pH 7.4), the samples containing 
CMCS became negatively charged and therefore soluble. As a result, at most 83% 
of the remaining VD was released from the polymeric matrix in the following 4 h. 
In addition, among the three tested complex formulas, the one with a CMCS: SPI 
mass ratio of 1:2 resulted in a least amount of released VD. This was probably 
attributed to the greater number of particles achieved by this formula compared 
with the other two, which was evidenced by a higher count rate as discussed in 
Section 4.3.1. The involvement of large quantities of nanoparticles in the 
encapsulation of VD might have reduced its release from the polymeric matrix. 
Based on the above results, CMCS/SPI complex nanoparticles demonstrated 
prominent protection on VD against degradation in the gastric fluid, together with 
an increased amount of VD being delivered to the small intestine, in comparison 




CMCS/SPI complex nanoparticles were successfully synthesized and employed as 
a delivery system for VD. The particles exhibited an average size of 162 to 243 
nm, and they maintained desirable solubility and stability after centrifugation and 
lyophilization. Compared with CMCS, the CMCS/SPI complex required lower 
concentration of CaCl2 to form nanoparticles, and it formed a significantly greater 
number of particles (more than two times higher as indicated by count rate) with 
lower average size. These factors contributed to an increase in both EE (80.5% to 
96.8%) and LC (2.99% to 6.08%). Besides, the complex nanoparticles inherited 
the desirable pH adaptability from SPI. Therefore, they could be applied flexibly 
over a wide range of pH as well as in an environment with fluctuating acidity. In 
comparison with the ones prepared with SPI, the complex nanoparticles provided 
improved EE (96.8% compared to 50.1%), reduced release of VD in simulated 
gastric fluid and enhanced release under simulated intestinal condition. FT-IR 
study showed that the complex nanoparticles provided stronger interaction with 
VD through hydrogen bonding in comparison with the ones formed with single 
ingredients, which might have facilitated the encapsulation and detained the 
release of VD. These results made the complex nanoparticles an attractive 





Chapter 5 Insight into Curcumin-loaded β-lactoglobulin 
Nanoparticles: Incorporation, Particle Disintegration and 
Releasing Profiles  
5.1 Abstract 
This chapter is aimed at developing protein nanoparticles with desirable loading 
capacity (LC) and low crosslinker concentration. Using β-lactoglobulin (BLG) and 
curcumin as a model system, we demonstrated that the LC could be improved by 
up to 157% by maintaining low antisolvent content before mild evaporation. 
Moreover, the optimal level of glutaraldehyde decreased by 50% as the 
curcumin/protein ratio increased, suggesting that toxic crosslinkers could be partly 
replaced with natural phenols such as curcumin. The BLG-curcumin nanoparticles 
showed average size of 164-214 nm, zeta potential of -42 mV, and LC of up to 
11%. Interestingly, BLG nanoparticles showed rapid disintegration and 
nutraceutical release in simulated gastric fluid (SGF) at pH 2, in spite of the 
known resistance of BLG against pepsin. However, they maintained integrity in 
SGF at pH 5. This phenomenon, followed by the extensive tryptic digestion, 
suggested the controlled release property of BLG nanoparticles. 
5.2 Introduction 
In the past few decades, protein-based nanoparticles have been studied extensively 
as a promising bioavailability enhancer for poorly absorbed bioactive compounds 
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[1, 22]. Known as amphiphilic molecules, proteins were capable of incorporating 
target compounds via various approaches, including hydrophobic interaction, 
electrostatic attraction, hydrogen bonding, and van der Waals force [133]. This 
characteristic enables protein nanoparticles to encapsulate non-polar, polar or 
charged compounds. In addition, proteins exhibit superior biocompatibility and 
nutritional value in comparison with synthetic polymers [25]. A wide array of 
proteins, such as serum albumin [23, 134], zein [51, 135], soy protein [25, 105, 
133], and sodium caseinate [33, 136], has been utilized by far to prepare 
nanoparticles. These nano-scaled assemblies of protein molecules provided 
encapsulated compounds with desirable solubility [32], stability [7], 
stimulus-responsive release [113, 137], and cellular uptake [20, 133], all of which 
resulted in considerable enhancement of their bioavailability. 
In spite of these advantages, the application of protein-based nanoparticles has 
been impeded by several drawbacks. Firstly, the loading capacity (LC, weight 
ratio between the loaded compound and the matrix) of protein nanoparticles is 
generally low compared to synthetic polymeric nanoparticles [138] or other 
encapsulation systems (such as the nanoemulsion and hydrogel) [127, 139]. The 
typical LC for hydrophobic compound-loaded protein nanoparticles is around 5% 
[6, 32, 140-142]. It should be pointed out a number of literatures claimed LC 
values over 50%, but these results were arguably inaccurate because of improper 
measuring methods, e.g., counting precipitated nutraceutical molecules as 
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encapsulated ones [143, 144], or neglecting the weight of a secondary coating 
polymer when calculating LC [32]. The second disadvantage lies in the toxicity of 
chemical crosslinkers. Crosslinking is necessary procedure for the preparation of 
nanoparticles with a number of water-soluble proteins (e.g., serum albumin and 
soy globulin), which dissociate readily into their monomeric forms upon the 
removal of antisolvents [105]. Compared with physical crosslinking with 
couterions (e.g., Ca2+), which is highly dependent on the pH and ionic strength of 
the environment [137], chemical (covalent) crosslinking with glutaraldehyde may 
provide protein nanoparticles with higher stability in various of physiologically 
relevant systems [105]. However, the involvement of chemical crosslinkers gives 
rise to safety concerns, because of their significant toxicity [112]. 
To overcome the abovementioned drawbacks of protein-based nanoparticles, two 
strategies were proposed in this study. The first strategy is the adjustment of 
antisolvent content before evaporation. Figure 5.1 compares the progression of 
solvent composition during the preparation of nanoparticles by conventional and 
modified procedures. In both methods, the protein is dispersed in water (step 1) 
and desolvated at high concentration of antisolvent in order to achieve a high yield 
of nanoparticles (step 2). After crosslinking (step 3), a simple procedure (step 3’) 
was added in the modified method to adjust the content of organic solvent to lower 
values, followed by a brief period of equilibration before evaporation (step 4). 
This added step was expected to improve the LC by enhancing the 
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protein-nutraceutical interaction and reducing nutraceutical precipitation. The 
principle and outcomes of this procedure will be covered in detail in Section 5.4.  
Meanwhile, lower levels of glutaraldehyde were applied for preparing BLG 
nanoparticles with higher drug/BLG ratios. This was inspired by a series of recent 
studies on epigallocatechin gallate (EGCG)-loaded protein nanoparticles [145, 
146]. As suggested by these studies, protein aggregated into nanoparticles in the 
presence of polyphenols such as EGCG, and these particles remained stable 
without additional crosslinkers. The strong interaction between protein and 
polyphenols, including hydrogen bonding and π-π interaction [147], made EGCG 
a possible crosslinker surrogate. Likewise, if the target compound e.g., (resveratrol 
or curcumin) shows certain similarity in the structure and protein affinity with 
EGCG, the dose of glutaraldehyde could be lowered accordingly. Excessive dose 
of glutaraldehyde may not only cause higher toxicity, but also lead to lower LC, 
considering that excessive crosslinking by both glutaraldehyde and the phenol 
might cause extensive formation of insoluble complexes.  
It should be pointed out that great efforts have been made to seek alternative 
crosslinkers (e.g., genipin and transglutaminase) for the preparation of protein 
network structures, such as protein oligomers or hydrogels [148-150]. However, 
with regard to protein nanoparticles, glutaraldehyde remains the major 
crosslinking agent. This is probably because nanoparticles are compact assembly 
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of proteins which are very close to each other. Glutaraldehyde is a relatively small 
molecule which can easily approach the functional groups (primary amino groups 
which is likely to be exposed at the surface of proteins) on protein nanoparticles. 
Other crosslinkers, such as transglutaminase, are relatively bulky molecules whose 
reactivity is hindered by the steric hindrance. By replacing glutaraldehyde partially 
with phenolic compounds such as curcumin, one may achieve satisfactory 
crosslinking effect while reducing the toxicity of the final product. 
 
Figure 5.1 Change in antisolvent content during the preparation for protein nanoparticles. 
Steps 1, 2, 3, and 4 represent dispersion, desolvation, crosslinking and evaporation, 
respectively. Compared to the conventional method (B), a new step (3’) was added 
between steps 3 and 4 in the new method (A), in order to lower the antisolvent content to 
40-60% before evaporation. 
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In this study, BLG was chosen as a model protein to implement these strategies. 
BLG is the major component of whey protein and a natural carrier for various 
lipophilic nutrients [47, 151]. Curcumin as an antioxidant [152] and 
chemopreventive [70] compound was selected as a model nutraceutical to be 
incorporated. According to previous literatures (excluding those that might have 
counted co-precipitated curcumin molecules as encapsulated ones), the LE of 
curcumin-loaded protein nanoparticles varied from 2 to 5% [32, 105, 133, 153, 
154]. The binding between curcumin and BLG nanoparticles in different 
water-acetone binary systems was firstly assessed by investigating the distribution 
of curcumin in different phases. The optimal acetone content before evaporation 
was then determined based on the result. The effect of glutaraldehyde level and 
curcumin loading on the LC was also investigated. The formed nanoparticles were 
characterized for their size, surface charge and morphology. Finally, since BLG is 
known for its remarkable resistance against pepsin and moderate digestibility by 
trypsin [155], the nanoparticles were anticipated to show controlled release 
property, i.e., minimal and maximal release in the stomach and small intestine, 
respectively. Therefore, the nanoparticles were studied for their integrity as well as 
releasing profile in PBS and simulated gastric/intestinal fluids.  
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5.3 Materials and Methods 
5.3.1 Materials 
Bovine BLG (90% purity), pepsin (3,200-4,500 units/mg), trypsin (10,000 BAEE 
units/mg), and curcumin (98% purity) were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Simulated gastric and intestinal fluids (abbreviated as SGF and 
SIF, respectively) were obtained from Ricca Chemical (Arlington, TX, USA). All 
other chemicals (acetone, glutaraldehyde, buffers, etc.) were of analytical grade. 
5.3.2 Preparation of curcumin-loaded BLG nanoparticles 
BLG nanoparticles were prepared by desolvation method [23] with several 
modifications. The whole process was undertaken in darkness with constant 
stirring (800 rpm). BLG was dissolved in deionized water at 10 mg/mL, and 
curcumin was dispersed in acetone at 4 mg/mL. Both dispersions were 
equilibrated for 1 h. To 2 mL BLG dispersion, 3 mL pure acetone was added 
dropwise, after which appropriate amount of curcumin solution was introduced to 
achieve predetermined curcumin/protein ratio (5%, 10% and 15%, w/w, same 
hereinafter). Additional acetone was then added to a total volume of 20 mL. After 
30 min of equilibration, glutaraldehyde (5 mg/mL aqueous solution) was 
introduced as a crosslinker. Theoretically, each milligram of BLG needs 40 μg 
glutaraldehyde for stoichiometric crosslinking [151]. This ratio is defined as 100% 
glutaraldehyde equivalent, and three levels of glutaraldehyde (25%, 50% and 100% 
equivalent) were applied in this study. After 16 h of crosslinking, aliquots of 2 mL 
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were withdrawn and mixed with 4 mL of aqueous acetone. The composition of the 
aqueous acetone was designed so that the final acetone content ranged from 30% 
to 90% (v/v, same hereinafter). After 1 h of equilibration, the acetone was 
evaporated mildly at room temperature under reduced pressure using a VWR 
Symphony vacuum oven (VWR International, Radnor, PA, USA). The pressure 
was firstly kept at 5×104 Pa for 20 min to remove dissolved air and then 
maintained at 4×103 Pa to remove the acetone. This procedure typically lasted for 
2-3 h, and additional water was supplemented to achieve a final volume of 6 mL. 
The dispersion (defined as the “final dispersion”) was stored at 4oC for subsequent 
assays. The initial and final pH of the dispersions ranged from 7.2 to 7.6. 
5.3.3 Quantitative analysis of free and bound curcumin 
Following the procedures described above, BLG-curcumin nanoparticles were 
prepared in 90% acetone, crosslinked using 100% equivalent of glutaraldehyde, 
and mixed with aqueous acetone to achieve various acetone contents. After 
equilibration for 1 h, the dispersion was centrifuged (9,000 g, 15 min, room 
temperature). The insoluble curcumin was recovered in the precipitate and 
dissolved in pure acetone, while the supernatant was subjected to dialysis 
centrifugation (5,000 g, 30 min, room temperature) using a Macrosep® centrifuge 
tube (MW cutoff 10 kDa, Pall Corp., Ann Harbor, MI). A preliminary study was 
conducted with 90% aqueous acetone containing 1 mg/mL curcumin. More than 
90% of the dissolved curcumin was able to pass the dialysis membrane and 
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recovered in the filtrate. The filtrate containing freely dissolved (non-bound) 
curcumin was recovered and diluted with acetone. Both dispersions mentioned 
above were further diluted with acetone to achieve a final water content of <1%. 
The resultant mixtures were then measured for their absorbance at 426 nm by a 
DU-730 UV/VIS spectrophotometer (Beckman Coulter Inc., Fullerton, CA, USA). 
The percentages of insoluble and dissolved curcumin were calculated using an 
established standard curve (R2=0.9991), and the ratio of nanoparticle-bound 
curcumin was derived by subtracting 100% by these two proportions. 
5.3.4 Characterization of curcumin-loaded BLG nanoparticles 
Freshly prepared “final dispersions” of curcumin-loaded BLG nanoparticles were 
subjected to the following measurements [151]. The particle size and count rate 
were determined by dynamic laser scattering (DLS) using a BI-200 SM 
Goniometer Version 2 (Brookhaven Instrument Corp., Holtsville, New York, USA) 
equipped with a 35 mW He-Ne laser beam. No dilution was undertaken prior to 
the assays. Two separate measurements were carried out on each sample in order 
to obtain accurate results. For count rate determination, the aperture pinhole size 
was fixed at 400 μm. To measure the particle size, appropriate aperture sizes were 
chosen to achieve a count rate between 100 and 300 kcps. The obtained data were 
analyzed using the Cumulant algorithm, and the quadratic mean particle size 
(z-average size) was reported.  
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The electrophoretic mobility of nanoparticle dispersions was determined by laser 
Doppler velocimetry using a Nano ZS90 Zetasizer (Malvern, UK). Each sample 
was measured for three times, and at least twelve runs were performed per 
measurement. The data were then converted to zeta potentials using the 
Smoluchowski model.  
The structure of curcumin loaded BLG nanoparticles was investigated by 
Fourier-transform infrared (FT-IR) analysis. Samples (3 to 5 mg) were freeze 
dried and mounted onto a Jasco FT/IR 4100 spectrometer (Jasco Inc., Easton, MD, 
USA). The infrared transmittance was recorded at wavenumbers between 1000 
and 4000 cm-1 with resolution of 4 cm-1. At least 100 scans were undertaken for 
each sample. The spectra were averaged, smoothed, and corrected for their 
baselines using the Spectra Manager software (Jasco Inc., Easton, MD, USA). 
The morphology of nanoparticles was observed under scanning electron 
microscopy (SEM). Approximately 40 μL of the dispersion (after evaporation and 
water supplementation) was cast dried on an aluminum pan, mounted on a 
conductive carbon tape, coated with gold/platinum using a sputter coater (Hummer 
XP, Anatech, CA, USA) and observed under SEM (Hitachi SU-70 Pleasanton, 
CA). Representative images were reported. 
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5.3.5 Determination of EE and loading capacity LC 
The EE of curcumin-loaded nanoparticles was determined as follows [105]. After 
evaporation and water supplementation as described in the section for nanoparticle 
preparation, the final dispersions were let stand at room temperature for 1 h and 
then centrifuged at 9,000 g for 30 min. The insoluble curcumin was recovered 
from the precipitate and dissolved in pure acetone. The supernatant was subjected 
to dialysis centrifugation as was discussed in the Section 5.3.3, and the free 
curcumin was collected in the filtrate. The two parts of curcumin were diluted 
with acetone and measured for their absorbance at 426 nm, which was converted 
to the curcumin content using the same standard curve as described before. The 
EE was calculated as follows:  
EE = 100 −  
𝐴𝐴𝑓𝑓𝑜𝑜𝑓𝑓𝑛𝑛𝑡𝑡 𝑜𝑜𝑜𝑜 𝑛𝑛𝑓𝑓𝑊𝑊𝑛𝑛𝑊𝑊𝑛𝑛𝑊𝑊𝑡𝑡𝑓𝑓𝑡𝑡𝑊𝑊𝑓𝑓 𝑛𝑛𝑓𝑓𝑓𝑓𝑛𝑛𝑓𝑓𝑓𝑓𝑊𝑊𝑛𝑛
𝑇𝑇𝑜𝑜𝑡𝑡𝑓𝑓𝑓𝑓 𝑓𝑓𝑓𝑓𝑜𝑜𝑓𝑓𝑛𝑛𝑡𝑡 𝑜𝑜𝑜𝑜 𝑛𝑛𝑓𝑓𝑓𝑓𝑛𝑛𝑓𝑓𝑓𝑓𝑊𝑊𝑛𝑛
 × 100     (1) 
In addition, after the dialysis centrifugation mentioned above, the retentate 
containing the curcumin-encapsulated nanoparticles was collected and lyophilized. 
The dry nanoparticles were weighed, and the LC was calculated as follows: 
  LC =
𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑜𝑜𝑜𝑜 𝑊𝑊𝑛𝑛𝑛𝑛𝑓𝑓𝑛𝑛𝑛𝑛𝑓𝑓𝑓𝑓𝑓𝑓𝑡𝑡𝑊𝑊𝑓𝑓 𝑛𝑛𝑓𝑓𝑓𝑓𝑛𝑛𝑓𝑓𝑓𝑓𝑊𝑊𝑛𝑛
𝑇𝑇𝑜𝑜𝑡𝑡𝑓𝑓𝑓𝑓 𝑤𝑤𝑊𝑊𝑊𝑊𝑊𝑊ℎ𝑡𝑡 𝑜𝑜𝑜𝑜 𝑛𝑛𝑓𝑓𝑛𝑛𝑜𝑜𝑛𝑛𝑓𝑓𝑓𝑓𝑡𝑡𝑊𝑊𝑛𝑛𝑓𝑓𝑊𝑊𝑛𝑛
  × 100    (2) 
5.3.6 In vitro release of curcumin in different buffering systems 
Release in PBS. Samples prepared with the following parameters were chosen for 
in vitro release study: curcumin loading of 5%, 10%, and 15% (w/w), initial 
acetone content of 90%, pre-evaporation acetone content of 50%, and 
126 
 
glutaraldehyde levels that resulted in optimal EE for each curcumin loading ratio. 
Samples were taken after evaporation but prior to supplementation of water. All 
buffers used in this section contained 5 mg/mL Tween 20. Unless specified, the 
PBS used in this section was at pH 7.2 and 0.1 mol/L. 
Two milliliters of the abovementioned samples was mixed with two milliliters of 
PBS (pH 7.2, 0.2 mol/L). After incubation at 37 °C for 30 min, the mixture was 
injected into a sealed dialysis tube (MW cutoff 10 kDa), which was then placed in 
a flask containing 60 mL PBS (preheated at 37 °C). The flask was then incubated 
in a reciprocal shaking bath (Thermo Scientific, Odessa, TX, USA) at 37 °C under 
constant shaking at 120 rpm. At predetermined time intervals, aliquots of 2 mL 
were withdrawn from the flask and diluted with appropriate amount of PBS. The 
resultant dispersion was measured for its absorbance at 426 nm, which was 
converted to the mass of released curcumin using a linear standard curve 
(R2=0.9993). After each measurement, 2 mL of fresh PBS was added to the flask 
to maintain sink condition. The kinetic release profile of curcumin was plotted as a 
function of time and curve fitted to the first order kinetic model: 
𝐶𝐶 = C0 + k ln 𝑡𝑡     (3) 
Where C indicates the cumulative percentage of released curcumin, C0 represents 
the initial percentage of curcumin present in the buffer, and t stands for the time.  
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Release in SGF and SIF. The nanoparticle dispersion with curcumin loading of 
10% was chosen. Two milliliters of the sample was incubated at 37 oC and then 
diluted with 8 mL of two preheated buffers: SGF-2 (commercial SGF, adjusted to 
pH 2.0, containing Tween 20, 0.5 g/mL, and pepsin at a BLG/pepsin ratio of 100:1, 
w/w) or SGF-5 (same as SGF-2, except that the pH was adjusted to 5.0). These 
buffers mimicked the gastric environment at the fast and fed state, respectively 
[156]. After mixing, 0.5 mL of the dispersion was withdrawn immediately, diluted 
with 2.0 mL PBS, and then subjected to dialysis centrifugation (5,000 g, 30 min) 
using a Macrosep® centrifuge tube (MW cutoff 100 kDa, Pall Corp., Ann Harbor, 
MI). The filtrate containing the released curcumin was diluted appropriately with 
PBS before spectrophotometric measurement at 426 nm. The absorbance was 
converted to the amount of released curcumin as described before. Meanwhile, the 
abovementioned mixture was incubated at 37 °C in the reciprocal shaking bath 
(120 rpm), and aliquots of 0.5 mL were withdrawn and measured as mentioned 
above at predetermined time intervals. Fresh SGF was supplemented after each 
measurement to maintain sink condition.  
On the other hand, another batch of the nanoparticle dispersions were mixed with 
SGF and digested for 60 min at 37 °C in the reciprocal shaking bath. The digesta 
was diluted with SIF (commercial SIF containing Tween at 0.5 g/mL and trypsin 
at a BLG/trypsin ratio of 100:1, w/w) and centrifuged as mentioned above, and the 
retentate containing intact nanoparticles was supplemented with PBS to 2 mL. The 
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dispersion was incubated at 37 °C for 15 min and then mixed with 8 mL preheated 
SIF. Immediately after mixing, 0.5 mL of the dispersion was withdrawn and 
subjected to dialysis centrifugation (5,000 g, 45 min, 4 °C), after which the filtrate 
was diluted with PBS and measured as discussed before. Similar procedures were 
followed to determine the percentage of released curcumin at desired time 
intervals, and fresh SIF was supplemented to maintain sink condition. The 
combined kinetic release profile of curcumin in SGF and SIF was plotted. 
5.3.7 In vitro disintegration of BLG nanoparticles 
The nanoparticle dispersion with curcumin loading of 10% was chosen for this 
study. Digestion in SGF was carried out following the same procedure as 
described in the previous section. Digestion in SIF was initiated by diluting the 
nanoparticle dispersion directly with SIF, without prior treatment with SGF. This 
was because the nanoparticles were either largely degraded (at pH 2.0) or intact (at 
pH 5.0), as indicated by the particle sizes, count rates and size distribution profiles 
observed at these two pH values. At desired time intervals, samples were drawn 
and measured for their particle sizes and count rates. 
5.3.8 Statistics 
All measurements were performed in triplicates. The results were expressed as 
means ± standard error. The data were subjected to analysis of variance followed 
by Tukey’s test with an experimentwise confidence level of α=0.10 using SAS 9 
software (SAS Institute Inc, Cary, NC). 
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5.4 Result and Discussion 
5.4.1 Binding of curcumin to BLG nanoparticles as a function of acetone 
content 
Acetone (%)















Figure 5.2 Effect of acetone content on the distribution of curcumin in BLG nanoparticle 
dispersion crosslinked with 100% equivalent of glutaraldehyde. 
In a water/acetone binary system containing BLG nanoparticles, curcumin 
molecules may exist in three forms: insoluble curcumin that was found in the 
precipitate, dissolved curcumin that permeated the dialysis membrane, and 
BLG-bound curcumin molecules. Figure 5.2 shows the distribution of curcumin 
in the nanoparticle dispersion as a function of acetone content. The data were 
obtained after diluting the crosslinked dispersion (90% acetone) rapidly with 
appropriate water/acetone mixtures to achieve predetermined acetone contents. As 
can be seen, the percentage of free curcumin increased significantly at acetone 
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content higher than 30% (v/v, same hereinafter) acetone. Similar results were 
obtained from a relevant study on BLG monomers [157], which reported that the 
secondary structure and the capability of binding retinol was deprived in 30% or 
higher concentration of ethanol. The results from previous and current studies 
suggested weak interaction between curcumin and BLG nanoparticles. On the 
other hand, more than 80% curcumin molecules were detected in the precipitate in 
the presence of 10-20% acetone. This was probably because (1) curcumin as a 
hydrophobic compound exhibits low solubility in 10-20% acetone, and (2) most 
protein molecules were partly or fully folded, so that there were not sufficient 
hydrophobic sites that associated with curcumin [105]. It was noteworthy that 
previous studies on BLG monomers [157, 158] showed considerable binding to 
ligands (such as retinol) at low organic solvent concentrations (such as 10-20% 
ethanol). However, the native binding sites on BLG were limited, and the 
ligand/BLG ratio in our study was much higher than that of the previous study 
(equimolar, which was translated to a weight ratio of 1.4%). In addition, most of 
these binding sites lost their activity in the presence of organic solvents [159]. 
Therefore, the curcumin-BLG association involved in our study might have taken 
place majorly on the hydrophobic sites exposed by desolvation [105], rather than 
the native binding sites. As acetone content decreased rapidly from 90% to 20%, 
these sites were possibly buried inside the protein molecules. In addition, the 
solubility of curcumin was greatly reduced as acetone content decreased to 20%. 
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As a result, the originally dissolved curcumin molecules might not be able to 
establish strong association with BLG before extensive precipitation occurred. 
In 30% acetone, a considerable percentage (71.5%) of curcumin molecules was 
found to associate with BLG. This phenomenon was possibly ascribed to two 
factors. Firstly, the high polarity of 30% acetone compared to 90% acetone drove 
more curcumin molecules to associate with other hydrophobic molecules, in order 
to minimize their contact with water. Secondly, a greater number of hydrophobic 
sites in BLG molecules were exposed in 30% acetone than in 20% acetone [105], 
which enabled the association and stabilization of more curcumin molecules. Such 
association might have been relatively strong, so that the majority of originally 
dissolved curcumin molecules were converted into the bound form without 
significant precipitation. 
Based on dependence of curcumin distribution on acetone content, it can be 
inferred that the evaporation process during which the acetone content decreases 
continuously may be critical for the encapsulation of curcumin. We hypothesized 
that the LC of BLG nanoparticles might be improved by the lowering the acetone 
content from 90% to 30-50% after crosslinking and equilibrating the dispersion for 
a period of time to allow sufficient curcumin-BLG binding. Thereafter, the 
dispersion should be evaporated mildly, so that the acetone content could be 
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maintained slightly above 30% for maximal time before declining gradually to 
lower levels. This hypothesis will be tested in the next section. 
5.4.2 Effect of acetone content and glutaraldehyde level on EE 
Figure 5.3 depicts the EE of curcumin-loaded BLG nanoparticles as a function of 
acetone content (before evaporation, same in this section) and glutaraldehyde level. 
In general, lower EE was observed as the curcumin content increased. In addition, 
regardless of the curcumin/BLG weight ratio and the glutaraldehyde concentration, 
a V-shape dependence of EE on acetone content was observed, with the highest 
EE achieved in the presence of 40-50% acetone. At 90% acetone, the LC was only 
3.6% and 2.3% for the nanoparticles mixed with 10% and 15% curcumin, 
respectively. These values increased to 5.3% and 3.4% in the presence of 30% 
acetone, and they increased more significantly to 9.1% and 10.9% when the 
acetone content was adjusted to 50%. The low LC at 90% acetone could be 
ascribed to two factors. Firstly, as discussed in the previous section, the majority 
of curcumin molecules existed in the freely dissolved form in 90% acetone. Due to 
the high acetone concentration in the bulk dispersion, the evaporation might have 
proceeded rapidly, leading to a sudden decrease in the local acetone concentration 
on the surface of the dispersion. Such phenomenon resulted in a marked increase 
in local solvent polarity, which drove free curcumin molecules to precipitate 
rapidly without establishing a strong association with BLG nanoparticles. 
Secondly, higher acetone percentage suggested lower content of water and 
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consequently lower volume in the final dispersion. For instance, the final volume 
of a 6 mL water/acetone mixture was 3 or 0.6 mL if its initial acetone content was 
50% or 90%, respectively. As a result, dispersion with 90% acetone content 
underwent more significant increase in the concentration of curcumin and BLG. 
This might have led to more extensive aggregation and precipitation as a result of 
intermolecular attraction.  
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Figure 5.3 Effect of acetone and glutaraldehyde content on the EE of BLG-curcumin 
nanoparticles at three curcumin-BLG mixing ratios: 5%, 10%, and 15%. 
For the samples containing 30% acetone, the curcumin-BLG interaction was 
maximal as shown in the previous section. However, after evaporation began, the 
acetone content was lowered immediately to critical values (20% or below) that 
favored the precipitation of curcumin, and such condition was maintained virtually 
during the whole process of evaporation. As a result, the EE obtained from these 
samples were also not satisfactory, although they were generally higher than those 
achieved by samples with 80-90% acetone. 
When the acetone content of the nanoparticle dispersion was adjusted to 50%, a 
relatively large number of curcumin molecules were bound to BLG nanoparticles, 
as was shown in Figure 5.2. During the slow evaporation process, the acetone 
content of the dispersion was maintained for a considerable period of time in an 
optimal range (30%-50%) where maximal curcumin-BLG association was 
observed. In addition, the mild evaporation led to a gradual increase in solvent 
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polarity, which served as a driving force for dissolved curcumin to associate with 
BLG nanoparticles [51, 105]. These factors resulted in minimal precipitation and 
maximum protein binding of curcumin, both of which contributed to higher EE.  
Besides acetone content, the glutaraldehyde level also played a critical role in the 
EE of BLG nanoparticles (Figure 5.3). At 5% curcumin loading, the EE increased 
gradually as the glutaraldehyde level increased from 25% to 100% equivalent. 
Glutaraldehyde acts as a crosslinker that hardens the structure of nanoparticles via 
inter-molecular amide bonds [3]. Higher glutaraldehyde concentration was 
beneficial for maintaining the compact structure of curcumin-loaded BLG 
nanoparticles, thus preventing the release and precipitation of curcumin molecules 
[105]. As the content of curcumin increased to 10% and 15%, however, the 
highest EE was observed when 50% equivalent of glutaraldehyde was applied. In 
fact, flocculation occurred probably as a result of excessive crosslinking at 
glutaraldehyde level 100% and curcumin/BLG ratio of 15% of above, which 
resulting in low EE under these conditions (data not shown).  
Based on these results, adjustment of acetone content was critical for achieving 
optimal LC and EE. In addition, lower glutaraldehyde dose could be applied to 
BLG nanoparticles with higher curcumin loading. This result further suggested 
that toxic crosslinkers such as glutaraldehyde could be partly replaced by natural 
phenolic compounds. Further studies need to be carried out to test this hypothesis. 
136 
 
5.4.3 Evidence on the crosslinking effect of curcumin 
To confirm the role of curcumin as a partial crosslinking agent, we measured the 
particle sizes and count rates of a series of samples containing different amounts 
of curcumin as well as glutaraldehyde. The rationale of this experiment was that 
well crosslinked nanoparticles are able to maintain their shape and size. Therefore, 
the average size and count rate of their dispersion after the evaporation of acetone 
should be similar to those before evaporation [105, 133]. As shown in Table 5.1, 
the dispersions with higher glutaraldehyde levels (e.g. 100%) showed less 
significant change in the particle sizes after evaporation. In addition, the ratio of 
count rate after evaporation to that before evaporation was significantly higher for 
the samples with higher glutaraldehyde contents. These phenomena provided 
indirect evidence on the crosslinking effect of glutaraldehyde. On the other hand, 
at any given glutaraldehyde level, the dispersions with higher curcumin-to-BLG 
weight ratios exhibited less significant change in the particle size and count rate 
after evaporation. This was especially remarkable at 25% glutaraldehyde level, 
where the sample with 15% curcumin exhibited much higher retention in count 
rate (65%) compared to that without curcumin (21%). These results shed some 
light on the possible crosslinking effect of phenolic compounds such as curcumin. 
Table 5.1 Particle sizes and count rates of curcumin loaded BLG nanoparticles * 
  Before evaporation After evaporation  
GA% CUR% PS (nm) CR (kcps) PS’ (nm) CR’ (kcps) CR’/CR (%) 
25 0 61.3±2.5b 135.7±7.9cd 251.2±12.5a 28.3±3.9f 20.8±1.7e 
25 5 62.4±1.7b 171.6±9.2b 262.9±10.4a 48.7±2.8e 28.4±1.2e 
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25 15 64.2±3.4ab 164.3±10.1b 104.0±9.8d 106.9±2.7c 65.1±3.4c 
50 0 77.5±3.1a 144.8±3.5cd 269.0±11.7a 73.5±4.5d 50.8±2.2d 
50 5 66.5±2.6ab 133.4±4.7cd 271.5±15.6a 92.6±3.2c 69.4±2.5c 
50 15 76.9±1.9a 214.4±7.2a 123.7±9.4d 153.1±7.1a 71.4±2.7c 
75 0 74.3±4.6a 176.6±6.4b 226.3±3.6b 127.3±4.1b 72.1±3.1c 
75 5 77.2±3.1a 126.0±5.8d 158.1±11.5c 100.2±3.2c 79.5±2.0bc 
75 15 63.9±2.6ab 144.8±8.2c 119.1±2.4d 144.7±4.5a 100.0±1.2a 
100 0 74.6±3.5a 133.8±9.1cd 104.6±7.4d 97.9±2.1c 73.5±0.3c 
100 5 76.0±4.2a 154.5±4.4c 68.0±3.9e 150.7±6.8a 97.5±1.2a 
100 15 70.1±1.9a 145.8±3.2cd 63.1±2.2e 122.0±2.4b 83.7±1.4b 
* GA: glutaraldehyde dose (in % equivalent). CUR: curcumin/BLG weight ratio. PS: 
particle size. CR: count rate. Data with different letters showed significant difference (n=3, 
P<0.05).  
 
Figure 5.4 FT-IR spectra of empty BLG nanoparticles and BLG/CUR nanoparticles with 
different CUR/BLG weight ratios and glutaraldehyde (GA) doses. 
The interaction between phenols and proteins has been extensively studied in the 
past decades. Although the exact mechanism has not been fully established, it is 
generally recognized that hydrogen bonding, hydrophobic interaction, and π-π 
stacking were involved in the complexation between these two types of 
compounds [147, 160]. In this study, FT-IR was applied to investigate the possible 
mechanisms involved in the crosslinking role of curcumin. Figure 5.4 showed the 
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FT-IR spectra of BLG nanoparticles containing different contents of curcumin and 
glutaraldehyde. The amide I (1627 cm-1, C=O stretching) and amide II bands 
(1526 cm-1, N-H bending and C-N stretching) in empty BLG nanoparticles shifted 
significantly in the presence of 5% or 15% curcumin, suggesting the possible 
involvement in the backbone carbonyl and/or amino groups in the BLG-curcumin 
interaction [105]. Furthermore, the wide band occurring at 3276 cm-1 (O-H 
stretching) exhibited a marked increase in its intensity in the presence of curcumin. 
This phenomenon suggested the extensive involvement of hydrogen bonding in 
the curcumin-loaded nanoparticles [137]. Interestingly, at 15% curcumin/BLG 
ratio, the sample with 25% glutaraldehyde exhibited significantly higher 
absorbance at 3276 cm-1 than that with 75% glutaraldehyde. This was confirmed 
by analyzing the relative percentage of areas of these two peaks (data not shown). 
This difference implied that more hydrogen bonds were formed between BLG and 
curcumin in order to stabilize the complex nanoparticles at low glutaraldehyde 
levels. Further studies need to be conducted to test this hypothesis. 





Figure 5.5 SEM image of curcumin-loaded BLG nanoparticles. 
All images were acquired from a same sample. Figure 5A shows the coexistence of larger 
and smaller particles. Figures 5B and 5C indicate that the larger particles might be the 
assembly of smaller ones. The white bars represent 200 nm. 
Table 5.2 summarizes the properties of curcumin-loaded BLG nanoparticles. For 
each curcumin loading ratio, the formula (shown in Table 5.2) yielding the 
highest EE was chosen for subsequent evaluation. The nanoparticles exhibited 
average size of 164-184 nm, with highly negative zeta potential. These properties 
were favorable for the dispersion stability of the formed particles. The 
polydispersity of the samples fell in the range of 0.100-0.250, indicating relatively 
narrow size distribution. The difference in the zeta potentials for BLG 
nanoparticles with 5% and 10% curcumin loading was statistically significant, and 
it was probably due to the consumption of the cationic amine groups in BLG 
molecules by different amount of glutaraldehyde [105]. The EE decreased with 
increasing curcumin/BLG ratio, but the LC kept increasing and reached 10.9% at 
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the curcumin/BLG ratio of 15%. This value was considerably higher than a 
number of protein-based nanoparticles and comparable to some synthetic 
polymeric encapsulation systems, which were summarized in the introduction.  

















0 50 100 85.4±6.7d 0.127±0.025b -44.7±1.4ab - - 
5 50 100 164.4±8.5c 0.187±0.034ab -46.6±2.8a 98.2±1.4a 4.9±0.1b 
10 50 50 186.1±13.7b 0.201±0.023a -42.1±1.6b 91.3±5.2b 9.1±0.5a 
15 50 50 213.9±8.2a 0.202±0.017a -42.4±1.9b 72.2±4.6c 10.9±0.7a 
 
* CUR: curcumin/BLG weight ratio. GA: glutaraldehyde. ZP: zeta potential. Data with 
different letters showed significant difference (n=3, P<0.05).  
** The percentages represented the acetone content before evaporation. 
Figure 5.5 shows the morphology of curcumin-loaded BLG nanoparticles 
observed under SEM. Since no significant difference was observed among the 
BLG nanoparticles with different curcumin/BLG weight ratios, only the images 
corresponding to 10% curcumin loading were presented. The particle appeared 
approximately spherical and exhibited smooth surface. Two major groups of 
particles were identified from the image: larger particles with an average size of 
around 200 nm (Figure 5.5A) and smaller ones showing diameters of 40~50 nm 
(Figure 5.5B). Figure 5.5C demonstrated that the former type of particles was 
possibly assembled from the latter ones. Such aggregates might have existed in the 
nanoparticle dispersion before drying, since their size was comparable to the 
average size obtained by DLS. 
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5.4.5 In vitro release of curcumin from BLG nanoparticles 
Figure 5.6A shows the release of curcumin from BLG nanoparticles in 
PBS/Tween 20 system. The three formulas (one for each curcumin loading ratio) 
shown in the previous section were chosen for this study. It is noteworthy that 
curcumin degrades rapidly in PBS, but its stability could be greatly improved in 
the presence of non-ionic surfactants such as Tween 20 [161]. Regardless of the 
curcumin loading ratio, the releasing profile showed satisfactory fit with the first 
order kinetic model (Table 5.3). This result suggested that the release of curcumin 
was controlled by its dissociation from the porous polymer matrix [162]. The 
possible reasons why the release rate for nanoparticles with low curcumin loading 
was higher than that with high curcumin loading were: (1) the particles with 
higher curcumin loading exhibited greater sizes, and their specific surface area 
was hence lower, (2) the solubility of curcumin in the PBS/Tween 20 system is a 
constant in a given environment, and the dissolution of curcumin was slowed 
down as its concentration approached the equilibrium value, and (3) higher 
loading indicated higher concentration of curcumin accumulated in the outer 
buffer, which slowed down the diffusion of curcumin through the dialysis 

















































Figure 5.6 Time-dependent release of curcumin from BLG nanoparticles in (A) 
PBS/Tween 20 and (B) simulated gastrointestinal environment 
The release of curcumin in SGF and SIF was shown in Figure 5.6B. Our 
preliminary results indicated overlapping releasing patterns for nanoparticles with 
5%, 10%, and 15% curcumin loadings (data not shown). Hence, only the releasing 
profile for nanoparticles with 10% curcumin loading is presented. The release in 
SGF was investigated at two different pHs: pH=2 that represents the gastric 
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condition in the fasting state and pH=5 that corresponds to the fed state [156]. 
After 1 h of digestion, the mixture was transferred to SIF to determine the release 
profile under simulated intestinal conditions. It was noteworthy that more than 70% 
of encapsulated curcumin was released in SGF at pH 2 (Figure 5.6B). This result 
is unexpected because BLG is known for its remarkable resistance against peptic 
digestion [155], and it was anticipated to prevent curcumin from being released in 
the stomach. We hypothesized from this result that the BLG nanoparticles were 
actually decomposed in SGF at pH 2, although the individual BLG molecules 
remained intact. This hypothesis will be tested and discussed in the next section. 
Table 5.3 Curve fitting of curcumin release profile from BLG nanoparticles 
CUR (%) * C0 (in percentage) k R2 
5 4.43 18.63 0.979 
10 4.95 14.41 0.970 
15 2.62 11.76 0.965 
* CUR: curcumin/BLG weight ratio. 
When dispersed in SGF at pH 5 (Figure 5.6B), the BLG nanoparticles exhibited 
significantly lower rate of release than at pH 2, with only 24% of encapsulated 
curcumin being released in 1 h. This phenomenon could be explained by two 
reasons. Firstly, pepsin tends to be much less active at pH 5 than at pH 2. 
Secondly, BLG exhibits an isoelectric point at around pH 5; therefore, the 
nanoparticles formed with BLG tended to form large agglomerates that were more 
resistant to peptic digestion. As a result, the curcumin molecules were more 
compactly encapsulated at pH 5 than at pH 2, leading to a lower release rate. 
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After being transferred to SIF (Figure 5.6B), the remaining curcumin molecules 
continued to be released from the nanoparticles. This was probably due to the 
degradation of residual BLG nanoparticles as well as the molecules, because of the 
known capability of trypsin to digest BLG [155]. The significant difference in the 
releasing pattern of dispersions previously treated at pH 2 and pH 5 was probably 
due to the different residual concentration of curcumin after the first digestion step. 
At the end of the two-step digestion, 70-80% of curcumin was recovered from the 
two buffers (SGF and SIF). Based on these results, BLG nanoparticles might not 
be suitable for the controlled release of curcumin in the fasting state, but they 
could release curcumin in a controlled and sustained manner if administrated 
during the fed state. 
5.4.6 Disintegration of BLG nanoparticles in different buffers 
We further investigated the disintegration of BLG nanoparticles in different 
buffers. The formula with 10% curcumin loading was chosen for this section. 
When incubated in SGF at pH 2 (Figure 5.7A), BLG nanoparticles exhibited a 
two-stage pattern of degradation. In the first 30 min, they showed a constant 
average size, while the count rate decreased continuously. These data suggested 
that, in spite of the decrease in number, there still existed a considerable number 
of BLG nanoparticles that maintained their size and probably morphology [105]. 
Thereafter, a rapid increase in the average size was observed, together with a slow 
decrease in the count rate. A possible explanation for this trend was that the 
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majority of smaller particles (around 160 nm) were decomposed by pepsin after 30 
min, but some larger aggregates still remained intact. As a result, the average size 
shifted markedly to higher values, whereas the count rate declined only mildly, 
since larger particles contributed much more significantly to the count rate than 
did smaller ones [23, 105]. This was supported by the fact that the polydispersity 
index increased gradually from 0.177 (uniform distribution, Figure 5.8A) to 0.855 
(broad distribution, Figure 5.8B), because of the increase in the relative content of 
larger particles. The data on size distribution obtained by DLS (Figure 5.8) also 
supported the disintegration of BLG nanoparticles. 
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Figure 5.7 Time-dependent disintegration of curcumin-loaded BLG nanoparticles in (A) 
SGF at pH 2, (B) SGF at pH 5, and (C) SIF 
It was intriguing that BLG nanoparticles were susceptible to peptic digestion, 
considering that BLG itself is resistant against pepsin. A previous literature on 
BLG-EGCG nanoparticles [146] showed that BLG molecules remained intact after 
120 min of peptic digestion (as evidenced by SDS-PAGE). Same results were 
obtained in our preliminary study. However, that study did not indicate whether 
BLG still maintained the morphology as spherical aggregates. Based on the 
findings from previous and current studies, we deduced that the intermolecular 
amide bonds produced by glutaraldehyde, instead of the original peptide bonds 
within BLG molecules, might be more prone to peptic digestion, and the breakage 
of these bonds might be responsible for particle disintegration. Our follow-up 
study (unpublished data) showed that nanoparticles prepared with cationized BLG 
(CBLG) exhibited remarkable resistance to pepsin, although this protein showed 
virtually the same resistance against pepsin as native BLG. Since CBLG contains 
abundant modified amine groups that could also be crosslinked by glutaraldehyde 
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[151, 163], it is likely that the different conformations of glutaraldehyde-induced 
amide bonds in native and cationized BLG resulted in the difference in particle 
digestibility. Another relevant study using turbidity also pointed out crosslinked 
BLG nanoparticles could be digested by pepsin, but the time needed for complete 
degradation was as long as 7 h [164]. The discrepancy between that and our study 
may be ascribed to the use of different enzyme activities and different measuring 
techniques (turbidity versus DLS measurement). However, that study was in 
consistence with the present one in that proteins with poor digestibility can 







































Figure 5.8 Intensity based size distribution of CUR-BLG nanoparticle dispersions before 
(A) and after (B) digestion in SGF (pH = 2, containing pepsin) 
On the contrary, the degradation of BLG nanoparticles proceeded at a much lower 
rate in SGF at pH 5 than at pH 2 (Figure 5.7B). During the experiment that lasted 
for 2 h, the average particle size did not show any significant change, while the 
count rate decreased by only 24%. The polydispersity maintained stable at 
0.127-0.159 during the digestion (Table 5.4), which also suggested the stability of 
the nanoparticles. These results were in consistence with the slow release of 
curcumin as was indicated in the previous section. Lower activity of pepsin and 
the agglomeration of BLG at this pH were possible reasons for this difference, as 
was discussed before.  
Table 5.4 Progression of polydispersity index of curcumin-loaded BLG nanoparticles in 
SGF (pH 2 and 5) and SIF * 
Time (min) PDI in SGF at pH 
2 
PDI in SGF at pH 
5 
PDI in SIF 
0 0.177±0.005e 0.127±0.004c 0.135±0.004b 
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15 0.189±0.004e 0.145±0.002a 0.149±0.003b 
30 0.204±0.002d 0.129±0.003c 0.158±0.005a 
45 0.211±0.007cd 0.145±0.006a 0.144±0.002b 
60 0.237±0.006c 0.159±0.008a 0.142±0.006b 
90 0.576±0.005b 0.146±0.007a 0.164±0.007a 
120 0.855±0.011a 0.139±0.003b 0.153±0.005ab 
* Data with different letters showed significant difference (n=3, P<0.05). 
When the particles were incubated with SIF, the particles were more rapidly 
digested, as was indicated by the sharp decrease in the count rate (Figure 5.7C). 
As discussed before, trypsin shows higher capacity to digest BLG [155], which 
was probably the main reason for the rapid digestion of BLG nanoparticles. 
Interestingly, the average size was kept steady at around 200 nm, a trend that was 
different from the situation in SGF at pH 2.0. The polydispersity index varied 
from 0.135 to 0.164 without any significant difference (Table 5.4). This result 
suggested that trypsin could not only break down smaller nanoparticles, but also 
disintegrate larger aggregates. In the follow-up study that lasted for 4 h, very low 
count rate (less than 10 kcps) was detected (data not shown) in SIF, suggesting 
that BLG nanoparticles were nearly completely decomposed.  
5.5 Conclusion 
The encapsulation and releasing process of curcumin-loaded BLG nanoparticles 
were systematically investigated. The association between BLG nanoparticles and 
curcumin was affected significantly by the content of antisolvents such as acetone. 
Therefore, adjustment of acetone to moderate values (40-50%) followed by mild 
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evaporation led to a remarkable improvement in EE and LC. In addition, the 
optimal dose of glutaraldehyde decreased at higher curcumin loadings, which 
suggested that curcumin could replace part of toxic crosslinkers and aid the 
maintenance of particle structure. The nanoparticles formed through the optimized 
procedure showed average size between 164-214 nm, high zeta potential of -42 
mV, and LC of at most 11%. Moreover, this study suggested that proteins that are 
resistant to peptic digestion could form nanoparticles that were digestible by 
pepsin at pH 2, probably because of the breakage of amide bonds formed with 
glutaraldehyde. As a result, no controlled release of curcumin was observed under 
simulated fast condition. However, satisfactory controlled release was achieved 
under simulated fed condition, i.e., digestion in SGF at pH 5 and then in SIF. The 
conclusions from this study may apply not only to the curcumin-BLG system, but 
also to a wide array of encapsulation systems consisting of a water-soluble protein 
encapsulant and a hydrophobic target compound. Therefore, this study provides 
insight into the assembly and disassembly of protein nanoparticles, and it may 
shed some light to the development of encapsulating systems with satisfying LC 




Chapter 6 Cationic beta-lactoglobulin Nanoparticles as a 
Bioavailability Enhancer: Protein Characterization and Particle 
Formation 
6.1 Abstract 
Cationic beta-lactoglobulin (CBLG) was developed as a bioavailability enhancer 
for poorly absorbed bioactives. At most 11 anionic amino acid residues of 
beta-lactoglobulin (BLG) were substituted by ethylenediamine (EDA), resulting in 
a highly positive surface charge (zeta potential up to 39 mV at pH 7.0) and 
significantly increased surface hydrophobicity. These changes conferred CBLG 
with desirable water solubility and improved mucoadhesion by at most 252%, 
according to quartz crystal microbalance (QCM) study. Furthermore, CBLG 
inherited the unique resistance to gastric digestion from BLG, while the digestion 
under simulated intestinal condition was significantly improved. The latter was 
possibly due to the formation of aspartic acid-EDA conjugates, together with the 
randomization of protein conformation related with decreased percentage of 
β-sheet. Compared to BLG, CBLG formed smaller (75-94 nm), more uniform 
nanoparticles by acetone-desolvation method. These merits made CBLG a useful 
material that provides desirable solubility, controlled release and enhanced 




In the past few decades, nano-encapsulation has been recognized as an effective 
approach to enhanced bioavailability of poorly absorbed nutraceuticals and drugs 
[2]. For oral-administered compounds, successful absorption requires an 
appropriate encapsulant with a number of features. These include sufficient 
loading capacity, high dispersion stability [2], resistance to gastric digestion [6], 
satisfactory mucoadhesion [165], increased cellular uptake [133], and prolonged 
circulation time [14]. The last property could be obtained through the fabrication 
of nano-scaled vehicles [166], while the rest of them could be conferred to the 
encapsulants by carefully tuning their surface properties, among which charge and 
hydrophobicity play critical roles [61].  
Cationic polymers, such as chitosan [10, 167], lactoferrin [21, 50] and polylysine 
[168], showed satisfactory mucoadhesive properties as well as cellular 
internalization efficacy. Such improvement was attributed to the enhanced 
electrostatic interaction with the anionic glycoproteins and glycolipids, which 
were abundant on the small intestinal wall or cell membrane [169, 170]. In 
addition, peptides that possess both positive net charge and a hydrophobic exterior 
(known as cell penetrating peptides or CPPs) were synthesized [18, 171, 172]. The 
conjugation of CPPs to drug-loaded nanoribbions [17], nanoparticles [173] or 
nanocomplexes [174] resulted in elevated cellular uptake. In spite of the 
abovementioned merits, there exist several drawbacks in these cationic 
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encapsulants that impeded the effective delivery of orally ingested bioactives. For 
example, chitosan-based nanoparticles were insoluble at neutral to basic pH, 
which might compromise their claimed mucoadhesion and cellular uptake 
enhancement in vivo. Such insolubility may also confine their application to acidic 
food systems. Cationic peptide- or protein-based delivery systems are soluble in 
water, but their susceptibility to peptic digestion in stomach may result in the loss 
of protection before absorption occurs [175]. These disadvantages necessitate the 
development of a water soluble, pepsin-resistant, cationic delivery system. 
Beta-lactoglobulin (BLG), a 162-residue globular protein, makes up 
approximately 60% of bovine whey protein [176]. Owing to its high water 
solubility and unique structure, BLG serves as a natural carrier for various 
nutrients, such as vitamins and fatty acids [47, 177]. Furthermore, BLG 
demonstrated a significant resistance to peptic digestion [178] due to its compactly 
folded conformation originated from the abundance of rigid β-sheet structures 
[179], while it was much more readily degraded by trypsin in small intestine. 
These characters provide BLG-based delivery systems with desirable controlled 
release property. By far, various encapsulating systems have been developed with 
BLG, including emulsions [180, 181], nanoparticles [44, 46] and nanocomplexes 




In this chapter, we are proposing a nanoparticle system prepared with cationic 
beta-lactoglobulin (CBLG). We hypothesized that CBLG and CBLG-based 
delivery systems could inherit the merits of both conventional cationic polymer 
and BLG, leading to a significant improvement in the encapsulation and 
absorption of bioactive compounds. It should be mentioned that a series of CBLGs 
were synthesized by Mattarella et al. [183] by amidation and esterification 
methods. However, their study was focused on functionality instead of 
encapsulation properties, and CBLGs prepared in that study might not be ideal for 
encapsulation due to their reduced solubility and increased digestibility [183]. To 
our knowledge, no study has been published by far on CBLG nanoparticles with 
the emphasis on encapsulation and delivery properties. 
This paper was the first part of our study on CBLG nanoparticles. 
Ethylenediamine (EDA) was employed to synthesize CBLGs with sufficient 
positive charge and increased hydrophobicity, without compromising its original 
water solubility. The CBLGs were investigated for their physicochemical and 
conformational characteristics, which were then employed to explain for their 
digestion-resistive and mucoadhesive properties. Finally, CBLG nanoparticles 
were prepared using a desolvation method, and its particle forming behavior was 
compared in parallel with BLG. 
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6.3 Materials and Methods 
6.3.1 Materials 
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO, 
USA): N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC, 97% purity), 
bovine beta-lactoglobulin (BLG, 90% purity), ethylenediamine dihydrochloride 
(EDA, 98% purity), 2, 4, 6-trinitrobenzenesulfonic acid (TNBS, 0.5 mg/mL water 
solution), 8-anilino-1-naphthalenesulfonic acid (ANS, 97% purity), pepsin 
(3,200-4,500 units/mg), trypsin (10,000 BAEE units/mg), papain (10 units/mg), 
trichloroacetic acid (TCA) and bovine serum albumin (BSA, 98% purity). Porcine 
stomach mucin (PSM, type III, contains 0.5-1.5% sialic acid) was obtained from 
Himedia Co., India. Hanks’ balanced salt solution (HBSS, pH 7.4) and phosphate 
buffer saline (PBS, 100 mM, pH 7.4) were purchased from Invitrogen Inc. 
(Carlsbad, CA, USA). All other reagents (sodium bicarbonate, acetone, acids and 
bases, etc.) were of analytical grade. 
6.3.2 Preparation of cationic beta-lactoglobulin (CBLG) 
CBLG was prepared by grafting positively charged EDA moieties to the 
negatively charged carboxyl groups on the aspartic and glutamic acid residues 
(Figure 6.1). This was achieved via a carbodiimide-aided approach that was 
previously reported [184]. In brief, 400 mg of BLG was dissolved in 5 mL 
deionized water, to which 50 mL of EDA solution at different concentrations (0.6, 
0.9, 1.2 and 1.5 mol/L) was added under mild stirring. The mixture was adjusted 
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to pH 4.75 with 1 mol/L HCl and equilibrated for 30 min. Cationization was 
initiated by the addition of 150 mg EDC and terminated by 540 μL acetate buffer 
(4 mol/L, pH 4.75) after 2 h. The dispersion was dialyzed against deionized water 
at 4 oC for 48 h and freeze dried. The moisture content of the final product was 
less than 5%, and the protein content was at least 90% according to Bradford assay 
calibrated with BSA. 
6.3.3 Determination of primary amino group contents and net charge 
The contents of primary amino groups were determined by TNBS assay [185]. 
BLG and CBLG were dissolved in 0.1 mol/L NaHCO3 buffer (pH 8.5) at a 
concentration of 100 μg/mL, and 0.5 mL of 0.2 mg/mL TNBS solution was added 
to 1 mL of each sample. After incubation at 37 oC for 2 h, the dispersion was 
mixed with 0.5 mL 10% sodium dodecyl sulfate (SDS) solution and 0.25 mL of 1 
mol/L HCl to terminate the reaction. The resultant mixture was cooled to room 
temperature and measured for its absorbance at 420 nm using a DU-730 UV/VIS 
spectrophotometer (Beckman Coulter Inc., Fullerton, CA, USA). A calibration 
curve (R2=0.9997) was established following a similar procedure, except that a 
series of concentrations of BSA (59 primary amino groups per molecule from its 
lysine residues) was employed instead of BLG/CBLG. The number of primary 
amino groups content was derived from the curve and then adopted to estimate the 
net charge of CBLG, considering that the introduction of each amino group altered 
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the net charge of BLG by +2 (Figure 6.1). The change in molecular weight upon 
cationization was assumed negligible. 
 
Figure 6.1 Illustration of the cationization procedure. 
Figure 6.1a presented the theoretical equation for EDA-induced cationization. Both Asp 
and Glu residiues were appropriate substrates. The net charge of each residue was altered 
by +2 (from -1 to +1) upon cationization. R and R’ were adjacent peptide chains. Figure 
6.1b compared the EDA-Asp/EDA-Glu conjugate with lysine to display their geometric 
similarity. 
6.3.4 Determination of zeta potential 
The dispersion of BLG or CBLG in PBS (10 mmol/L, pH 7.0, same hereinafter) 
and HBSS (140 mmol/L, no calcium or magnesium, pH 7.4, same hereinafter) was 
measured for its electrophoretic mobility by laser Doppler velocimetry using a 
Nano ZS90 Zetasizer (Malvern Inc., Malvern, UK). Each sample (1 mg/mL) was 
measured for three times, and at least twelve runs were performed per 
measurement. The data were then converted to zeta potentials using the 
Smoluchowski model.  
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6.3.5 Determination of surface hydrophobicity 
ANS fluorescence assay was carried out to determine the surface hydrophobicity 
of BLG and CBLG dispersions [186] in two buffers, i.e., PBS and HBSS. Stock 
solutions of proteins (BLG or CBLG, both at 1 mg/mL) and ANS (100 μg/mL) 
were prepared in a same buffer and filtered through a 0.22 μm Acrodisc® syringe 
filter membrane (Pall Co., Newquay, UK). The filtrates were mixed and diluted to 
achieve a fixed ANS concentration of 50 μg/mL and a protein concentration 
ranging from 5 to 50 μg/mL. After 1 h of incubation at 25 oC, the mixture was 
observed for its fluorescence intensity (FI) on a PerkinElmer Victor X3 multilabel 
plate reader (PerkinElmer Inc., Waltham, MA, USA). The excitation and emission 
wavelengths were 355 and 460 nm, respectively. For each protein sample, a linear 
regression equation was established for FI versus protein concentration (R2>0.995), 
and the slope (So) was used as an index for surface hydrophobicity. 
6.3.6 Secondary structure determination  
Fourier-transform infrared (FT-IR) study was conducted to monitor the structural 
change of BLG upon cationization. The lyophilized samples (3 to 5 mg) were 
mounted onto a Jasco FT/IR 4100 spectrometer (Jasco Inc., Easton, MD, USA). 
The infrared transmittance was acquired at the wavenumbers from 1000 to 4000 
cm-1 at a resolution of 2 cm-1. At least 100 repeated scans were undertaken for 
each sample. The spectra were averaged, smoothed, corrected for their baselines 
and converted to absorbance with the Spectra Manager software (Jasco Inc., 
Easton, MD, USA).  
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For quantitative study, the IR spectra were subjected to Fourier self-deconvolution 
(FSD) using the OMNIC software (Thermo Scientific, West Palm Beach, FL, 
USA). A band width at half-height of 23 cm-1 and an enhance factor (K value) of 
2.7 was adopted over the wavenumbers ranging from 2000 to 1300 cm-1, 
according to previous literatures [179, 187]. The FSD spectra were then curve 
fitted assuming a Gaussian band profile. The resolved peaks were validated only 
when they were also found on the inverted secondary derivative (ISD) spectra 
obtained over the same wavenumber range [179]. Peak assignment was carried out 
following literatures on native BLG [179, 187], and the content of each secondary 
structure was expressed as its percentage of peak area in the FSD spectra. 
6.3.7 Determination of in vitro digestibility 
Two enzymes, pepsin and trypsin, were employed to investigate the degradation of 
BLG and CBLG. For peptic digestion [178], the samples and pepsin were 
dissolved separately at 1 mg/mL in 0.1 mol/L HCl, which was adjusted to pH 2.0 
with 0.1 mol/L NaOH. For tryptic digestion, both the samples and trypsin were 
dispersed separately at the same concentrations in a NaHCO3 buffer (0.1 mol/L, 
pH 8.0, same hereinafter). The dispersions were then preheated at 37 oC for 15 
min. To 15 mL of protein solution, 75 μL of the enzyme solution was added, thus 
achieving a substrate-to-enzyme ratio of 200:1 (w/w). The resultant suspensions 
were incubated at 37 oC for preset times (10 min to 4 h), after which aliquots of 
1.5 mL were drawn from the dispersions and mixed with 1.5 mL TCA solution (10% 
160 
 
in water, w/v). The mixtures were allowed to stand at room temperature for 15 
min and then centrifuged (9,000 g, 20 ℃, 20 min). The precipitate was discarded, 
and the absorbance of the supernatant at 280 nm was recorded. For comparison 
purpose, a series of mixtures were prepared with BLG/CBLG and papain at a 
substrate-to-enzyme ratio of 20:1 (w/w) in NaHCO3 buffer. After 4 h of incubation 
at 37 oC, the hydrolysates were subjected to TCA precipitation, centrifugation and 
spectrophotometric measurement as mentioned above. According to previous 
literature [155], almost 100% of the BLG was degraded by papain within 2 h. 
Therefore, the absorbance at 280 nm of the supernatant after papain digestion was 
indicative for complete proteolysis, and the data obtained from all other treatments 
were divided by this value to provide an apparent digestibility. 
6.3.8 Determination of mucoadhesive properties 
Turbidity analysis [10]. Samples (BLG or CBLG) and mucin (PSM) were 
dispersed at 10 and 1 mg/mL in PBS, respectively, and they were both passed 
through a 1.2 μm Acrodisc® syringe filter. Thereafter, 4 mL of PSM dispersion 
was mixed with 0.1, 0.2 and 0.4 mL protein solution in order to achieve a protein 
concentration of 0.25, 0.5 and 1 mg/mL, respectively. The mixture was then 
incubated at 37 oC for 1 h and cooled to room temperature. The absorbance of 400 
nm was recorded, using pure PSM dispersion as blank.  
Quartz crystal microbalance (QCM) analysis [11]. In the QCM study, two thin 
layers of PSM and protein were deposited sequentially onto a gold-coated AT-cut 
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quartz crystal with a fundamental frequency of 4.95 MHz (QSX-301, Q-Sense Co., 
Linthicum, MD, USA), and the mass of deposited polymers was reflected by the 
change in frequency (Δf). Prior to the deposition, the crystal was soaked in 
Piranha solution (NH3·H2O: H2O2: H2O=1:1:5, v/v/v) for 15 min at 70 oC and 
dried with nitrogen. The crystal was then mounted on the Q-Sense E1 
microbalance (Q-Sense Co., Linthicum, MD, USA), after which PBS was injected 
at a flow rate of 0.224 mL/min using a peristaltic pump (Ismatec Reglo, 
Glattbrugg, Switzerland). After the acquisition of a constant Δf, PSM solution 
(400 μg/mL in PBS, filtered through a 220 nm membrane) was introduced to the 
crystal chamber. This triggered a significant increase in Δf, which reached another 
plateau after approximately 10 min. A second rinse of PBS was applied to remove 
loosely bound PSM, after which the BLG/CBLG solution (1 mg/mL in PBS, 
passed through a 220 nm membrane) was injected to the chamber at a same flow 
rate. After 15 min of protein adsorption, the chamber was subjected to a final rinse 
of PBS, until the attainment of the third plateau of Δf. Changes in Δf, up to the 
13th overtone, were collected by QTools 3 (Q-Sense Co., Linthicum, MD, USA). 
The fifth overtone was converted to deposited mass (in ng/cm2 crystal surface) 
using the Sauerbrey model. Mucoadhesion was expressed as the mass ratio of 
BLG/CBLG to PSM deposited on the crystal surface. 
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6.3.9 Preparation of BLG/CBLG nanoparticles 
Nanoparticles were prepared with BLG/CBLG via a desolvation process [44, 105]. 
Constant stirring (600 rpm) was applied throughout the mixing and crosslinking 
process. The protein was dissolved in deionized water at a preset concentration of 
10 to 20 mg/mL (pH 7.5-8.0), and the dispersion was equilibrated for 1 h at room 
temperature. Thereafter, pure acetone was added dropwise to achieve an 
acetone/water ratio of 80/20 or 90/10 (v/v). The contents of protein and acetone 
were adjusted, so that the final protein concentration in the binary solvent was 
kept at 2 mg/mL. After 30 min of equilibration, glutaraldehyde was added as a 
crosslinker. The glutaraldehyde/protein mass ratio was set at 40 μg/mg in this 
study based on the lysine content of BLG (16 mol/mol), and it was adopted for all 
protein samples regardless of the extent of cationization. After 6 h of crosslinking, 
the acetone was evaporated under a constant nitrogen flow and replaced with same 
volume of deionized water. The resultant suspension containing the protein 
nanoparticles was stored at 4 oC for subsequent assays. 
6.3.10 Determination of particle size and count rate 
The particle size and count rate were determined [133] by dynamic laser scattering 
(DLS) using a BI-200 SM Goniometer Version 2 (Brookhaven Instrument Corp., 
Holtsville, New York, USA) equipped with a 35 mW He-Ne laser beam. All 
dispersions were measured without dilution. The following parameters were 
adopted: laser power of 10 mW, detection wavelength of 637 nm, scattering angle 
of 90°, temperature of 25 oC, and measurement time of 1 min. The refractive 
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indices and viscosities of different acetone/water systems were applied for all 
assays, since they were not significantly altered by protein or glutaraldehyde in 
our study (data not shown). Two separate measurements were carried out to obtain 
accurate results. For count rate determination, the aperture pinhole size was fixed 
at 400 μm; to measure the particle size, appropriate aperture pinhole sizes were 
chosen to achieve a count rate of 100-300 kcps. The obtained data were analyzed 
using cumulant algorithm, and the quadratic mean particle size was reported. 
6.3.11 Scanning electron microscopy (SEM) 
The morphology of BLG/CBLG nanoparticles was observed using a Hitachi 
SU-70 SEM (Hitachi, Pleasanton, CA, USA). Approximately forty microliters of 
the nanoparticle dispersions was dripped and cast-dried on an aluminum pan, 
which was cut into appropriate sizes and adhered to a 1-inch specimen stub with 
conductive carbon tapes (Electron Microscopy Sciences, Ft. Washington, PA, 
USA). To avoid the charging effect, a thin layer (<20 nm) of gold and platinum 
was deposited to the samples using a sputter coater (Hummer XP, Anatech, CA, 
USA) prior to the observation. Representative images were reported. 
6.3.12 Statistics 
All measurements were performed in triplicates. The results were expressed as 
means ± standard error. The data were subjected to analysis of variance (P < 0.05) 
followed by Tukey’s test with an experimentwise confidence level of α=0.10, 
using SAS 9 software (SAS Institute Inc., Cary, NC, USA). 
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6.4 Results and Discussion 
6.4.1 Change in protein net charge upon cationization 
The numbers of amino and carboxyl groups of BLG and CBLG were compared in 
Table 6.1. The numbers in the sample names (0.6, 0.9, 1.2 and 1.5) indicated the 
molarity of EDA applied in the cationization process. A native BLG molecule 
possesses 16 lysine (TNBS-reactive), 3 arginine, 10 aspartic acid, and 16 glutamic 
acid residues [188], all of which results in an overall charge of -7 per molecule. 
Our TNBS assay showed 16.3 reactive primary amino groups on BLG, which was 
in consistence with the theoretical value.  





TBNS reactive  
–NH2 per molecule** 






BLG 0 16.3±0.2d 19.3 25.7 -7 
C-0.6M 0.6 21.4±0.4c 24.4 20.6 +3 
C-0.9M 0.9 24.4±0.3b 27.4 17.6 +9 
C-1.2M 1.2 26.6±0.2a 31.6 13.4 +17 
C-1.5M 1.5 27.3±0.5a  31.3 13.7 +17 
*  Data with different letters showed significant difference (n=3, P<0.05). 
** Reactive amino groups included the ones in the lysine residues and those introduced 
by cationization. Total amino groups were reactive amino groups plus the ones in the 
arginine residues. Total carboxyl groups represented the ones in the aspartic acid and 
glutamic acid residue. This number was deducted by one upon the addition of each amino 
group. The net charge (rounded up) was calculated by summing up the electric charges of 
all residues on BLG or CBLG. 
When increasing amount of EDA was added during the cationization process, the 
number of primary amino groups increased progressively to a maximum of 27.3 
per molecule. Meanwhile, the deduced number of total carboxyl groups was 
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decreased from 25.7 to 13.7. These changes gave rise to a dramatic change in the 
net charge to +17 for C-1.2M and C-1.5M. The relatively high density of positive 
charges possessed by CBLG may benefit their mucoadhesive properties greatly as 
well as the cellular uptake, thus promoting the bioavailability of the bound 
nutraceuticals or drugs. It should be pointed out that cationic polymers may 
exhibit considerable cytotoxicity [189, 190]. However, the toxicity of cationic 
protein was found to be the lowest amongst all cationic polymers [191], probably 
owing to the biocompatibility of the original protein. The cytotoxicity of CBLG 
will be investigated in our next study. 
6.4.2 Surface charge and hydrophobicity 
The impact of cationization on the surface charge and hydrophobicity of BLG was 
summarized in Table 6.2. The zeta potential of BLG in PBS was -37.0 mV, which 
was comparable with previously reported results [192]. As the degree of 
cationization increases, the zeta potential shifted significantly toward a more 
positive value. This phenomenon confirmed the shift in molecular net charges, and 
it was indicative for adequate exposure of the conjugated EDA moieties on the 
surface of the molecule. It was noteworthy that the zeta potentials of C-1.2M (36.8 
mV) and C-1.5M (38.9 mV) were comparable in magnitude to that of native BLG 
(-37.0 mV). According to the American Society for Testing and Materials [5], a 
zeta potential with an absolute value of higher than 30 mV were indicative for 
“moderate to good” stability of colloidal systems, due to the strong electrostatic 
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repulsion between the charged molecules or particles. The dispersion stability of 
CBLG was confirmed by our preliminary study (data not shown), in which CBLG 
was soluble in pure water or PBS at concentrations higher than 80 mg/mL. 
Table 6.2 Zeta potential and surface hydrophobicity of BLG and CBLG * 
 In PBS In HBSS 








BLG -37.0±0.1e 108.5±9.6e -18.3±0.2d 68.0±7.2e 
C-0.6M 18.1±0.3d 740.1±10.2d 6.7±0.1c 305.8±11.4d 
C-0.9M 27.2±0.5c 850.2±11.4c 11.4±0.2b 421.5±15.4c 
C-1.2M 36.8±0.4b 1022.3±17.6b 16.1±0.3ab 571.0±14.2b 
C-1.5M 38.9±0.4a 1269.8±15.4a 17.5±0.3a 628.9±16.3a 
* Data with different letters showed significant difference (n=3, P<0.05). 
BLG was reported to exhibit a relatively low surface hydrophobicity (So) in PBS 
of approximately 100 [192]. This result was also confirmed by our study. The So 
of CBLG, on the other hand, was at most 1070% higher than that of BLG. In 
addition, the highest So achieved by CBLG (1270) was comparable with that of 
BSA (1000-2000) [193], a protein known for its high surface hydrophobicity. The 
remarkable increase in So by cationization was also observed on cationic BLG 
prepared by esterification and amidation [183], and it was probably attributed to 
the following three reasons. Firstly, the introduction and exposure of the 
hydrophobic backbones of EDA played a major role in increased protein-ANS 
hydrophobic binding, which yielded a higher So [183]. The positive charge on 
EDA, on the other hand, did not contribute to the hydrophilicity or hydrophobicity 
of BLG, because it did not alter the magnitude of net charge on the Asp or Glu 
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residue (-1 for unmodified Asp or Glu residues; +1 for the cationized ones). 
Secondly, CBLG might have formed a certain amount of electrostatic complexes 
with the anionic ANS, which exhibited minor fluorescence [194]. Thirdly, the 
randomization of BLG chain might have increased the quantum yield of ANS and 
led to an elevated apparent So [195]. This will be demonstrated in the next section. 
In addition to these three factors, enhanced protein aggregation upon cationization 
was also taken into consideration. However, no significant difference in turbidity 
was observed between BLG and CBLG solutions (data not shown). Therefore, this 
phenomenon was excluded from the possible reasons. 
HBSS was selected as a second buffer for evaluating zeta potential and So, 
because of its resemblance to intracellular fluids. This buffer exhibited a similar 
pH (7.4) with the PBS used in our study (7.0), but it contained thirteen-fold higher 
concentration of salt. As shown in Table 6.2, both BLG and CBLG exhibited 
decreased zeta potential (in terms of their magnitude) and So, which was consistent 
with previous studies [183, 196]. The reduced zeta potential was possibly 
attributed to the charge screening effect caused by increased ionic strength. Such 
change may result in weakened intra- and inter-molecule electrostatic repulsions 
and, therefore, the adoption of more compact conformations by BLG/CBLG. 
Consequently, the exposure of the grafted hydrophobic EDA moieties might have 
been diminished in the presence of HBSS, and the surface hydrophobicity was 
hence decreased. In addition, the partial electrostatic complexation between 
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protein and ANS might also have been compromised by charge screening, leading 
to a decrease in fluorescence intensity. In spite of these observations, the 
improvements in zeta potential and So by cationization were as remarkable in 
HBSS as were in PBS. These results suggested that CBLG might adhere to cell 
membrane more effectively through both electrostatic and hydrophobic interaction, 
thus enhancing the cellular uptake of the bound compounds of interest.  
6.4.3 Secondary structure 
The conformation of protein is a key factor that governs its physicochemical and 
functional properties. Conformational changes of protein have a significant 
influence on the hydrogen bonding intensity at the proximity of peptide bonds, 
altering their stretching patterns and consequentially changing the IR absorbance 
of the corresponding peaks, among which amide I (C=O stretching) exhibited the 
highest sensitivity [197]. As can be seen in Figure 6.2A, three characteristic peaks 
of native BLG were observed at 1631 (amide I, C=O stretching), 1521 (amide II, 
C-N stretching and N-H bending), and 1450 (amide III, CN stretching, NH 
bending) cm-1. These observations were in consistence with previous literature 
[179], indicating the predominance of β-sheet of BLG. After cationization, there 
was a significant shift of amide I to higher wavenumbers (1640 cm-1 for C-1.5M), 
while the shifts of amide II and III were not observed. This change suggested a 





Figure 6.2 FT-IR spectra of BLG and C-1.5M. 
Figure 6.2A: original spectra showing amide I, II and III bands. Figures 6.2B and 6.2C: 
Fourier self-deconvolved (FSD) and curve-fitted spectra depicting detailed secondary 
structure profiles of BLG (2B) and C-1.5M (2C). 
For quantitative assessment, the spectra were further subjected to FSD and 
Gaussian curve fitting procedure. Ten peaks were resolved and confirmed for both 
BLG and CBLG (Figures 6.2B and 6.2C), which were assigned to different 
secondary structure components according to previous studies [179, 187]. As 
shown in Table 6.3, there was a significant increase in the percentages of α-helix 
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(by 34%) [199], turns (by 33%) [25] and random coil (by 26%) [200], at the 
expense of β-sheet (decreased by 29%) [201]. Such structural change was closely 
related to the consumption of glutamic acid and aspartic acid, both of which were 
found majorly in the β-sheet segments of BLG [202]. The conjugation of EDA 
moieties onto these amino acids might have weakened their ability to stabilize the 
relatively rigid β-sheet and produced flexible structures, such as helices, turns and 
coils. Such conformational transformation suggested a less rigid and more 
randomized structure of CBLG compared to BLG, which was expected to have a 
positive impact on the encapsulation, transportation and delivery of nutraceuticals 
or drugs. These hypotheses will be tested in the follow-up study focused on the 
incorporation, stabilization and controlled release of nutrients and drugs. 
Table 6.3 Assignment and relative band areas of infrared Fourier self-deconvolved spectra 
for BLG and CBLG * 









     
Side chain 1610 ** 1604 ** 
β-sheet 1620 14.15 1614 6.28 
β-sheet 1630 20.71 1624 15.39 
β-sheet 1638 12.72 1634 15.53 
Random coil 1648 12.54 1642 17.14 
α-helix 1656 9.96 1651 13.33 
Turns 1666 10.26 1660 12.82 
Turns 1676 7.59 1671 11.48 
Turns 1685 6.94 1681 9.58 
β-sheet 1695 5.13 1693 6.78 
     
Total α-helix  9.36  13.06 
Total β-sheet  52.12  36.94 




Total turns  12.72  16.80 
*  The sample C-1.5M was employed for the FSD process. 
** The IR intensity due to side chain vibration was excluded in the calculation for 
secondary structures. 
6.4.4 Proteolysis profiles  
BLG is known for its resistance to peptic digestion [178], a major advantage over 
other proteins with respect to the transportation and delivery of nutraceuticals and 
drugs. This character was confirmed by our study (Figure 6.3A), in which only 9% 
of BLG was degraded after 4 h of incubation with pepsin. As for CBLG, a similar 
resistance was observed, although the percentage of digested protein increased 
slightly to 13%. This indigestibility of BLG by pepsin is attributed to the stability 
of the β-sheet-predominated structure [178]. In addition, pepsin cleaves preferably 
the peptide bonds formed between hydrophobic amino acids [203], which are not 
sufficiently exposed as evidenced by a low surface hydrophobicity. As discussed 
in the previous section, a lower content of β-sheet in CBLG might have resulted in 
decreased chain rigidity and increased flexibility compared to native BLG. 
However, the results from peptic digestion suggested that such change had only 
limited influence on the exposure of hydrophobic amino acid residues. In light of 
this result, it was speculated that the significant increase in So discussed before 
was more likely due to the exposure of EDA moieties than that of the original 
hydrophobic residues in BLG. 
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It was also noted that the Glu-/Asp-EDA conjugates produced upon cationization 
might be poor substrates for pepsin, in spite of the hydrophobicity caused by EDA. 
This was probably because that these conjugates exhibited little geometric 
similarity to any naturally occurring hydrophobic amino acids. In addition, the 
positive charge on EDA might have inhibited the catalytic triad on pepsin from 
approaching its substrate. As a result, CBLG inherited the high resistance to peptic 
digestion from BLG, which may enable it to minimize the loss of the encapsulated 
nutraceuticals and drugs in the stomach. 
Compared to pepsin, trypsin exhibited a higher capacity in digesting BLG, 
yielding an apparent digestibility of 25% (Figure 6.3) in the first 20 min. The 
abundance of positively charged amino acids (lysine and arginine) in BLG may 
account for this phenomenon, considering that they were typical substrates of 
trypsin [183]. As for CBLG, the EDA-aspartic acid conjugate carried as much 
positive charge as lysine, it showed to a certain extent of geometric similarity to 
lysine as illustrated in Figure 6.1. These two characteristics, together with its 
sufficient exposure as discussed before, made EDA-aspartic acid conjugates a 
possible substrate for tryptic digestion. Consequentially, the apparent digestibility 
of CBLG was increased to at most 43% as expected. Similar results were reported 




Figure 6.3 In vitro digestions of BLG and CBLG in the presence of (A) pepsin and (B) 
trypsin 
Improved digestibility by trypsin may have two different impacts on the 
transportation and delivery of nutraceuticals or drugs. On one hand, it suggested a 
more complete degradation of the protein matrix, leading to a more efficient 
release of the bound compound in small intestine. This property, together with the 
resistance to gastric digestion, is expected to confer CBLG nanoparticles with 
satisfactory controlled release feature. This hypothesis will be tested in our 
follow-up study. On the other hand, accelerated decomposition of the protein 
matrix in digestive system implied weaker protection to the entrapped compounds 
in the circulation process. This disadvantage, however, could be overcome by 
choosing proper cationizing reagents. For example, polyethylenimine (PEI) carries 
an equally high density of positive charges as EDA, and it provides considerable 
steric hindrance to the protein due to its branched structure [61]. Cationization of 
BLG by PEI, therefore, might detain both peptic and tryptic digestions, providing 
maximal protection to the incorporated compounds after intestinal absorption.  
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6.4.5 Mucoadhesive properties  
The gel-like layer of mucin on the wall of small intestine serves as the first barrier 
for nutrient absorption [9]. The adhesion to this negative charged, highly 
glycosylated protein is vital for the diffusion and transportation of enteric 
nutraceuticals or drugs, and it is one of the key components of the rationale of 
protein cationization. Two methods, turbidity and QCM assay, were employed in 
this study to validate the improved mucoadhesion of CBLG. In the turbidity 
analysis (Figure 6.4A), BLG-PSM mixture exhibited a negative absorbance at 
both 400 nm and 500 nm (the latter not shown), regardless of the BLG. This result 
was probably due to the negative net charges on both BLG and PSM, which 
inhibited the association between these two molecules through a strong 
electrostatic repulsion. On the contrary, the dispersions containing CBLG and 
PSM exhibited a highly positive absorbance. The relatively low absorbance of 
C-0.6M compared to other CBLGs was probably attributed to its lower surface 
charge as discussed before. These phenomena suggested the extensive formation 
of CBLG-PSM aggregates, which might have been driven by electrostatic 
attraction and, less importantly, hydrophobic interaction. 
The enhanced mucoadhesion property of CBLG was also evidenced by QCM 
analysis. Figures 6.4B and 6.4C were typical QCM diagrams obtained with 
PSM-BLG and PSM-CBLG, respectively. The two stepwise increases in the 
adsorbed mass corresponded sequentially to the deposition of PSM onto the gold 
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crystal and the adsorption of BLG/CBLG onto the PSM layer. Compared with 
BLG, CBLG adsorbed to PSM at a significantly higher level. Furthermore, the 
adsorption of CBLG reached equilibrium within a shorter time, as suggested by a 
steeper slope of the second step. A quantitative comparison in the mucoadhesive 
properties was displayed in Table 6.4 based on QCM analysis. The mass ratio of 
adsorbed protein to that of PSM increased in parallel with the cationization 
degrees, reaching a maximum of 1.259 (C-1.5M) that was 252% higher than that 
corresponding to BLG (0.357). It was worth noting that a certain amount BLG 
adsorbed to PSM in the QCM study, which was not observed in turbidity analysis. 
A possible explanation for this discrepancy was that part of the hydrophilic 
oligosaccharide chains that covered originally on the protein segment of PSM [9] 
might have been re-orientated to facilitate its deposition on the gold crystal. Such 
process facilitated the exposure of the more hydrophobic protein moieties [9], 



























Figure 6.4 Mucoadhesive properties of BLG and CBLG. 
Figure 6.4A: turbidity measurement at a PSM concentration of 1 mg/mL and different 
BLG/CBLG concentrations. Figures 6.4B and 6.4C: QCM analysis showing the 
mucoadhesion of BLG (4B) and C-1.5M (4C), obtained at a PSM and BLG/CBLG 
concentration of 0.4 and 1 mg/mL, respectively. The 5th overtone was used for graph 
plotting and mass calculation. 
Elevated mucoadhesive property of CBLG is one of its major merits. It resulted in 
shorter dwelling time in the small intestine, which suggested reduced opportunity 
for protein digestion and nutrient degradation. Both of these factors facilitated the 
absorption of CBLG and CBLG-bound molecules in their intact form. Although a 
number of studies have showed comparable mucoadhesion of other cationic 
polymers [10, 11, 60], most of them were conducted under acidic conditions (pH 
2-6). This was possibly due to the low solubility at neutral or basic pH of these 
polymers. Such disadvantage would have a negative impact on the mucoadhesive 
capability in small intestine, whose average pH is around 7. CBLG, on the other 
hand, exhibited high solubility at neutral pH due to its amphiphilic nature. Such 
advantage made CBLG a suitable candidate for the transportation of nutraceuticals 
and drugs across the small intestine. 
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Table 6.4 Mucoadhesion properties of BLG and CBLGs * 




Mass ratio  
(Pro: PSM) 
BLG 238±12c 85±14c 0.357±0.052e 
C-0.6M 359±17a 231±15b 0.643±0.013d 
C-0.9M 378±15a 308±20ab 0.815±0.020c 
C-1.2M 243±12c 240±15b 0.988±0.044b 
C-1.5M 294±10b 370±14a 1.259±0.071a 
*  Data with different letters showed significant difference (n=3, P<0.05).  
6.4.6 Particle formation behaviors  
The particle forming properties of BLG and CBLG investigated by DLS were 
compared in Table 6.5. In our preliminary study (data not shown), both BLG and 
C-0.6M aggregated spontaneously into nanoparticles in the presence of 80% 
aqueous ethanol. The other CBLGs (C-0.9M, C-1.2M and C-1.5M), however, did 
not show any observable aggregation even in 95% ethanol. Acetone, on the other 
hand, was able to initiate the particle formation of BLG and all CBLGs. It is 
generally believed that the formation of protein nanoparticles begins with the 
exposure of functional groups (hydrophobic site, thiol group, etc.), which induced 
intermolecular association and particle formation [44, 105]. Such process requires 
the contact between protein and antisolvent molecules, which triggers the 
unfolding of peptide chains [204]. When BLG was cationized, a considerable part 
of its exterior was covered by the grafted EDA moieties, as indicated by the highly 
positive zeta potential. Such coverage produced extra hindrance for relative polar 
organic solvents such as ethanol, due to the size of the cationizer (EDA) and the 
increase in surface hydrophobicity it induced [205]. This explained why ethanol 
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desolvated BLG and C-0.6M effectively but did not work for CBLGs with higher 
cationization degrees. In addition, C-0.6M might have exhibited weaker 
electrostatic repulsion due to a lower surface charge, which also facilitated the 
aggregation. As for acetone, it possessed a stronger protein denaturation capacity 
than ethanol [204]. In addition, its relatively low polarity suggested better contact 
with the hydrophobic surface of CBLG [206], which further promoted the 
desolvation and protein unfolding processes.  
Table 6.5 Characters of BLG and CBLG nanoparticles* 
Sample Acetone 
% 
Particle size  
nm 




BLG 80 139.1±5.7b 47.4±5.2d 0.255±0.003b 
BLG 90 136.3±11.2b 386.2±7.8a 0.142±0.002d 
C-0.6M 80 172.3±6.2a 402.4±7.1a 0.086±0.002e 
C-0.6M** 90 - - - 
C-0.9M 80 170.4±10.7a 30.8±2.3e 0.293±0.004a 
C-0.9M 90 93.5±3.4c 314.6±10.2bc 0.095±0.004c 
C-1.2M 80 165.0±5.2a 26.1±1.4f 0.255±0.006b 
C-1.2M 90 75.4±6.7c 259.4±12.5c 0.104±0.003c 
C-1.5M 80 155.7±10.1a 15.8±1.6g 0.297±0.005a 
C-1.5M 90 81.5±4.2c 280.4±13.1c 0.124±0.002c 
*  Data with different letters showed significant difference (n=3, P<0.05). A fixed protein 
concentration of 2 mg/mL was adopted. 
** No data available due to protein precipitation. 
As shown in Table 6.5, the particles formed with BLG or CBLG exhibited an 
average size of 75-172 nm, which was ideal for the encapsulation and 
transportation of nutraceuticals and drugs [20]. In addition, all samples except 
C-0.6M exhibited lower particle size, higher count rate and lower polydispersity in 
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90% acetone as compared to 80% acetone. The count rate of a colloidal dispersion 
is proportional to the quantity of particles and the sixth power of the average size; 
therefore, these results suggested that a significantly greater number of 
nanoparticles with lower, more uniformly distributed size were formed in 90% 
acetone. The precipitation of C-0.6M in 90% acetone was probably due to the lack 
of electrostatic stabilization as discussed before.  
 
Figure 6.5 SEM images for nanoparticles formed by BLG (6.5A) and C-1.5M (6.5B). 
The white scale bars indicated for 100 nm. Images were taken after acetone was 
evaporated and replaced with same volume of deionized water. 
Figure 6.5 displayed the morphology of BLG (A) and CBLG (B) nanoparticles 
observed under SEM. The particles were approximately spherical, and they 
exhibited a narrow size distribution between 50 and 80 nm. The maintenance of 
particle structure after the evaporation of acetone evidenced successful 
crosslinking of the particle structure by glutaraldehyde. The fact that the sizes 
observed under SEM were lower than those obtained by DLS was probably due to 
the shrinkage of nanoparticles under vacuum. Similar results were reported 




CBLG, a highly water-soluble cationic protein, was synthesized successfully with 
BLG and EDA. The attachment of EDA moieties induced a reversal in zeta 
potential (from -37 to +39 mV), together with a significant increase in surface 
hydrophobicity. FT-IR study showed the increase in helical and random secondary 
structure upon cationization at the expense of rigid β-sheets. Such conformational 
change led to an increase of apparent digestibility by trypsin, whereas the original 
resistance to peptic digestion of BLG was maximally retained. With regard to 
absorption, CBLG exhibited significantly enhanced association with PSM in 
turbidity assay compared with BLG, and its adsorption to PSM layer was 
improved by up to 252% in the QCM study. Nanoparticles with sub-100 nm size 
and narrow size distribution were prepared with CBLG using acetone as an 
antisolvent, evidenced by DLS and SEM. These features made CBLG and 
CBLG-based nanoparticles a suitable candidate for the encapsulation and delivery 
of poorly bioavailable nutraceuticals or drugs. Follow-up studies are being carried 
out on CBLG nanoparticles to evaluate their encapsulation capacity, controlled 






Chapter 7 Cationic β-lactoglobulin Nanoparticles as a 
Bioavailability Enhancer: Comparison between Ethylenediamine 
and Polyethyleneimine as Cationizers 
7.1 Abstract 
In this chapter, cationic beta-lactoglobulin (CBLG) was synthesized by two 
strategies: extensive conjugation of ethylenediamine (EDA) and limited 
cationization with polyethyleneimine (PEI). Both methods provided CBLG with 
remarkable water solubility and resistance to peptic digestion. Compared with 
EDA-derived CBLG (C-EDA), PEI-derived CBLG (C-PEI) exhibited higher zeta 
potential (54.2 compared to 32.4 mV for C-EDA), which resulted in significantly 
elevated mucoadhesion (439% and 118% higher than BLG and C-EDA, 
respectively) in quartz crystal microbalance (QCM) study. In addition, PEI caused 
lesser extent of conformational disruption on BLG compared to EDA as evidenced 
by FTIR measurement. This character, together with the steric hindrance provided 
by PEI, caused a phenomenal reduction in tryptic digestibility by at least 75% 
compared to C-EDA. In the presence of aqueous acetone, C-PEI aggregated 
spontaneously into nanoparticles with average size of 140 nm and narrow size 
distribution. These merits made C-PEI a useful material that provides desirable 




In the past decades, nano-scaled encapsulating and delivery systems have attracted 
increasing attention as transporters for nutraceuticals or drugs [1, 207]. Numerous 
nanoencapsulation strategies and systems have been developed by now, providing 
target compounds with desirable solubility [208], satisfactory stability [121], 
controlled release property [137] and elevated bioavailability [209]. It is generally 
believed that the success of delivery is highly dependent on the surface properties 
of the encapsulant, among which charge and hydrophobicity play a critical role 
[42]. For instance, cationic polymers such as chitosan [39], polylysine[59] and 
lactoferrin [50], have demonstrated significantly higher mucoadhesive capacity 
and cellular internalization compared with anionic macromolecules. This 
phenomenon was largely attributed to two factors. The first factor is the affinity of 
the polycations to the negatively charged glycoproteins, which are abundant on the 
epithelia cells or tissues (e.g., small intestine wall) [16]. The second advantage for 
cationic encapsulants is their ability to acquire a negative charged “corona” 
consisting majorly of serum proteins, which bind strongly to specific ligand on the 
cell membrane and thus promote the cellular internalization [210].  
By far, a wide array of cationic polymers has been exploited as novel 
encapsulating systems [39, 50, 174]. However, these polymers are either insoluble 
at neutral pH (e.g., chitosan) or susceptible to digestion by either pepsin or trypsin 
(e.g., polylysine). Therefore, the protection provided by these materials would be 
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easily diminished when they enter the gastrointestinal tract, which is one of the 
major drawbacks of these polycations. Beta-lactoglobulin (BLG), a 162-residue 
globulin, makes up approximately 60% of bovine whey protein [47]. BLG is 
highlighted for two unique features, namely, high surface charges and abundance 
of rigid β-sheet secondary structure. The first characteristic ensures the dispersion 
stability of BLG-based encapsulating systems even near its isoelectric point (~pH 
5.0). The second property endows BLG with remarkable resistance against peptic 
digestion [164], thus providing maximal stability and controlled release for 
oral-administrated bioactives.  
To take advantage of both BLG and cationic polymers, our lab synthesized 
cationic BLG (CBLG) by grafting ethylenediamine (EDA) to the glutamic acid 
(Glu) or aspartic acid (Asp) residues of BLG [151]. The products exhibited highly 
positive surface charge, which resulted in significantly improved mucoadhesion. 
In addition, EDA-derived CBLG inherited the resistance to pepsin in simulated 
gastric environment, but the digestion by trypsin was significantly elevated. A 
possible explanation for this phenomenon lied in the formation of Glu-/Asp-EDA 
conjugates [151], which showed similar geometry and electric charge status to 
lysine. Since lysine is a known substrate for trypsin [205], generation of 
Glu-/Asp-EDA conjugates might result in a significant increase in tryptic 
digestibility. While increased tryptic digestibility provided EDA-derived CBLG 
with certain degree of controlled release property, such change was unfavorable 
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for delivering bioactive compounds that requires prolonged protection after 
leaving digestive tract and entering systemic circulation. Furthermore, the 
disintegration of EDA-derived CBLG implied the inability t`o gain the serum 
protein corona [210]. This could not only compromise the efficacy of cellular 
uptake, but also lead to considerable cytotoxicity, since the negatively charged 
corona played a crucial role in counterbalancing the toxicity induced by cationic 
polymers [211]. Increased digestibility of CBLG, therefore, might be detrimental 
for its function as a bioavailability enhancer for nutraceuticals or drugs.  
Polyethyleneimine (PEI, structure shown in Figure 1.2) is a cationic polymer 
whose repeating units consist of an amine group and two methylene groups 
(-NH-CH2-CH2-). Owing to its low toxicity [212, 213], PEI has been permitted by 
FDA to be added as an enzyme immobilizing agent in the beer industry [214]. 
Amongst all commercially available PEI categories, branched PEI contains 
abundant primary amino groups that are reactive for cationization. Because of the 
high content of amino groups (one unit of positive charge in a mass unit of 43), 
conjugation of only a few PEI molecules is sufficient to introduce a significant 
amount of positive charge to the protein, without greatly altering its conformation 
[215]. By far, PEI has been used as a cationizer for various proteins [42], resulting 




Figure 7.1 Schematic illustration on the structure of PEI- and EDA-derived CBLG. 
The conjugates between EDA and Glu/Asp residues exhibit similar geometry and electric 
charge with lysine, a substrate for trypsin. 
Hereby, we propose the synthesis of CBLG using branched PEI as a cationizer. 
The anticipated structures of EDA-derived CBLG (C-EDA) and PEI-derived 
CBLG (C-PEI) are illustrated in Figure 7.1. We expected that C-PEI exhibit 
similar resistance against pepsin and superior mucoadhesion, compared with BLG 
or C-EDA. In addition, we hypothesized that the product could maintain its 
integrity under simulated intestinal condition, because of the absence of 
Asp-/Glu-EDA conjugate, as well as steric hindrance provided by the highly 
branched PEI backbone. The product was compared in parallel with BLG and 
C-EDA, with respect to its conjugation degree, surface charge, secondary structure, 
in vitro digestibility and mucoadhesion. Finally, C-PEI-based nanoparticles were 
fabricated by organic solvent desolvation method, and the unique particle forming 
behaviors of this modified protein were reported.  
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7.3 Materials and Methods 
7.3.1 Materials 
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO, 
USA): bovine BLG (90% purity), ethylenediamine dihydrochloride (EDA, 98% 
purity), branched polyethyleneimine (PEI600 and PEI1200, with average MW of 
600 and 1200 Dalton, respectively), sinapinic acid, pepsin (3,200-4,500 units/mg), 
N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC, 97% purity), trypsin 
(10,000 BAEE units/mg), and trichloroacetic acid (TCA). Porcine stomach mucin 
(PSM, type III, contains 0.5-1.5% sialic acid) was obtained from Himedia Co., 
India. All other reagents (trifluoroacetic acid, sodium bicarbonate, simulated 
gastric and intestinal fluids, etc.) were of analytical grade. 
7.3.2 Preparation of cationic beta-lactoglobulin (CBLG) 
CBLG was prepared by grafting cationic EDA or PEI moieties to the anionic 
carboxyl groups on the Asp and Glu residues on native BLG [151]. This was 
achieved via a previously reported EDC-aided reaction [62]. BLG and the 
cationizers (EDA or PEI) were dissolved in deionized water at 20 and 100 mg/mL, 
respectively. The pH was then adjusted to 4.75 using 1 mol/L HCl for BLG 
solution or concentrated HCl for cationizer dispersion. Thereafter, 5 mL of BLG 
solution was added slowly to 30 mL cationizer dispersion under mild stirring, and 
the mixture was incubated at room temperature for 15 min. Cationization was 
initiated by the addition of 30 mg EDC and terminated by adding 108 μL sodium 
187 
 
acetate buffer (4 mol/L, pH 4.75) after 4 h. The resultant dispersion was subjected 
to dialysis centrifugation (5,000 g, 30 min), using a Macrosep® centrifuge tube 
(Pall Corp., Ann Harbor, MI) with a built-in filtering membrane. Tubes with 
different MW cutoff values (10,000 for EDA and PEI-600-derived CBLG and 
100,000 for PEI-1200-derived CBLG) were chosen for different samples in order 
to maximize the removal of unreacted chemicals, without compromising protein 
yield significantly. The retentate obtained after centrifugation was further dialyzed 
against deionized water at 4 oC for at least 48 h and freeze dried. The moisture 
content of the final product was less than 5%, and the protein content was above 
90% according to Bradford assay calibrated with BSA. The samples were 
designated as C-EDA for EDA-derived CBLG and C-P600/C-P1200 for CBLG 
synthesized with PEI-600/ PEI-1200. 
7.3.3 Determination of molecular weight and net charge 
The molecular weights (MW) of BLG and CBLG were measured by matrix 
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry in linear mode [216]. The samples were dispersed at 25 mg/mL in 
deionized water containing 1 μL /mL trifluoroacetic acid (TFA). The matrix 
solution was prepared by dissolving 10 mg sinapinic acid in a mixture of 200 μL 
pure acetonitrile and 200 μL water (containing 0.2 μL TFA). Prior to analysis, 1 
μL matrix solution was spotted onto the target plate, and 1 μL of the sample 
solution was doped above the matrix layer. A second matrix layer (0.5 μL) was 
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then dripped on top of the abovementioned two layers. Each layer was air dried at 
room temperature before doping the next one. The target plate was then loaded 
into a Shimadzu Axima-CFR MALDI-TOF spectrometer (Shimadzu North 
America, Columbia, MD, USA). Spectra were obtained by illuminating the 
samples with a N2 laser beam (130 mJ per shot, 2 shots per second) and analyzed 
with the Kompact software. For each sample, at least 150 spot spectra were 
collected and averaged, and the peak values on the spectra were reported.  
The amount of electric charge on CBLG was estimated based on the MW. The 
change in MW upon cationization (ΔM) was firstly converted to the conjugation 
degree (CD, number of EDA or PEI molecules grafted to a single BLG molecule), 
using the equation CD=ΔM/m, where m represented the theoretical mass change 
when one cationizer was attached. The value of m was 42 for EDA, which was 
calculated by subtracting its MW (60) by the MW of water (18). For PEI-600 and 
PEI-1200, the values of m were estimated as 582 and 1182, respectively. The net 
charge was then calculated as follows: Net charge = z × CD - 7, where the number 
“-7” was the net charge of BLG molecules, CD was the conjugation degree, and z 
was the amount of positive charge on the cationizer. For EDA, the value of z was 
2. For PEI, the z value was estimated as (molecular weight + 26) / 43 [215].  
7.3.4 Determination of zeta potential 
Samples were dispersed in PBS (10 mmol/L, pH 7.0, same hereinafter) and 
measured for their electrophoretic mobility by laser Doppler velocimetry, using a 
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Nano ZS90 Zetasizer (Malvern Inc., Malvern, UK). Each sample (1 mg/mL) was 
measured for three times, each time containing at least twelve runs. The data were 
then converted to zeta potentials using the Smoluchowski model.  
7.3.5 Secondary structure determination  
The structural change of BLG upon cationization was investigated by 
Fourier-transform infrared (FT-IR) analysis. Samples (3 to 5 mg) were freeze 
dried and mounted directly onto a Jasco FT/IR 4100 spectrometer (Jasco Inc., 
Easton, MD, USA). The infrared transmittance was recorded at wavenumbers 
between 1000 and 4000 cm-1 at resolution of 2 cm-1. At least 100 repeated scans 
were undertaken for each sample. The spectra were averaged, smoothed, corrected 
for their baselines and converted to absorbance using the Spectra Manager 
software (Jasco Inc., Easton, MD, USA). For quantitative study on protein 
conformation, Fourier self-deconvolution (FSD) was undertaken on the obtained 
IR spectra, using the OMNIC software (Thermo Scientific, West Palm Beach, FL, 
USA). Peak finding and assignment were performed according to our previous 
study [151]. 
7.3.6 Determination of in vitro digestibility 
Samples were subjected to in vitro digestion test using two enzymes, i.e., pepsin 
and trypsin, following a procedure described in our previous study [151]. In brief, 
samples were dissolved in simulated gastric or intestinal fluid, incubated at 37 oC 
for 15 min, mixed with pepsin or trypsin solution at a substrate-to-enzyme ratio of 
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200:1 (w/w). At predetermined time intervals, aliquots of the sample were mixed 
with TCA solution to terminate digestion and then centrifuged. Digested protein 
was recovered in the supernatant and measured for its absorbance at 280 nm. For 
comparison purpose, another aliquot of the sample was digested by papain, which 
was known to digest BLG completely [151]. The absorbance observed for peptic 
or tryptic digestion was divided by the one obtained from papain digestion, thus 
giving the apparent digestibility for the samples.  
7.3.7 Determination of mucoadhesion 
Quartz crystal microbalance (QCM) analysis [11]. In the QCM study, two thin 
layers of PSM and protein (BLG or CBLG) were deposited sequentially on a 
gold-coated AT-cut quartz crystal with a fundamental frequency of 4.95 MHz 
(QSX-301, Q-Sense Co., Linthicum, MD, USA). The deposition of the two 
polymers induced the mass change of the crystal, which was reflected by the 
change in frequency (Δf). Prior to each treatment, the crystal was soaked in 
Piranha solution (NH3·H2O: H2O2: H2O=1:1:5, v/v/v) for 15 min at 70 oC, rinsed 
by deionized water and ethanol, and finally dried with nitrogen. The crystal was 
then mounted onto a Q-Sense E1 microbalance (Q-Sense Co., Linthicum, MD, 
USA), after which PBS was injected at a flow rate of 0.224 mL/min using a 
peristaltic pump (Ismatec Reglo, Glattbrugg, Switzerland). After obtaining a 
constant frequency, PSM solution (400 μg/mL in PBS, filtered through a 220 nm 
membrane) was pumped into the crystal chamber. The frequency was significantly 
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changed due to the deposition of PSM, and it reached another plateau after 
approximately 10 min. The chamber was rinsed with PBS for approximately 5 min 
to remove loosely deposited PSM molecules, after which protein solution (1 
mg/mL in PBS, passed through a 220 nm membrane) was injected at a same flow 
rate. After 15 min of protein adsorption, the frequency became stable again, and 
the chamber was subjected to a final rinse of PBS, until the last plateau of 
frequency was observed. Changes in frequency, up to the 13th overtone, were 
collected by QTools 3 (Q-Sense Co., Linthicum, MD, USA) throughout the whole 
process. The Δf of the fifth overtone was converted to deposited mass (in ng/cm2 
crystal surface) by QTools 3, using the Sauerbrey model. Mucoadhesion was 
expressed as the mass ratio between deposited BLG/CBLG and PSM. The 
temperature of the chamber was kept at 37 oC during the measurement. 
Turbidity analysis [10]. Samples (BLG or CBLG) and PSM were dispersed in 
PBS at 10 and 1 mg/mL, respectively, and they were both passed through a 1.2 μm 
Acrodisc® syringe filter. The two stock solutions were then diluted appropriately 
to achieve a fixed PSM concentration of 1 mg/mL and different protein 
concentrations (0.25, 0.5 and 1 mg/mL). The mixture was then incubated at 37 oC 
for 1 h and cooled to room temperature. The absorbance at 400 nm of the mixture 
was recorded by a DU-730 UV/VIS spectrophotometer (Beckman Coulter Inc., 
Fullerton, CA, USA), using pure PSM dispersion (1 mg/mL, filtered as described 
above) as blank.  
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7.3.8 Preparation of BLG/CBLG nanoparticles 
Nanoparticles were prepared with BLG/CBLG by desolvation [105] method. 
Constant stirring (600 rpm) was applied throughout the particle formation process. 
The protein was dissolved in deionized water at 10 mg/mL (pH 7.5-8.0), and the 
resultant dispersion was equilibrated for 1 h at room temperature. To initiate 
particle formation, pure acetone was added dropwise to achieve an acetone/water 
ratio of 90/10 (v/v). The suspension changed from a clear solution into an opaque 
dispersion, which was equilibrated for 30 min. A crosslinker (glutaraldehyde) was 
then added to harden the particle structure. Based on the lysine content of BLG 
(16 mol Lys per mol BLG), the amount of glutaraldehyde needed for sufficient 
crosslinking is 40 μg/mg. After cationization, the content of primary amino groups 
in the protein increased significantly, and greater amount of glutaraldehyde was 
therefore required. In this study, the mass ratio between glutaraldehyde and 
protein ranged from 40 to 160 μg/mg. Prior to the crosslinking process, the 
dispersion was diluted with 90% (v/v) aqueous acetone by fivefold. The reason for 
dilution will be discussed in the Section 7.4.5. After 8 h of crosslinking, the added 
acetone was evaporated under a constant nitrogen flow and replaced with same 
volume of deionized water. The resultant suspension containing the nanoparticles 
was evaporated under nitrogen flow to remove acetone, supplemented with 
deionized water to the original volume (before dilution), and stored at 4 oC for 
subsequent assays.  
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7.3.9 Determination of particle size and count rate 
The particle size and count rate of BLG/CBLG nanoparticle dispersions were 
determined [133] by dynamic laser scattering (DLS) using a BI-200 SM 
Goniometer Version 2 (Brookhaven Instrument Corp., Holtsville, New York, USA) 
equipped with a 35 mW He-Ne laser beam. The measurements were undertaken at 
two stages during the nanoparticle formation process: before dilution and after 
water supplementation. No dilution was applied before the assays. The following 
parameters were adopted: laser power of 10 mW, detection wavelength of 637 nm, 
scattering angle of 90°, temperature of 25 oC, and measurement time of 1 min. The 
refractive indices and viscosities of different acetone/water systems were applied 
for all assays, since they were not significantly altered by low concentration of 
protein or glutaraldehyde in our study (data not shown). Two separate 
measurements were carried out on each sample in order to obtain accurate results. 
For count rate determination, the aperture pinhole size was fixed at 400 μm; to 
measure the particle size, appropriate aperture pinhole sizes were chosen to 
achieve a count rate between 100 and 300 kcps. The obtained data were analyzed 
using cumulant algorithm, and the quadratic mean particle size was reported. 
7.3.10 Scanning electron microscopy (SEM) 
The morphology of BLG/CBLG nanoparticles was observed using a Hitachi 
SU-70 SEM (Hitachi, Pleasanton, CA, USA) [105]. Approximately forty 
microliters of the nanoparticle dispersion was pipetted onto an aluminum pan and 
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air dried. The pan was then cut into appropriate sizes and adhered to a 1-inch 
specimen stub with conductive carbon tapes (Electron Microscopy Sciences, Ft. 
Washington, PA, USA). Prior to observation, a thin layer (<20 nm) of gold and 
platinum was deposited to the samples using a sputter coater (Hummer XP, 
Anatech, CA, USA). Representative images were reported. 
7.3.11 Statistics 
All measurements were carried out in triplicates. The results were expressed as 
means ± standard error. Analysis of variance (P < 0.05) was performed on the data 
using SAS 9 software (SAS Institute Inc., Cary, NC, USA). The results were then 
subjected to Tukey’s test with an experimentwise confidence level of α=0.10. 
7.4 Results and Discussion 
7.4.1 Effect of cationization on net charge and zeta potential 
Figure 7.2 showed the mass/charge ratio (m/z) distribution of native and 
cationized BLG. BLG exhibited a major peak at m/z=18215 with a shoulder at 
m/z=18314. These values corresponded to mono-charged bovine BLG variants A 
and B, respectively [216, 217]. Meanwhile, doubly charged BLG molecules were 
also observed at m/z=9116 (variant A) 9158 (variant B). Upon cationization, a 
significant shift towards higher values of m/z was observed. The peak for C-EDA 
centered at m/z=19188, indicating that approximately 21 EDA molecules were 
grafted to one BLG molecule. This result was in agreement with that obtained by 
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TNBS assay (data not shown), which indicated that approximately 19 EDA 
molecules were conjugated on one BLG molecule. The reason why this number 
was higher than that achieved in our previous study (11 EDA per BLG molecule) 
was probably prolonged reaction time [151]. For PEI-derived CBLG, they 
exhibited a wider distribution of m/z values, probably because of the 
polydispersity in MW of commercially available PEI products as indicated by the 
manufacturer. The central m/z values for C-P600 and C-1200 were 21305 and 
23231, respectively. As estimated from these results, an average of five PEI-600 
and four PEI-1200 molecules were attached respectively to one BLG molecule.  
 
Figure 7.2 MALDI-TOF spectra for BLG and CBLG. 
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Table 7.1 summarized the net charges and zeta potentials of BLG and CBLG. 
Native BLG, taking average of its two variants, possesses 16 Lys, 3 Arg, 10 Asp 
and 16 Glu residues [217], all of which results in an overall net charge of -7 per 
molecule. Upon cationization with EDA, the net charge of BLG shifted to +25. 
When PEI-600 and PEI-1200 were used as cationizers, the net charge shifted more 
dramatically to +58 (C-P600) and +102 (C-P1200), in spite of relatively low 
conjugation degrees. It should be pointed out, however, that the estimated net 
charge for PEI-derived CBLG was the maximal theoretical value that could only 
be achieved when all of the amino groups on PEI were protonated. The actual 
charging status of PEI-derived CBLG was highly dependent on the structure of 
PEI (e.g., chain length, degree of branching, content of primary and secondary 
amino groups), as well as the environment (pH, ionic strength, etc.) [151].  












in PBS (mV) 
BLG - 18215 - -7 -35.8±0.7d 
C-EDA EDA 19188 20.8 +35 32.4±1.0c 
C-P600 PEI-600 21305 5.2 +58 46.8±1.5b 
C-P1200 PEI-1200 23231 4.2 +102 53.4±1.3a 
* The conjugation degrees were estimated from the peak MW measured by MALDI-TOF. 
Zeta potential reflects the surface charge and stability of colloidal particles. As 
shown in Table 7.1, native BLG exhibited a zeta potential of -35.8 mV, which 
was consistent with previous studies [151]. The zeta potential changed 
significantly to 32.4 mV upon conjugation with EDA, and it shifted towards more 
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positive values for C-P600 (46.8 mV) and C-P1200 (53.4 mV). The high zeta 
potentials of PEI-derived CBLG were probably due to the abundance of amino 
groups on PEI. Moreover, a considerable part of these amino groups was pushed 
towards the surface of CBLG (Figure 7.1), owing to the extended polymeric 
chains of PEI. This caused extensive exposure of protonated amino groups, which 
contributed to the highly positive zeta potential of C-PEI. As a result, all CBLG 
sample were soluble in water or PBS at concentrations higher than 100 mg/mL, 
without any observable precipitation in several weeks (data not shown). 
7.4.2 Change in protein structure upon cationization 
The FT-IR spectra of BLG and different CBLG samples were displayed in Figure 
7.3. Native BLG exhibited three characteristic peaks: amide I (1631 cm-1, C=O 
stretching), amide II (1520 cm-1, C-N stretching and N-H bending), and amide III 
(1450 cm-1, C-N stretching, N-H bending). The position of amide I (1631 cm-1) 
was indicative for the predominance of β-sheet secondary structure in BLG, which 
was consistent with previous literatures [47]. After cationization with EDA, the 
amide I peak shifted to 1639 cm-1, which suggested the formation of other 
secondary structures at the expense of β-sheet. No other peak was observed with 
significant shifting. These phenomena could be explained by the fact that C=O 
stretching is more sensitive to conformational change than other common 
stretching or bending patterns in proteins [179]. As protein molecules changed in 
their secondary structure, the intra-molecular hydrogen binding was either 
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strengthened or weakened, both of which altering the C=O pattern and leading to a 
shift in the amide I peak. 
When PEI was used as a cationizer, the shift in amide I was not as significant as 
that for C-EDA. This phenomenon indicated a lower degree of conformational 
change induced by PEI compared with EDA. A possible explanation was that only 
four to five Glu or Asp residues of BLG were substituted by PEI, whereas more 
than 20 EDA molecules were attached to BLG. As Glu and Asp are found mainly 
in the β-sheet region of BLG [202], lower conjugation degree might be beneficial 
for the preservation of original protein structure. On the other hand, amide II and 
amide III exhibited a significant shift towards higher wavenumbers. Such results 
were more likely attributed to the IR absorption of PEI molecules rather than the 
change in protein conformation that they induced, considering the abundance of 
C-N and N-H bonding in PEI [218]. In addition, wide adsorption humps centered 
at 1075 and 1099 cm-1 were observed for C-P600 and C-P1200, respectively. 
These peaks were assigned for C-N stretching of alkyl amines, which were typical 






Figure 7.3 Original and Fourier self-deconvoluted FT-IR spectra of BLG and CBLG. 
 
Table 7.2 Assignment and relative band areas of infrared Fourier self-deconvolved BLG and 
CBLG 














         
Side chain 1610 * 1604 * 1603 *  * 
β-sheet 1620 14.15 1614 6.28 1614 11.20  12.30 
β-sheet 1630 20.71 1624 15.39 1624 13.14  19.78 
β-sheet 1638 12.72 1634 15.53 1631 18.89  14.80 
Disordered 1648 12.54 1642 17.14 1641 13.93  12.98 
α-helix 1656 9.96 1651 13.33 1649 12.22  12.35 
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Turns 1666 10.26 1660 12.82 1659 13.58  12.60 
Turns 1676 7.59 1671 11.48 1669 8.28  9.23 
Turns 1685 6.94 1681 9.58 1681 5.12  4.25 
β-sheet 1695 5.13 1693 6.78 1691 3.63  1.70 
         
Total content 
α-helix  9.36  13.06  13.20  12.28 
β-sheet  52.12  36.94  46.87  46.81 
Disordered  25.80  33.20  28.02  26.98 
Turns  12.72  16.80  11.91  13.93 
* The IR intensity due to side chain vibration was excluded in the calculation for 
secondary structures. 
For further investigation on the secondary structure, the spectra were subjected to 
FSD and curve fitting. As shown in Table 7.2, native BLG contained 52.5% 
β-sheet. The predominance of β-sheet was in consistence with previous reports 
[187], in which it was considered responsible for the rigidity and indigestibility of 
BLG. When BLG was cationized with EDA, there was a significant conversion of 
β-sheet (decreased by 29%) into α-helix (increased by 34%), turns (increased by 
33%) and random coil (increased by 26%) [179]. This change was attributed to the 
consumption of Asp and Glu, both of which are present in abundance in β-sheets 
[220, 221]. Similar results were also observed on PEI-derived CBLG; however, 
the conformational change induced by PEI was not as significant as that cause by 
EDA. The content of β-sheet was decreased by 7% and 10% for C-P600 and 
C-P1200 respectively. As suggested by these data, conjugation of a smaller 
number (4 or 5) of bulky cationic molecules might have led to a lesser extent of 
conformational change, compared with the grafting of a greater number (more 
than 20) of small cations, although the former approach introduced a significantly 
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greater amount of positive charge. In addition, the compositions of secondary 
structures for C-P600 and C-P1200 were not significantly different as shown in 
Table 7.2. This result suggested that, compared with the size of the cationizer, the 
structure (monomeric or polymeric) and number of cationic moieties might have 
played a more important role in determining the secondary structure of BLG. This 
postulation was further supported by a follow-up study (data not shown), in which 
cationization of BLG with PEI-1800 resulted in a similar extent of conformational 
change as PEI-600 and PEI-1200. Based on the discussions above, PEI might be a 
better reagent for cationizing BLG while preserving its unique structure. A similar 
hypothesis was also proposed in previous literatures [42].  
7.4.3 In vitro digestibility of BLG and CBLG  
The digestion profiles of BLG and CBLG are depicted in Figure 7.4. Native BLG 
is highlighted for its resistance against peptic digestion. This characteristic was 
confirmed by our study, in which only 9% of BLG was digested by pepsin in SGF 
after 4 h. When BLG was cationized by EDA or PEI, its digestibility increased to 
17% and 15%, respectively. This phenomenon was probably due to the disruption 
of β-sheet structure as discussed in the previous section. This change might have 
led to higher flexibility of BLG molecules and increased exposure of their 
digestible sites, resulting in elevated accessibility of pepsin to BLG. Similar 
results were also reported and discussed in a previous literature [205]. In spite of 
the notable increase, the peptic digestibility of CBLG remained at a low level. 
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Therefore, CBLG was expected to provide significant protection to incorporated 
nutraceuticals or drugs against digestion in the stomach. 
Under the simulated intestinal condition, approximately 25% of BLG was digested 
by. A higher tryptic digestibility (32%) was observed for C-EDA, probably due to 
the formation of Asp-EDA/Glu-EDA conjugates [151]. As discussed before, such 
amino acid derivatives exhibited similar geometric structure and electronic 
charging status with lysine, a major substrate of trypsin. Therefore, cationization 
by EDA might have produced suitable sites for tryptic cleavage, thus increasing 
the apparent digestibility. PEI, on the contrary, is a polymer with bulky branches 
and multiple positive charges, and the conjugate formed between Asp/Glu and PEI 
did not exhibit such similarity to lysine. In addition, the polymeric network of PEI 
might have acted as a barrier for trypsin (Figure 7.1). As a result, the tryptic 
digestibility of C-P600 (8%) or C-P1200 (6%) was significantly lower than that of 
BLG or C-EDA. In addition, C-P600 and C-P1200 exhibited similar tryptic 
digestibility. Such phenomenon indicated that the structure and number of 
conjugated cationic groups might be more important than their size in determining 
the apparent digestibility of CBLG. This was in agreement with the discussion in 
Section 7.4.2. Based on these results, PEI-derived CBLG may provide satisfactory 
protection against both peptic and tryptic digestion, and such protection might 
remain effective after the target compound enters the circulation system. This 
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feature is favorable for the encapsulation and delivery of nutraceuticals and drugs 
that are susceptible to degradation or clearance by the circulation system. 
 
Figure 7.4 In vitro peptic (A) and tryptic (B) digestion profiles of BLG and CBLG. 
7.4.4 Mucoadhesive properties  
Mucin is a highly glycosylated and negative charged protein [222]. Existing in 
abundance as a gel-like layer covering the small intestine wall, mucin serves as the 
first barrier for the entry of nutraceuticals or drugs into the circulation system [60]. 
Affinity to the mucin layer, known as mucoadhesion, is therefore a key factor that 
determines the bioavailability of oral-administrated bioactives. In this study, two 
assays (turbidity and QCM) were performed to evaluate the mucoadhesion of BLG 
and CBLG. In the turbidity analysis (Figure 7.5A), native BLG did not display 
any observable absorbance when mixed with mucin in PBS. On the other hand, 
CBLG exhibited significant absorbance at 400 nm, which was indicative for the 
extensive formation of mucin-CBLG aggregates. In addition, the absorbance of 
C-P600 or C-P1200 was more than twice that of C-EDA. The electrostatic 
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attraction between anionic mucin and cationic EDA/PEI moieties played a critical 
role in the aggregation process.  
 
 
Figure 7.5 Mucoadhesion of BLG and CBLG measured by (A) turbidity and (B) QCM-D 
The improvement in mucoadhesion by cationization was also evidenced by the 
QCM study. As shown in Figure 7.5B, native BLG showed low affinity to the 
mucin layer that was pre-deposited onto the quartz crystal. After cationization, the 
mucoadhesion of BLG was increased significantly by 147%, 439%, and 366% for 
C-EDA, C-P600, and C-P1200, respectively (Table 7.3). Improved mucoadhesion 
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was likely contributed by the high density of positive charge introduced with EDA 
or PEI. In addition, PEI-derived samples demonstrated more significant 
improvement in mucoadhesive properties than EDA, probably owing to its highly 
positive surface charge. The similarity in the mucoadhesive properties of C-P600 
and C-P1200 was probably due to the similarity in their conformation that was 
discussed before. In our preliminary study (data not shown), the surface 
hydrophobicity of C-P600 or C-P1200 was comparable to that of native BLG, and 
it was significantly lower than that of C-EDA. Combining these results, we 
postulated that the electrostatic attraction rather than hydrophobic interaction 
might have played a dominating role in the mucoadhesion process for cationic 
proteins. Based on the results on mucoadhesion and protein digestion, PEI-derived 
CBLGs might be a better solution for enhancing the bioavailability of 
nutraceuticals or drugs.  
Table 7.3 Mass accumulation of BLG and CBLG samples on mucin estimated from QCM 
assay * 
Sample Mucin ng/cm2 Protein ng/cm2 Mass ratio (P:M)* 
BLG 238.3±15.4a 85.4±9.7c 0.357±0.005c 
C-EDA 195.4±10.7b 172.2±12.5b 0.881±0.100b 
C-P600 239.1±20.8a 460.1±40.1a 1.924±0.215a 
C-P1200 228.7±19.7a 380.8±32.3a 1.665±0.234a 
* Data with different letters indicate for significant difference (P<0.10, experimentwise) 
** Weight ratio between deposited protein and mucin. 
It was worth mentioning that all studies on mucoadhesion were undertaken at 
neutral pH. Although some common cationic polymers (e.g., chitosan and its 
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derivatives) were reported to show comparable mucoadhesive capability [36], 
these polymers were only positively charged at acidic pH, and they became 
insoluble at neutral or basic pH due to the deprotonation of their functional groups. 
The retention of positive charge over a wide range of physiologically relevant pH 
is a major advantage of CBLG over other polycations, and such property makes 
EDA- and PEI-derived CBLG an attractive vehicle for transporting bioactives 
through oral administration.  
7.4.5 Nanoparticle forming behavior of BLG and CBLG 
The particle formation capabilities of BLG and CBLG were summarized in Table 
7.4. In 90% acetone, native BLG formed particles with an average size of 136.3 
nm. After crosslinking with glutaraldehyde and evaporation of acetone, the 
particles exhibited slightly increased size with decreased count rate. These results 
suggested that the majority of the particles maintained their size and structure 
[105], and also indicated for successful crosslinking by glutaraldehyde. Similar 
results were observed for C-EDA, which aggregated into smaller particles that 
kept virtually consistent size and count rate.  
When PEI-derived CBLGs were used as particle formers, the results on particle 
sizes and count rates were within a similar range as compared to BLG and C-EDA. 
However, two major differences were observed with respect to their particle 
forming behaviors. Firstly, the amount of glutaraldehyde needed for C-P600 and 
C-P1200 was at least 100% higher than that for BLG and C-EDA. Otherwise, the 
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nanoparticles were prone to dissociation as indicated by greatly decreased count 
rate of the dispersion (data not shown). This was probably because of the 
substantial increase in the number of primary amino groups upon conjugation with 
PEI. Since primary amino groups were the major substrate for 
glutaraldehyde-induced crosslinking [23], increased number of these groups 
suggested the requirement for higher dose of glutaraldehyde in order to achieve 
complete crosslinking. Furthermore, the large amount of positively charges 
introduced by PEI resulted in strong electrostatic repulsion between CBLG 
molecules. Such change necessitated more covalent bonds to overcome the 
repulsive force and maintain the compact structure of nanoparticles. Although 
excessive glutaraldehyde could be removed by dialysis, it is necessary to 
determine the level of residual glutaraldehyde as well as the toxicity of the final 
product. Substitution of glutaraldehyde by other reagents (genipin, citric acid, etc.) 
might also help lowering the toxicity of CBLG nanoparticles. Further studies are 
needed to address these issues. 







 Count rate 
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BLG 40 100% 136.3±7.6a 150.4±3.5d 386.2±20.5a 359.7±16.7a 
C-EDA 40 100% 93.5±5.2c 116.7±1.5e 314.6±11.4b 298.4±22.1b 
C-P600 80 100% 145.6±2.4a 194.3±4.2b 259.1±30.1a 280.4±14.5b 
C-P600 80 200% 144.1±3.1a 160.3±4.4d 187.3±16.5c 177.9±16.2c 
C-P1200 80 100% 132.7±7.5a 400.2±8.9a 351.1±18.9ab 80.7±9.4de 
C-P1200 80 200% 126.5±6.1b 170.6±6.7c 150.3±12.6c 100.4±7.5d 
C-P1200 80 400% 115.4±4.2b 120.4±2.5e 80.6±9.4d 68.5±6.5e 
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Figure 7.6 Schematic illustration on the preferential crosslinking among C-PEI 
nanoparticles. 
At higher concentrations (a), crosslinking across adjacent nanoparticles was favored, 
resulting in the formation of gel-like structure. Upon dilution (b), crosslinking was more 
likely to take place within a single particle. Such process contributed to the maintenance 
of nanoparticle morphology. 
The second difference was that a dilution procedure was needed, especially for 
C-P1200. In our preliminary study, C-P1200 formed a significant number of 
nanoparticles in 90% acetone, but these particles were unable to maintain their 
morphology after evaporation. At lower glutaraldehyde doses (40-80 ug/mg 
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protein), the nanoparticle dispersion became a clear solution after evaporation. 
When higher doses of glutaraldehyde (120-160 ug/mg protein) were applied, the 
dispersion turned into a dark-colored gel. A possible explanation for these 
phenomena lied in the structure of branched PEI molecules. PEI possesses a 
highly branched structure with a large number of amino groups. However, only 
30-40% of them are primary amino groups [61], which are reactive with 
glutaraldehyde. When PEI-derived CBLG formed nanoparticles, the surface of the 
particles was probably covered by PEI branches as indicated by the highly positive 
zeta potential. The distance between two reactive amino groups, together with 
internal steric hindrance caused by the PEI network, could therefore impede 
glutaraldehyde molecules from effectively crosslinking within a single particle. 
On the other hand, due to the large number of nanoparticles in the dispersion, 
there was an increased chance for two nanoparticles to approach each other, 
exposing their primary amino groups that could be connected by glutaraldehyde 
Figure7.6a). This could possibly explain the formation of gel instead of individual 
particles by C-P1200 after evaporation. When the dispersion was diluted, the odd 
for inter-particle crosslinking was greatly reduced, whereas the opportunity for 
crosslinking within a same particle was virtually unchanged (Figure 7.6b). 
Therefore, the average size and count rate of particles were better maintained. 
However, further studies need to be carried out to test such hypothesis and to 




Figure 7.7 SEM images of nanoparticles formed with (A) BLG, (B) EDA-derived CBLG, 
(C) PEI-derived CBLG, before evaporation, and (D) PEI-derived CBLG, after 
evaporation. 
Figure 7.7 showed the morphology of nanoparticles formed by BLG (A), C-EDA 
(B) and C-P600 (C). The particles were approximately spherical and smooth in 
surface. The sizes of BLG and C-EDA nanoparticles were slightly larger than that 
of C-P600 nanoparticles, which was consistent with the data from DLS study. This 
difference was possibly caused by the repulsion between the bulky, highly charged 
PEI moieties on C-P600. The reason why sizes observed under SEM were 
generally lower than those obtained by DLS was probably the shrinkage of 
particles under vacuum [51]. Figure 7.7D displayed the structure of C-P600 
nanoparticles after crosslinking and evaporation. Most particles maintained their 




CBLG was successfully synthesized from BLG using two strategies: coupling 
BLG with a larger quantity of cationic monomers (EDA) or with a smaller number 
of polycations (PEI-600 and PEI-1200). Both methods led to the reversal of net 
charge of BLG molecules, together with satisfactory dispersion stability at neutral 
pH. Compared with the EDA-involved approach, PEI-derived cationization 
resulted in lower conjugation degree, but the net charge and zeta potential 
obtained from the latter approach was significantly higher than that achieved 
through the former one. In the in vitro digestion study, cationization with PEI led 
to less significant conformational change of BLG, resulting in better inheritance of 
the resistance against peptic digestion from native BLG. In addition, PEI-derived 
CBLG was more resistant against tryptic digestion than BLG as well as C-EDA. 
Substantial improvement in mucoadhesion was observed for PEI-derived CBLG 
compared to BLG or C-EDA, probably owing to the steric hindrance provided by 
PEI. Lastly, in the presence of acetone and glutaraldehyde, PEI-derived CBLG 
could aggregate into nanoparticles with average size at 140 nm, and the formed 
particles maintained their morphology after evaporation. These characteristics 
made PEI-derived CBLG an attractive candidate as a bioavailability enhancer for 





Chapter 8 Cationic beta-lactoglobulin Nanoparticles as a 
Bioavailability Enhancer: Effect of Surface Properties and Size on 
the Transport and Delivery in vitro 
8.1 Abstract 
The chemical structure and environmental factors dictate the surface properties of 
nutraceutical or drug carriers, determining their stability and behavior in various 
physiological processes following oral administration. In this chapter, we firstly 
illustrated how these two factors influenced the surface charge, hydrophobicity, 
and size of cationized beta-lactoglobulin (CBLG) molecules and nanoparticles, a 
novel drug delivery system that we developed recently, followed by exploring the 
relationship between their surface properties and performances. The CBLG 
nanoparticles were able to transport most of the encapsulated drug intact through 
the gastrointestinal (GI) tract owing to its minimal particle digestion. Other 
advantageous properties of CBLG-based systems included superior mucoadhesion, 
permeation across the small intestine epithelia, and cellular uptake. Moreover, in a 
comparison between BLG/CBLG molecules and nanoparticles, the individual 
molecules exhibited better tight junction opening capacity and higher cytotoxicity, 
whereas the nanoparticles displayed superior mucoadhesion, permeation across the 
Caco-2 monolayer, and cellular uptake. Finally, as CBLG molecules or 
nanoparticles absorbed the negatively charged serum proteins in the cell culturing 
medium, their surface properties, cytotoxicity, and cellular uptake were 
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significantly altered. This research not only provided an attractive 
nutraceutical/drug delivering vehicle but also shed some light on the fate of 
nano-sized drug carriers upon oral administration. 
8.2 Introduction 
Nanoparticles as a promising bioavailability enhancer of poorly absorbed nutrients 
and drugs have been studied extensively in recent decades [223, 224]. Proteins as 
biopolymers are gaining increasing interest as encapsulants, owing to their natural 
abundance, biodegradability, and biocompatibility [225, 226]. In addition, proteins 
are amphiphilic polymers which could interact adequately with both the solvent 
and different types of drugs via electrostatic and hydrophobic interaction, as well 
as extensive hydrogen bonding [105]. Compared to polysaccharides that exhibit an 
extended linear or branched structure, proteins tend to adopt a more compact and 
flexible conformation that favors the formation of nanoparticles and inclusion of 
drugs [137]. Despite these merits, there exist several drawbacks that impede the 
application of protein-based nanoparticles. Firstly, oral administration is the most 
convenient route for the administration of drugs or nutraceuticals. However, many 
conventionally utilized proteins are rapidly digested in the GI tract, thus losing the 
protective effect on the entrapped compound [163]. In addition, most naturally 
abundant proteins are negatively charged [105, 227], which implies insufficient 
adsorption to biological surfaces such as the small intestinal epithelia and cell 
membranes, both of which carry negative net charges [170, 228]. Therefore, it is 
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meaningful to develop novel protein derivatives that overcome the shortcomings 
of native proteins while inheriting their advantages. 
The transport and delivery of the encapsulated drugs in human body is a complex 
process that involves a number of biological interactions. Many of these 
procedures, ranging from the transport in the GI tract to the internalization by 
targeted cells or tissues, require the delicate design of drug-loaded vehicles that 
could interact appropriately with specific biological surfaces or compounds [228]. 
It is rational to deduce that these interactions are highly dependent on the surface 
properties of the drug carriers where the contact takes place, and that these 
properties are determined by both the chemical composition of the encapsulants 
and the environment they are situated in [229, 230]. In vitro studies provide a 
powerful tool reveal such dependency. Compared to in vivo studies which are 
focused on the overall effect of drug encapsulation, in vitro analyses enable us to 
illuminate the influence of structural and environmental factors on the fate of 
drug-loaded vehicles in individual processes, providing valuable guidance on the 
precise design of novel drug carriers.  
Recently, we developed a novel protein derivative, cationic beta-lactoglobulin 
(CBLG) [151, 163]. Native BLG, a major component of the whey protein, is a 
highly water soluble globulin that possesses inherent patches for binding lipophilic 
nutrients. It also exhibits a unique resistance by pepsin together with moderate 
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digestibility by trypsin. The CBLG inherited these advantages from native BLG, 
and it exhibited marked mucoadhesion due to its positive charge. In this study, we 
synthesized nanoparticles from native BLG and two CBLGs with similar surface 
charge but distinct structures. The surface charge, surface hydrophobicity, and 
average size of BLG/CBLG molecules and nanoparticles were compared in 
different solvents to assess the combined effect of chemical structure and 
buffering solution. Furthermore, we evaluated the performances of BLG/CBLG 
molecules or nanoparticles in some key processes relevant to the delivery of 
oral-administrated nutraceutical/drug carriers: digestion, mucoadhesion, 
permeation across the small intestine, and cellular uptake. The role of surface 
properties and size on the behavior of BLG/CBLG molecules or nanoparticles will 
be discussed in details.  
8.3 Materials and Methods 
8.3.1 Materials 
The following chemicals were purchased from Sigma-Aldrich (St. Louis, MO, 
USA): bovine BLG (90% purity), ethylenediamine dihydrochloride (EDA, 98% 
purity), branched polyethyleneimine (MW 600, abbreviated as P600), 
N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC, 97% purity), fluorescein 
isothiocyanate (FITC) curcumin (98% purity), pepsin (3,200-4,500 units/mg), and 
trypsin (10,000 BAEE units/mg). Porcine stomach mucin (PSM, type III, contains 
0.5-1.5% sialic acid) was obtained from Himedia Co., India. All reagents involved 
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in cell study were purchased from Life Technologies (Grand Island, NY, USA). 
All other reagents were of analytical grade. 
8.3.2 Synthesis and characterization of CBLG molecules and nanoparticles 
CBLG was synthesized via an EDC-aided coupling reaction [151]. BLG and the 
cationizers (EDA or PEI) were dissolved in deionized water at 20 and 100 mg/mL, 
respectively. The pH was then adjusted to 4.75 using 1 mol/L HCl for BLG 
solution or concentrated HCl for cationizer dispersion. Thereafter, 5 mL of BLG 
solution was added slowly to 30 mL cationizer dispersion under mild stirring, and 
the mixture was incubated at room temperature for 15 min. Cationization was 
initiated by the addition of 30 mg EDC and terminated by adding 108 μL sodium 
acetate buffer (4 mol/L, pH 4.75) after 4 h. The resultant dispersion was subjected 
to dialysis centrifugation (5,000 g, 30 min), using a Macrosep® centrifuge tube 
(MW cutoff 10 kDa, Pall Corp., Ann Harbor, MI) with a built-in filtering 
membrane. The retentate obtained after centrifugation was further dialyzed against 
deionized water at 4 oC for at least 48 h and freeze dried. The moisture content of 
the final product was less than 5%, and the protein content was above 90% 
according to Bradford assay calibrated with BSA. The samples were designated as 
C-EDA and C-P600 for EDA- and P-600-derived CBLG, respectively. 
Nanoparticles were prepared from BLG and CBLG by organic solvent desolvation 
as previously described [151]. The protein was dissolved in deionized water at pH 
7.5 and a concentration of 1 (BLG), 0.75 (C-EDA), or 0.6 mg/mL (C-P600). After 
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one hour of equilibration, pure acetone was added dropwise to achieve an 
acetone/water ratio of 90/10 (v/v, same hereinafter), which triggered the formation 
of nanoparticles. Glutaraldehyde as a crosslinker was added thereafter to harden 
the particle structure. The mass ratios between glutaraldehyde and protein were 40, 
80, and 120 μg/mg protein for BLG, C-EDA, and C-P600, respectively, as 
determined in our previous reports [163]. After 8 h of crosslinking, the added 
acetone was supplemented with water to achieve an acetone/water ratio of 50/50, 
and the acetone was evaporated under a constant nitrogen flow. The obtained 
dispersion was filtered through a 0.22 μm Acrodisc syringe filter membrane (Pall 
Co., Newquay, UK). The filtrate was then subjected to dialysis centrifugation 
(5,000 g, 30 min, molecular weight cutoff = 100 kDa) to remove free protein 
molecules and unreacted glutaraldehyde, as well as to enrich the nanoparticles to a 
concentration of 5 mg/mL, the latter of which was estimated by weight 
determination after lyophilization. To synthesize the curcumin-loaded 
nanoparticles, a curcumin/acetone stock solution (2 mg/mL) was applied in place 
of pure acetone in the desolvation process. All samples were stored at 4 oC until 
subsequent analyses. The nanoparticles prepared with BLG or CBLG were named 
as the terms of the constituent proteins followed by the abbreviation “NPs”. 
The molecular weights (MW) of BLG and CBLG were determined by matrix 
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry as described Section 7.3.3. The difference in MW before and after 
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cationization (ΔM) was adopted to calculate the conjugation degree and net charge 
of CBLG as discussed in Section 7.3.3. The dispersions of BLG, CBLG, and their 
nanoparticles were then diluted in three different buffers, namely, Hank’s 
balanced salt solution (HBSS), Dulbecco's modified Eagle's medium (DMEM), 
and DMEM supplemented with FBS. The dispersions in DMEM with FBS were 
subjected to dialysis centrifugation as described above to remove unbound serum 
protein, while the other dispersions were measured without such treatment. All the 
dispersions were measured for their ζ-potentials by laser Doppler velocimetry 
using a Nano ZS90 Zetasizer (Malvern Inc., Malvern, UK). The surface 
hydrophobicity (So) of the samples was measured using 
8-anilino-1-naphthalenesulfonic acid (ANS) as a hydrophobic probe [151], as 
described in Section 6.3.5.  
The particle sizes and count rates were measured by dynamic laser scattering 
(DLS) as described in Section 7.3.9. No dilution was carried out before the 
measurement. The data were analyzed using the cumulant algorithm, and the 
quadratic mean particle size was reported.  
8.3.3 Determination of the releasing profile and particle disintegration 
Curcumin as a model drug was incorporated into BLG or CBLG nanoparticles, 
which were analyzed for their releasing profiles by a previously reported method 
[227]. Release was initiated by mixing 2 mL of the sample with 8 mL SGF 
(commercial SGF containing 5 mg/mL Tween 20 and pepsin at a substrate/enzyme 
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ratio of 100:1, w/w), followed by incubation at 37 oC in a reciprocal shaking bath 
(120 rpm). At predetermined time intervals, 0.5 mL of the mixture was withdrawn, 
diluted with 2.0 mL PBS (pH 7.2, 100 mM, containing 5 mg/mL Tween 20) and 
analyzed for its particle size and count rate by DLS. Another aliquot of 0.5 mL 
was withdrawn and diluted using the same procedure, followed by dialysis 
centrifugation (5,000 g, 30 min) using a Macrosep® centrifuge tube (MW cutoff = 
100 kDa, Pall Corp., Ann Harbor, MI). The curcumin-containing Tween-20 
micelles were diluted appropriately with PBS and then measured for the content of 
released curcumin spectrophotometrically at the wavelength of 426 nm. When 
surfactant such as Tween 20 is added, the released curcumin maintained its 
stability, as was demonstrated in previous literatures [231]. Fresh mixture of SGF 
and Tween 20 was supplemented after each measurement to maintain sink 
condition.  
On the other hand, another batch of the samples was mixed with SGF at a same 
ratio and digested for 60 min at 37 °C. The digesta was diluted with PBS and 
centrifuged as mentioned above, and the retentate containing intact nanoparticles 
was supplemented with PBS to 2 mL. The dispersion was incubated at 37 °C for 
15 min and then mixed with 8 mL preheated SIF (commercial SIF added with 5 
mg/mL Tween 20 and trypsin at a BLG/trypsin ratio of 100:1, w/w). The 
progressions in drug release, particle size, and count rate in SIF were tested 
following the similar procedure as that for SGF.  
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8.3.4 Determination of mucoadhesive properties 
The mucoadhesion properties of BLG/CBLG molecules and nanoparticles were 
assessed by quartz crystal microbalance (QCM) analysis [151], using a 
gold-coated AT-cut quartz crystal with a fundamental frequency of 4.95 MHz 
(QSX-301, Q-Sense Co., Linthicum, MD, USA). PBS (pH 7.2, 10 mM) was used 
for dilution and rinsing in this section. Prior to the measurement, the crystal was 
soaked in Piranha solution (NH3·H2O: H2O2: H2O=1:1:5, v/v/v) for 15 min at 70 
oC, dried with nitrogen, and then mounted on the Q-Sense E1 microbalance 
(Q-Sense Co., Linthicum, MD, USA). Different dispersions were passed through 
the sample chamber using a peristaltic pump (Ismatec Reglo, Glattbrugg, 
Switzerland) in the following sequence: PBS, mucin dispersion (400 μg/mL in 
PBS, filtered through a 220 nm membrane), PBS, sample dispersion (diluted with 
PBS to 100μg/mL), and PBS. The deposition of mucin on the gold chip and that of 
BLG/CBLG on the mucin layer triggered a significant reduction in the oscillation 
frequency of the chip, which was recorded by the QTools 3 software (Q-Sense Co., 
Linthicum, MD, USA). The fifth overtone of the frequency was converted to 
deposited mass (in ng/cm2 crystal surface) using the Sauerbrey model. 
Mucoadhesion was expressed as the mass ratio of BLG/CBLG to mucin deposited 
on the crystal surface. 
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8.3.5 Cell culture 
Human colon adenocarcinoma cell line (Caco-2) was provided by the American 
Type Culture Collection (Manassas, VA, USA). The cells were cultured in 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v, 
same in this section) fetal bovine serum (FBS) and 1% penicillin-streptomycin in a 
humidified incubator with 5% CO2 at 37 °C. The growth medium was changed 
every other day, and the cells were subcultured after reaching 80-90% confluence.  
8.3.6 Transport of nanoparticles via Caco-2 cell monolayer 
Caco-2 cells were seeded at a density of 3 × 105 cells/cm2 on a Costar Transwell 
12-well plate (Corning Costar Corp., NY), which contained a tissue culture-treated 
microporous insert (diameter = 12 mm, growth area = 1.1 cm2) in each well. The 
culturing medium was replaced every 48 h for the first 6 days and every 24 h 
thereafter. The transepithelial electrical resistance (TEER) values, measured with 
an EVOM2 Epithelial Voltohmmeter (World Precision Instruments, Sarasota, FL, 
USA), reached 600-800 Ω/cm2 after 16-20 days. Prior to the assay, the culture 
media in both apical and basolateral compartments were carefully aspirated and 
replaced with pre-warmed HBSS, which was incubated at 37 oC for 30 min and 
displaced. Depending on the type of study, the apical (for apical-to-basolateral 
transport) or basolateral (for basolateral-to-apical transport) part of the plate was 
designated as the donor compartment and filled with proper volumes of samples 
(dispersed in HBSS). The other one defined as the receiving compartment was 
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added with HBSS only. At designated time intervals, appropriate amount of 
samples was withdrawn from the receiving compartment and analyzed for their FI, 
and an equal volume of fresh HBSS was then replenished to each receiving well. 
The apparent permeability coefficient (Papp) was calculated as follows: 
𝑃𝑃𝑎𝑎𝑎𝑎𝑎𝑎 =  
∂Q
A𝐶𝐶0 ∂t
           (1) 
Here ∂Q/∂t was the permeability rate, A stood for the surface area of the 
membrane filter, and C0 represented the initial concentration in the donor 
compartment.  
8.3.7 Cell uptake study 
For quantitative study,, all samples were labeled with FITC using an FITC 
Labeling Kit (Thermo Fisher Scientific Inc., Rockford, IL). The cells were seeded 
in a black 96-well plate at 3×104 cells/well and incubated until a confluence of 80% 
was achieved. The growth medium was then replaced with a transport buffer 
(DMEM with or without FBS) and incubated at 37℃ for 30 min. Two hundred 
microliters of the labeled suspension was incubated with the cells for 4 h. At 
designated time intervals, the cell monolayer was washed with PBS three times to 
remove unabsorbed nanoparticles. The cells were then lysed with a solution 
containing 0.5% Triton X-100 and 0.2 mol/L NaOH to expose the internalized 
nanoparticles. The fluorescent intensity was then measured using a PerkinElmer 
Victor X3 multilabel plate reader (PerkinElmer Inc., Waltham, MA) with an 




All measurements were performed in triplicates. The results were expressed as 
means ± standard error. To identify statistically significant difference, the data 
were subjected to analysis of variance followed by Tukey’s test with an 
experimentwise confidence level of α=0.10, using SAS 9 software (SAS Institute 
Inc., Cary, NC, USA). 
8.4 Results and Discussion 
8.4.1 Characterization of BLG and CBLG nanoparticles 
Figure 8.1 illustrates the surface structures of BLG/CBLG and compares several 
characteristics that are closely related to drug delivery. Upon cationization, the 
zeta potential was altered significantly to from -35.8 mV for BLG to 39.4 and 46.8 
mV for C-EDA and C-P600, respectively, which was anticipated to favor the 
mucoadhesion and cellular uptake. On the other hand, the surface hydrophobicity 
(So) of C-EDA was 13-fold higher than that of BLG, whereas the So of C-P600 
was 60% lower than that of BLG. According to our previous study [151, 163], the 
disparity in So was explained by the different extents of conformational change 
and the hydrophobic/hydrophilic nature of the EDA/P600 backbone [205]. 
Another important factor regarding the surface properties was that the positively 
charged amine groups are compactly distributed on the polymeric branches of 
P600, thus creating a multivalent environment which may benefit the 
mucoadhesion and cellular uptake of C-P600 [232, 233]. As for the nanoparticles, 
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they tended to exhibit a more negative (or less positive) zeta potential and higher 
surface hydrophobicity, compared to their molecular form. The first change could 
be explained by the consumption of cationic amine groups by crosslinking with 
glutaraldehyde [105], while the latter one was probably due to the partial protein 
unfolding by organic solvents [25]. 
 
Figure 8.1 Structure and physiochemical characteristics of BLG and CBLG. 
* Theoretical value when all of the amine groups on P600 are protonated. 
When drug-encapsulating systems are consumed via oral administration, they are 
exposed successively to various physiological buffers that may also alter their 
surface properties [229, 230]. When conducting in vitro tests, one should use 
appropriate buffers that are relevant to the intended application of the drug carriers, 
and the effect of the buffering solutions on the outcome should not be overlooked. 
Two of the most commonly used buffers for cell culture studies [151], HBSS and 
DMEM, contained abundant ions that deprived the surface charge of the samples 
225 
 
and decreased their zeta potentials by up to 48% (in terms of their magnitude, 
same hereinafter, Figure 8.2A). This resulted in lower electrostatic repulsion 
among the charged groups, leading to extensive aggregation of BLG/CBLG 
molecules and nanoparticles as evidenced by greater average sizes (Figure 8.2C). 
Moreover, the reduction in electrostatic repulsion rendered the proteins and 
nanoparticles to adopt a more compact structure with less hydrophobic chains 












































































































Figure 8.2 Zeta potential (A), surface hydrophobicity (B) and particle size (C) of 
BLG/CBLG molecules and nanoparticles 
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FBS contains abundant negatively charged proteins such as bovine serum albumin 
(BSA) [234]. In FBS-containing DMEM, all the samples exhibited negative zeta 
potentials at around -20 mV and higher surface hydrophobicities, both of which 
are the characteristics of BSA [193]. These changes indicated the acquisition of a 
negatively charged serum protein corona [235], resulting in a significant increase 
in the particle size by up to 198% (Figure 8.2C). Amongst all samples, C-EDA 
nanoparticles exhibited the greatest increase in average size, possibly due to its 
high surface hydrophobicity that resulted in more significant aggregation via 
hydrophobic interaction. 
In the following sections, the performance of BLG and CBLG molecules or 
nanoparticles in several biological procedures will be compared systematically, 
and their behaviors under these conditions will be correlated to the surface 
properties as discussed above. 
8.4.2 Transport of BLG/CBLG nanoparticles through the GI tract 
The first harsh environment that the drug encapsulants are exposed to is the GI 
tract, which contains strong acid and various enzymes [227]. Investigation on the 
particle disintegration and drug release is critical for biopolymer-based 
nanoparticles, since many biomacromolecules degrades readily in the digestive 
system. Figure 8.3A depicted the releasing profile of curcumin from the 
BLG/CBLG nanoparticles. The weight ratio between curcumin and BLG was 10%, 
and the encapsulation efficiency was over 95% (preliminary data not shown). 
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These numbers were higher than those achieved with many other polymers, such 
as zein [32] and soy protein [105]. As can be seen, more than 80% of the 
encapsulated curcumin was released from the BLG nanoparticles into SGF in the 
first 30 min, and the percentage continued to increase to 95% after the 
nanoparticles were placed in SIF. On the other hand, nanoparticles formed by 
CBLG exhibited significantly lower rate of release, with less than 25% of the 
curcumin being released after the treatments with SGF and SIF.  
The rapid drug release from BLG nanoparticles was unexpected, because BLG 
molecules were resistant against pepsin and only moderately digested by trypsin 
[151]. This phenomenon prompted us to investigate the disintegration of BLG 
nanoparticles. As shown in Figure 8.3B, BLG nanoparticles showed an increase 
in their average size by 6-fold when treated in SGF, accompanied by a decrease by 
39% in the count rate (Figure 8.3C). At the end of treatment, only 17% of the 
count rate was retained. Given the fact that the count rate changes proportionally 
to the number of the particles as well as the sixth power of the particle size [23], 
these results suggested that the number of smaller nanoparticles in the dispersion 
decreased significantly, whereas the larger particles were relatively stable [227]. 
When transferred into the SIF, both the size and count rate declined continuously, 
suggesting the decomposition of both smaller and larger particles. On the contrary, 
CBLG nanoparticles maintained remarkable stability against peptic and tryptic 
digestions, which could explain the low releasing rate of curcumin in these 
229 
 
samples. This character made CBLG nanoparticles an attractive candidate for 
delivering poorly absorbed nutrients or drugs via oral administration. 
The difference in the particle integrity against digestive enzymes was speculated 
to arise from the covalent bonds maintaining the particle structure. Glutaraldehyde 
as a crosslinker reacts with the primary amine groups on the lysine residue of 
native BLG [23], forming amide bonds that might be susceptible to peptic and 
tryptic digestion. After cationization, the grafted EDA and P600 moieties might 
have reacted with glutaraldehyde and formed a significant number of amide bonds 
that were more difficultly digested, because their geometric and physicochemical 
properties were greatly different from the ones formed between glutaraldehyde 
and lysine. Alternatively, they might have shielded the glutaraldehyde-lysine 
bonds through steric hindrance, preventing them from being cleaved. A follow-up 
study using native BLG and a different crosslinker (such as an enzyme or 





















































































































Figure 8.3 Releasing profile (A) and particle disintegration (B and C) of curcumin-loaded 
BLG/CBLG nanoparticles. 
8.4.3 Mucoadhesion  
Once the drug carriers arrive intact at the small intestine, they adsorb to and pass 
through the small intestine epithelia. The transport across the small intestine 
depends on two procedures, namely, adhesion to the mucosa (mucoadhesion) and 
the permeation across the small intestine epithelia. Mucin as an anionic 
glycoprotein covers the small intestine mucosa, forming the first barrier for 
incoming nutrients or drugs [236]. Cationic polymers such as chitosan or poly 
(amido amine) (PANAM) dendrimers are highly mucoadhesive owing to their 
electrostatic attraction with mucin [237]. Some neutral (e.g., cellulose derivatives) 
or anionic (e.g., sodium alginate) macromolecules also demonstrate considerable 
mucoadhesion probably through extensive hydrogen bonding [238]. In our study, 
BLG showed a very low protein/mucin weight ratio of 0.171. On the contrary, 
C-EDA and C-P600 exhibited a protein/mucin ratio of 0.743 and 1.148, 
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respectively (Figure 8.4A), which were significantly higher than those for other 
biopolymers, including chitosan and hydrophobically modified polysaccharides 
[13]. The improvement in mucoadhesion could be rationally ascribed to the 
abundant positive charge of these two biopolymers. Furthermore, C-P600 
possesses both highly positive charge and strong hydrogen bonding capacity [239], 
which imparted it with the greatest mucoadhesion capacity.  
 
Figure 8.4 Mucoadhesion of BLG/CBLG molecules (A) and nanoparticles (B) 
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Intriguingly, as shown in Figure 8.4B, the nanoparticles showed much higher 
mucoadhesion than their constituent molecules, in spite of the fact that the former 
exhibited less positive charges than the latter. The protein/mucin ratio of C-EDA 
and C-P600 nanoparticles increased phenomenally to 4.275 and 10.013, 
respectively, which were over 15 and 40 times higher than that of BLG 
nanoparticles (0.254). When protein molecules aggregated into nanoparticles, the 
total surface area was greatly reduced. As a result, the charged or hydrophilic 
groups might have been distributed densely on the newly formed surface of the 
nanoparticles in order to maximize their contact with water. This created a 
multivalent surface that could facilitate the interaction with the mucin layer [54, 
240]. Another possible explanation was that nanoparticles as an assembly of 
biopolymers might have adhered to the mucin layer more cooperatively, although 
further studies are necessary to test this hypothesis. 
8.4.4 Permeation across the small intestine epithelia 
The transport of drugs across the small intestine epithelia could be promoted by 
two factors: disruption of the tight junctions between the epithelial cells [241] and 
enhanced endocytosis by these cells [34]. The former process is monitored by the 
progression of transepithelial electrical resistance (TEER) of Caco-2 monolayers. 
As shown in Figure 8.5, BLG molecule and nanoparticles did not show any 
significant (P<0.10) impact on the TEER values during the 2-hour period of 
treatment. On the other hand, C-EDA and C-P600 molecules were capable of 
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reducing the TEER by up to 27% and 88%, respectively, suggesting their ability of 
opening the tight junction between the Caco-2 cells to different extents. The fact 
that C-P600 reduced the TEER more profoundly than C-EDA might be ascribed to 
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Figure 8.5 Transepithelial electrical resistances (TEER) of Caco-2 monolayers in the 
presence of BLG/CBLG molecules (A) and nanoparticles (B) 
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Regardless of the type and concentration of samples, a satisfactory recovery in 
TEER was observed after the termination of treatment, with the TEER values 
reaching more than 95% of the original values after 22 h. This result was much 
better than that achieved using pure PEI as a tight junction opening reagent [242], 
which could alleviate the safety concern on the CBLG nanoparticles to some 
extent. 
It was noteworthy that C-EDA and C-P600 nanoparticles exhibited lower 
capability of tight junction disruption than the protein molecules, causing a 
decrease of at most 17% and 32% respectively in the TEER. This phenomenon 
was consistent with the studies by Vllasaliu et al. [243] and Ma et al. [244] who 
reported higher TEER-lowering capacities for chitosan molecules compared to 
chitosan nanoparticles. Although the authors ascribed such difference to the 
consumption of positive charges during particle preparation, which led to weaker 
electrostatic attraction, we considered that the minor change might not be 
sufficient to cause this marked change in TEER. Instead, we postulated that the 
difference between the size of the protein molecules (several nanometers) and 
nanoparticles (approximately 100 nm) might have played an essential role. 
Ranaldi et al. [242] and Schipper et al. [241] found that polycations such as 
chitosan and PEI disrupted the tight junction by weakening the negative charge on 
the cell membrane, followed by the contact with cytoskeletal F-actin resulting in a 
conformational change, together with the dislocation of tight junction proteins 
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including ZO1 and occludin. Based on these findings, we hypothesized that 
protein molecules could diffuse to and interact with the cytoskeleton more rapidly 
than the nanoparticles because the former exhibits smaller size and higher surface 






































Figure 8.6 Apparent permeabilities of different samples across the Caco-2 monolayer 
The apparent permeabilities across the Caco-2 monolayer of different samples 
were compared in Figure 8.6. In the apical-basolateral permeation study, BLG 
molecules and nanoparticles exhibited the lowest Papp value (0.216 × 10-6 and 
0.208 × 10-6 cm/s, respectively) among all samples, followed by C-EDA (0.238 × 
10-6 cm/s) and C-P600 molecules (1.140 × 10-6 cm/s). Furthremore, the Papp values 
for C-EDA and C-P600 nanoparticles were more than 20 and 30 times higher than 
that of native BLG molecules or nanoparticles, and they were comparable with a 
237 
 
number of polymers, such as chitosan [245] and PANAM dendrimers [240]. The 
basolateral-to-apical permeabilities were approximately 86% higher than those 
observed in the apical-to-basolateral analysis, but the ranking among different 
samples was not altered.  
The permeability of both the protein molecules and nanoparticles decreased in the 
same order (C-P600>C-EDA>BLG) as for their tight junction disrupting 
capacities, which confirmed the advantage of cationic polymers in crossing the 
small intestine lining. However, it was unexpected that the nanoparticles 
demonstrated better permeability across the Caco-2 monolayer than the constituent 
molecules, although the latter demonstrated a more pronounced reduction in 
TEER. This result suggested that mechanisms other than tight junction opening 
might dominated the permeation process. Firstly, nanoparticles exhibited better 
mucoadhesion properties than the molecules as shown in this study; therefore, 
they were able to contact and permeate the mucin layer secreted by the Caco-2 
cells more rapidly. Secondly, as will be demonstrated in the following section, 
nanoparticles were much more effectively internalized by the Caco-2 cells, which 
favored their transport via the transcellular approach. This effect was also reported 
in previous literature as a major mechanism causing the permeation of protein 
nanoparticles across the Caco-2 monolayer [34].  
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8.4.5 Cell viability 
After the transport across the small intestine, the drug carriers reach the circulation 
system where a broad variety of serum proteins adsorb onto their surface [246]. 
Such process alters the surface properties of drug carriers, which influences their 
interaction with the cells as will be discussed in this section. The reason why we 
chose a cancer cell line (Caco-2) in this study was that particles with a diameter of 
100-600 nm tend to pass through the loose blood vessels surrounding the tumor 
tissues, a phenomenon known as enhanced permeation and retention (EPR) or 
passive targeted delivery [247].  
Figure 8.7 compared the viability of Caco-2 cells exposed to different doses of 
samples. When dispersed in FBS-free DMEM (Figure 8.7A), C-P600 molecules 
exhibited significant cytotoxicity, reducing the viability of Caco-2 cells to 71% 
and 52% at the concentrations of 200 and 500 μg/mL, respectively. C-P600 
nanoparticles, on the contrary, did not show any observable toxicity in this study. 
Cationic polymers and nanoparticles are known to be toxic to a broad range of cell 
lines [234], which has been frequently correlated to their ability to breach the 
negatively charged cell membranes through electrostatic attraction [234, 248]. 
Interestingly, Leroueil et al. found that the membrane breaching was induced by 
cationic nanoparticles in a size-independent manner [249]. However, this study 
did not point out whether successful membrane breaching could translate directly 
into potent cytotoxicity. On the other hand, Yen et al. [250] and Pan et al. [251] 
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found that the cytotoxicity of nanoparticles varied with the size and charge of the 
feed, with the smallest cationic (e.g., those smaller than 10 nm) particles being the 
most toxic. Bannunah et al. also reported that cationic polystyrene nanoparticles 
with an average size of 50 nm were slightly more toxic than those with an average 
size of 100 nm [252]. These results were similar to our study on C-P600 molecules 
and nanoparticles, suggesting that mechanisms other than cell membrane 
breaching might also be essential for the cytotoxicity of macromolecules or 
nanoparticles. Possible factors may include translocation of nanoparticles into the 
cytoplasm and the interaction with specific cellular components [253], although 
detailed pathways are yet to be established for each specific cell line.  
On the other hand, dispersion in FBS-supplemented DMEM was shown to 
mitigate the cytotoxicity of C-P600 molecules significantly, increasing the cell 
viability to 92% and 88% at the concentrations of 200 and 500μg/mL, respectively. 
This could be explained with the study by Wang et al. [235], who claimed that the 
serum protein corona surrounding the cationic nanoparticles or 
biomacromolecules could be robustly retained until reaching the lysosome, thus 
protecting the cells from damage due to the positive surface charge. All other 
samples, regardless of the concentration, exhibited a cell viability of about 100% 












































































Figure 8.7 Cytotoxicity of Caco-2 cells of samples dispersed in DMEM without (A) or 
with (B) FBS 
241 
 
8.4.6 Uptake by Caco-2 cells 
As shown in Figure 8, nanoparticle samples showed significantly higher cellular 
uptake than their constituent molecules, a trend that was observed without regard 
for the type of protein and buffer as well as the concentration. For molecules, 
C-P600 demonstrated the highest cellular uptake (up to 5.74% in DMEM without 
FBS, Figure 8.8A, same hereinafter), followed by C-EDA (up to 1.86%) and BLG 
(up to 0.13%). On the other hand, the cellular uptake of nanoparticles followed the 
order of C-EDA (up to 26.5%)>C-P600 (up to 15.8%)>BLG (up to 6.82%). These 
results suggested the prominent influence of surface charge and hydrophobicity on 
the cellular uptake. CBLG molecules and nanoparticles exhibited significantly 
higher uptake compared to the BLG counterparts, which was likely attributed to 
their positive charge. C-EDA nanoparticles exhibited higher uptake than C-P600 
nanoparticles possibly owing to its high hydrophobicity that facilitated the cell 
internalization via endocytosis [254]. For the molecules, they might have entered 
the cells mainly via direct translocation as their small sizes were unfavorable for 
endocytosis [255]. Therefore, C-P600 molecules bearing higher density charge 
may enter the cells more effectively than C-EDA. 
The comparison between protein molecules and nanoparticles suggested a 
size-dependency of cellular uptake. This was similar with previous articles on gold 
nanoparticles [256, 257], which showed higher cellular uptake of nanoparticles 
with an average size of 25-75 nm compared with those with smaller (e.g., several 
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nanometers) or greater (e.g., above 100 nm) sizes. Lin et al. [258] suggested that 
cationic nanoparticles could be trafficked into cells following four steps: adhesion, 
direct translocation, endocytosis, and mixed entry. The direct translocation was 
caused by the disrupted electric field near the cell membrane, which is 
independent of particle size as discussed in the previous section [249]. However, 
as such process weakens the transmembrane potential gradually, it becomes no 
longer active at a certain point. Thereafter, endocytosis became the chief pathway 
for the entry of cationic nanoparticles. Since endocytosis is known to be closely 
related to the curvature of the incoming nanoparticles, which determines the 
effectiveness of cell membrane wrapping and endosome formation, the size and 
shape of the feed could play a major role in the cellular uptake at this stage [255]. 
As for anionic samples (BLG molecules and nanoparticles), they have been 
revealed to enter the cells mainly through endocytosis [34]. In addition, the 
endocytotic pathways for positively and negatively charged nanoparticles by 
Caco-2 cells are also different, as indicated by Bannunah et al [252]. Vesicular 
trans-monolayer transport was observed for both nanoparticles. In addition, 
calthrin-mediated endocytosis, and macropinocytosis played a major role in the 
internalization for positively charged nanoparticles, whereas lipid raft-associated 
pathway (caveolae-mediated endocytosis) was determined as the primary 
mechanism for the cellular uptake. Put together, the cellular uptake of 
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biomolecules or nanoparticles should be size- and charge-dependent, as confirmed 









































































Figure 8.8 Uptake by Caco-2 cells in DMEM without (A) or with FBS (B) 
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Lastly, although the supplementation of FBS in DMEM reduced the cellular 
uptake of C-EDA molecules and nanoparticles by at most 40%, it did not exhibit 
any significant (P<0.10) influence on the internalization of BLG and C-P600 
molecules or nanoparticles. As a result, the uptake of C-EDA nanoparticles was 
merely 16% higher than that of C-P600 nanoparticles in the presence of FBS 
(Figure 8.8B). A recent study by Fischer et al. [191] revealed that the complex 
formed by cationic nanoparticles and serum proteins bound to the scavenger 
receptor on the surface of cell membrane, thus altering the cellular uptake of the 
nanoparticles. Furthermore, the effect of serum protein on the cellular uptake 
depended strongly on the particle size. This finding partly explained for the results 
obtained from our study, considering that the size of C-EDA particles was 
significantly higher than that of C-P600 particles. 
8.5 Conclusion 
In this study, we exploited CBLG molecules and nanoparticles to assess the 
impact of protein structure and physiological environment on the surface 
properties of the drug/nutraceutical carriers, and we related these characteristics to 
their performance in a series of processes that are relevant to drug/nutraceutical 
administration via oral route. The surface decoration by cationizers altered the 
surface properties (mainly the charge and hydrophobicity) of BLG molecules and 
nanoparticles, conferring them with satisfactory dispersion stability, particle 
integrity against digestive enzymes, sustained release in the GI tract, remarkable 
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mucoadhesion, desirable permeability across Caco-2 monolayer, and elevated 
cellular uptake. Furthermore, the form of samples (molecules or nanoparticles) 
also played a major role in these biochemical interactions. The processes studied 
in our study could be roughly divided into three categories. First, the processes 
that mainly involve the contact with a charged surface (e.g., mucoadhesion) may 
take place more effectively in the presence of larger nanoparticles, probably 
because of their appropriate curvatures, multivalency, and cooperative binding. 
Second, the procedures requiring rapid diffusion and interaction with certain 
biomacromolecules (e.g., tight junction opening and cytotoxicity) may proceed 
more effectively in the presence of smaller protein molecules, which possessed 
larger surface area and faster diffusion rate. Third, in the complex biological 
processes involving both of the abovementioned classes of procedures (e.g., 
cellular uptake and permeation across the Caco-2 monolayer), an optimal size that 
balances the performances in all these steps may exist. Finally, the surface 
properties and performances of all samples were significantly affected by the 
buffering system where they were situated. Binding of serum proteins in FBS 
mitigated the cytotoxicity of cationic polymers, but it also compromised the 
uptake of CBLG. Both changes could be attributed to the change in their surface 
properties. The principles extracted from our study may be utilized to explain the 
different performances of various drug/nutraceutical carriers both in vitro and in 
vivo. Moreover, our study provided some guidance for the design of 
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drug/nutraceutical carriers with well-defined surface properties, leading to 
controllable transport and delivery of the incorporated drugs/nutraceuticals. 
Follow-up studies on the performance of CBLG nanoparticles in various cell lines 





Chapter 9 Summary and perspectives 
9.1 Summary 
This project systematically investigated the preparation, characterization, and 
application of protein-based nanoparticles as effective transporting and delivering 
vehicles for poorly absorbed nutraceuticals or drugs. Extensive emphasis has been 
put on elucidating the structure-function relationship for natural and minimally 
modified polymers. The interplay among the matrix, the encapsulated compound, 
and the environment in which the delivery vehicles is situated was found to have a 
significant effect on the efficacy of nutraceutical (or drug) encapsulation and 
delivery. A series of encapsulating and delivery systems have been designed by far 
for two different bioactive compounds, vitamin D3 and curcumin. 
1. Soy protein as one of the most commonly utilized plant proteins possesses 
desirable water solubility together with a considerable content of hydrophobic 
amino acids. The latter property indicates strong interaction between the protein 
and hydrophobic bioactives, which facilitates the encapsulation of these 
compounds. Nanoparticles were successfully synthesized with soy protein by the 
organic desolvation method. The formation of soy protein nanoparticles involves 
partial unfolding of protein molecules, limited aggregation in the presence of the 
antisolvent, crosslinking via chemical bonds, and refolding of the constituent 
monomers. Curcumin as a chemopreventive compound was successfully 
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incorporated into the soy protein nanoparticles. Satisfactory EE and 
time-dependent release profile were observed. The nanoparticles were further 
subjected to conjugation with folic acid, a cancer cell-targeting ligand. Compared 
to the native soy protein nanoparticles, folic acid-conjugated particles exhibited a 
93% increase in the accumulation in tumor cells such as Caco-2, indicating that 
they may be a competitive candidate for the protection and target delivery for 
anti-cancer drugs. Other benefits resulting from folic acid conjugation included 
better particle forming capacity, higher EE, and more complete release in vitro. To 
overcome the rapid digestion of soy protein nanoparticles in the gastrointestinal 
tract, carboxymethyl chitosan was employed as a second coating layer by a simple 
ionic gelation method, using Ca2+ as an ionic crosslinker. The SPI/CMCS complex 
inherited both the desirable particle forming capacity of SPI and the dispersion 
stability of CMCS. In addition, the formed particles exhibited satisfactory EE for 
vitamin D3 and controlled releasing profile in vitro. These characteristics made 
SPI/CMCS complex nanoparticles an attractive candidate for delivering water 
insoluble micronutrients via oral administration. 
2. Beta lactoglobulin (BLG) is the major component of whey protein, and it 
serves as a natural carrier for many lipophilic nutrients. This protein exhibits high 
water solubility and unique resistance against pepsin. A systematic study was 
conducted with the focus on improvement in the EE and LE, as well as reduced 
usage of toxic crosslinkers. Our study suggested that the interaction between BLG 
249 
 
and curcumin could be promoted by tuning the antisolvent content before 
evaporation. An LC and EE of up to 11% and 98% respectively could be achieved 
under the optimal condition. Additionally, curcumin served not only as a target 
compound but also as a partial crosslinker, which reduced the required dosage of 
glutaraldehyde by as much as 50%. Moreover, cationic beta lactoglobulin (CBLG) 
was developed as a multifunctional bioavailability enhancer for nutraceuticals. 
Nanoparticles with small average size (<100 nm) and narrow size distribution 
have been prepared by organic solvent desolvation method. These novel 
biopolymer nanoparticles inherited the merits from native BLG, exhibiting 
remarkable stability against precipitation and significant controlled-release 
properties. Besides, the positive charge on CBLG promoted the mucoadhesive 
capacity by over 40 times, and the cellular uptake was also significantly enhanced 
compared to native BLG. The nanoparticles remained intact in simulated gastric 
and intestinal fluids, with minimum leakage of curcumin in the GI tract. Surface 
properties, such as charge and hydrophobicity, together with the size, showed a 
pronounced impact on the protection, transport, and delivery of the entrapped 
compounds. These advantages made CBLG nanoparticles an attractive candidate 
as a bioavailability enhancer for poorly absorbed drugs or nutraceuticals. 
9.2 Future studies 
While protein-based nanoparticles demonstrated remarkable versatility and 
efficiency in the encapsulation and delivery of nutraceuticals or drug, further 
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studies are needed to overcome the weakness of current delivery systems or to 
confer them with novel features. Some possible areas of research pertaining to 
protein-based delivery systems are discussed below. 
1. As introduced in previous sections, various chemicals such as organic 
solvents, crosslinkers, catalysts, and co-surfactants are involved in the preparation 
of protein-based nutraceutical carriers. Many of these chemicals exhibit certain 
toxicity and elicit considerable public health concerns. For example, 
glutaraldehyde as a common crosslinking agent is toxic to the respiratory and 
reproductive system, and positive results on the genetic toxicity has also been 
documented 93. Unlike the organic solvents or catalysts which can be removed by 
evaporation or dialysis, glutaraldehyde is integrated into the nutraceutical carrier 
by forming chemical bonds, and it may be released in human body when such 
bonds are cleaved by digestive enzymes. Such facts prompted the pursuit for 
natural crosslinkers such as genipin 94 and microbial transglutaminase (MTGase) 
95. In spite of the satisfactory performance of these compounds in crosslinking 
protein molecules and preparing hydrogels 95, 96, their application in systems such 
as nanoparticles has not been reported by far. The compact structure and the small 
intermolecular distance in the nanoparticles may be the major barrier for enzymes, 
preventing them from accessing and leaving the reactive sites. Combination of 
bulky enzymes with flexible substrates (e.g., short peptides or small organic 
molecules) may help overcoming this difficulty by producing small reactive 
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intermediates as an effective crosslinker. On the other hand, as introduced before, 
phenols such as EGCG show the ability to maintain the particle structure by 
non-covalent interaction, which may also be employed to synthesize “green” 
protein nanoparticles. 
2. Systematic evaluation of the efficacy and toxicity associated with 
protein-based systems. Novel nutraceutical carriers, especially those with a 
nanoscaled size, have elicited considerable public concern. This is probably 
because of the lack of knowledge in whether the nanosized nutraceuticals (e.g., 
lipophilic vitamins that are entrapped in a nanoemulsion droplet) and carriers are 
metabolized via a similar or distinct pathway in human body compared with 
conventional microsized nutraceuticals (e.g., lipophilic vitamins that are 
micro-emulsified by the bile in the small intestine). In vitro and in vivo model 
studies are needed to understand the behaviors and fates of both the nutraceuticals 
and the carriers when administrated to a living body. The effects of the surface 
properties and particle/droplet size may be of special interest, since these 
characteristics govern a wide range of biological interactions.  
3. The allergenicity associated with various proteins, including soy protein and 
BLG, leads to extensive concern on the safety of protein-based delivery systems. 
Although the particle forming process involves partial denaturation by organic 
solvent and sometimes thermal treatment, it remains unclear whether these 
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procedures can cause a conformational change sufficient to reduce or remove the 
allergenicity of the proteins. Conjugation with polymers such as polysaccharides 
has been shown to lower the allergenicity of soy proteins by a great extent; 
therefore, it is of interest to find out if other hybridization processes (such as 
cationization with PEI or ionic association with a polysaccharide) may exert a 
similar influence on the allergic properties of the protein-based delivery systems. 
4. Sensory properties are another important factor affecting consumer 
acceptance on the protein-based nutraceutical carriers. It is of interest to find out 
whether proteins can mask the unpleasant flavor of certain nutraceuticals such as 
DHA or curcumin. The effect of processing (e.g., thermal treatment) on the flavor 
may also be assessed. 
5. The application of protein-based carriers in the areas related to the food 
industry but different from nutraceutical delivery may also be pursued. For 
instance, proteins with suitable surface modification might serve as a potential 
carrier for pesticides or antimicrobial agents, providing satisfactory solubility, 
stability, and cell penetrating efficacy to the incorporated compounds. 
6. From a more practical perspective, several issues must be addressed before a 
protocol for manufacturing protein-based nutraceutical carriers can be scaled up. 
Due to the delicate conformation of proteins, all of the systems described above 
are susceptible to environmental change. For example, the size and uniformity of 
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the nanoparticles is highly dependent on the organic solvent, pH, temperature, and 
ionic strength. A slight variation in the microenvironment may lead to either 
insufficient or excessive aggregation, which poses a daunting challenge to the 
consistency of product quality. Same challenges also apply to other encapsulation 
and delivery systems such as emulsions, gels, and molecular complex, which also 
require careful control over the synthesizing condition. Novel techniques such as 
microfluidic processing may provide more precisely controlled liquid diffusion 
and mixing, giving result to more predictable particle size, narrower size 
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